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Abstract of Thesis 
Cardiac resynchronisation therapy (CRT) devices and implantable cardioverter 
defibrillators (ICDs) are frequently implanted in patients with heart failure and those at 
risk of ventricular arrhythmia (VA). Approximately 30-50% of patients undergoing CRT 
implantation fail to derive any improvement, depending on heart failure aetiology and 
the metric used to evaluate response. Furthermore, appropriate ICD therapy only occurs 
in one third of patients implanted with an ICD indicating better risk stratification of VA 
is needed. This thesis therefore aims to explore novel ways to improve complex cardiac 
implantable electronic device therapy outcomes. 
 
Initially, this thesis explores the feasibility and potential benefit of using real-time 
cardiac CT image overlay guidance and multisite left ventricular (LV) pacing as two 
distinct approaches to improve CRT response rates through optimal LV lead delivery. 
Real-time CT image overlay appears safe and feasible with significant improvements in 
echocardiographic volumetric response outcomes at 6-months follow-up compared to 
baseline. However, whilst multisite LV pacing appears feasible and safe, no evidence was 
found to support its use in improving CRT response in patients with left bundle branch 
block and intermediate QRS prolongation of 120-150 ms. 
 
Finally, this thesis investigates the role of scar heterogeneity, quantified by mean 
entropy using cardiac magnetic resonance texture analysis (CMR-TA), as a potential 
metric for ICD risk stratification. For the first time, mean entropy, calculated using CMR-
TA, was identified as an independent predictor of appropriate ICD therapy in patients 
with mixed cardiomyopathy and ischaemic cardiomyopathy-only, suggesting a potential 
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role in predicting VAs and risk stratifying patients for ICD implantation. Furthermore, 
lower scar heterogeneity, quantified by mean entropy using cardiac MRI texture 
analysis, was found to be associated with successful ATP whereas higher scar 
heterogeneity was associated with more aggressive VAs unresponsive to ATP requiring 
shock therapy. 
4 
Table of Contents 
Abstract of Thesis ...................................................................................................... 2 
Table of figures ........................................................................................................ 10 
Table of tables ......................................................................................................... 13 
Declaration .............................................................................................................. 15 
Acknowledgments ................................................................................................... 16 
Thesis outline ........................................................................................................... 18 
Abbreviations .......................................................................................................... 20 
Chapter 1: Background and literature review ........................................................... 21 
1.1 Heart failure ........................................................................................................ 22 
1.1.1 The prevalence of heart failure .......................................................................................... 22 
1.1.2 The pathophysiology of heart failure ................................................................................. 25 
1.1.3 Pharmacotherapy options for heart failure with reduced ejection fraction ...................... 27 
1.1.4 Cardiac resynchronisation therapy for heart failure .......................................................... 30 
1.2 Improving the outcomes of chronic right ventricular pacing in the heart failure 
population ....................................................................................................................... 33 
1.2.1 Introduction ....................................................................................................................... 33 
1.2.2 Chronic Right Ventricular Pacing and its Deleterious Effects ............................................. 34 
1.2.3 Pathophysiology of the Detrimental Effects of Right Ventricular Pacing ........................... 35 
1.2.4 Alternate Right Ventricular Pacing Sites ............................................................................ 36 
1.2.5 BLOCK-HF and BioPace Studies .......................................................................................... 42 
1.2.6 The Role of CRT in Patients with Atrial Fibrillation Undergoing AV Node Ablation ........... 45 
1.2.7 Conclusions on chronic RV pacing in the heart failure population .................................... 48 
5 
1.3 Evaluating CRT response ...................................................................................... 50 
1.4 Strategies to improve CRT delivery ...................................................................... 54 
1.4.1 The rationale for targeting dyssynchrony .......................................................................... 55 
1.4.2 The rational for avoiding left ventricular scar .................................................................... 56 
1.5 Image guidance for CRT ....................................................................................... 57 
1.5.1 Echocardiography to guide LV lead implantation .............................................................. 57 
1.5.2 Myocardial perfusion imaging to guide LV lead implantation ........................................... 58 
1.5.3 Cardiac magnetic resonance to guide LV lead implantation .............................................. 59 
1.5.4 Cardiac Computed Tomography to guide LV lead implantation ........................................ 61 
1.6 Left ventricular multisite pacing .......................................................................... 63 
1.7 Implantable cardioverter-defibrillators in the heart failure population ................ 65 
1.7.1 Improving ICD risk stratification ......................................................................................... 65 
1.8 Summary and hypotheses ................................................................................... 69 
Chapter 2: Real-time cardiac CT image overlay to guide optimal left ventricular lead 
implantation for CRT upgrades ................................................................................ 71 
2.1 Introduction ........................................................................................................ 72 
2.2 Methods .............................................................................................................. 74 
2.2.1 Recruitment and follow-up ................................................................................................ 74 
2.2.2 Pre-procedural Cardiac CT dyssynchrony imaging protocol ............................................... 75 
2.2.3 Pre-procedural cardiac CT scar imaging and dyssynchrony analysis .................................. 76 
2.2.4 Image overlay using the Guide CRT platform prototype .................................................... 79 
2.2.5 Real-time CT guided CRT workflow .................................................................................... 80 
2.2.6 Target segment selection protocol .................................................................................... 82 
2.2.7 Intra-procedural CT Guided CRT workflow ........................................................................ 82 
2.2.8 RADI pressure wire protocol .............................................................................................. 86 
2.2.9 Statistical analysis .............................................................................................................. 86 
6 
2.3 Results ................................................................................................................. 87 
2.3.1 Cardiac CT planning outcomes ........................................................................................... 88 
2.3.2 CT guided CRT implant outcomes ...................................................................................... 91 
2.3.3 CT planning and CT guided outcomes ................................................................................ 92 
2.3.4 Validation of CT target with the acute hemodynamic response ........................................ 93 
2.4 Discussion ........................................................................................................... 95 
2.4.1 Feasibility of using real-time CT image overlay guidance for left ventricular lead 
placement ......................................................................................................................................... 95 
2.4.2 Safety of using a CT guided approach ................................................................................ 97 
2.4.3 Comparison with similar studies ........................................................................................ 99 
2.4.4 Real-time Cardiac CT versus Cardiac MRI Guidance for CRT and Future Directions ........ 103 
2.4.5 Study limitations .............................................................................................................. 105 
2.5 Conclusion ......................................................................................................... 108 
Chapter 3: An interim analysis of Standard care versus TRIVEntricular pacing in Heart 
Failure (STRIVE HF): A prospective multicentre randomised control trial of 
triventricular pacing versus conventional biventricular pacing for cardiac 
resynchronisation therapy ..................................................................................... 109 
3.1 Introduction ...................................................................................................... 110 
3.2 Methods ............................................................................................................ 112 
3.2.1 Recruitment and follow-up .............................................................................................. 112 
3.2.2 Randomisation ................................................................................................................. 113 
3.2.3 Two-dimensional transthoracic echocardiographic studies ............................................. 115 
3.2.4 Implant procedure ........................................................................................................... 115 
3.2.5 Definitions ........................................................................................................................ 117 
3.2.6 Endpoints ......................................................................................................................... 117 
3.2.7 Statistical analysis ............................................................................................................ 119 
3.3 Results ............................................................................................................... 120 
7 
3.3.1 Primary endpoint ............................................................................................................. 124 
3.3.2 Secondary endpoints ........................................................................................................ 126 
3.4 Discussion ......................................................................................................... 129 
3.4.1 Safety of triventricular pacing .......................................................................................... 130 
3.4.2 Comparison with similar studies ...................................................................................... 132 
3.4.3 Limitations ........................................................................................................................ 133 
3.5 Conclusion ......................................................................................................... 135 
Chapter 4: Mean entropy predicts implantable cardioverter-defibrillator therapy 
using cardiac magnetic resonance texture analysis of scar heterogeneity .............. 136 
4.1 Introduction ...................................................................................................... 137 
4.2 Methods ............................................................................................................ 139 
4.2.1 Study population .............................................................................................................. 139 
4.2.2 CMR protocol and analysis ............................................................................................... 139 
4.2.3 Cardiac Magnetic Resonance Tissue Analysis (CMR-TA) .................................................. 140 
4.2.4 Follow-up and endpoint ................................................................................................... 142 
4.2.5 Statistical analysis ............................................................................................................ 142 
4.3 Results ............................................................................................................... 144 
4.3.1 Primary endpoint ............................................................................................................. 144 
4.3.2 Predictors of appropriate ICD therapy in the entire cohort ............................................. 146 
4.3.3 Predictors of appropriate ICD therapy in the ICM and NICM groups ............................... 149 
4.3.4 Survival analysis ............................................................................................................... 154 
4.3.5 Reproducibility of mean entropy ..................................................................................... 155 
4.4 Discussion ......................................................................................................... 157 
4.4.1 CMR Texture Analysis ....................................................................................................... 157 
4.4.2 CMR Texture Analysis in the ICM and NICM groups ........................................................ 157 
4.4.3 Comparison with previous studies ................................................................................... 158 
4.4.4 Predictors of appropriate ICD therapy and clinical translation ........................................ 159 
8 
4.4.5 Limitations ........................................................................................................................ 163 
4.5 Conclusion ......................................................................................................... 164 
Chapter 5: High mean entropy is associated with anti-tachycardia pacing failure in 
patients receiving ICD therapy: Insights using cardiac magnetic resonance texture 
analysis of scar heterogeneity and in silico computer modelling ............................ 165 
5.1 Introduction ...................................................................................................... 166 
5.2 Methods ............................................................................................................ 168 
5.2.1 Study population .............................................................................................................. 168 
5.2.2 CMR protocol and analysis ............................................................................................... 168 
5.2.3 Cardiac Magnetic Resonance Tissue Analysis (CMR-TA) .................................................. 169 
5.2.4 Follow-up and primary endpoint ..................................................................................... 169 
5.2.5 Computer modelling of left ventricular scar .................................................................... 170 
5.2.6 Statistical analysis ............................................................................................................ 173 
5.3 Results ............................................................................................................... 174 
5.3.1 Predictors of ICD shock therapy ....................................................................................... 176 
5.3.2 Analysis of patients receiving ATP therapy ...................................................................... 177 
5.3.3 In silico modelling results ................................................................................................. 178 
5.4 Discussion ......................................................................................................... 179 
5.4.1 Potential mechanistic explanations for ATP failure ......................................................... 179 
5.4.2 Comparison with previous studies ................................................................................... 181 
5.4.3 Clinical importance ........................................................................................................... 182 
5.4.4 Limitations ........................................................................................................................ 183 
5.5 Conclusion ......................................................................................................... 185 
Chapter 6: Conclusion ............................................................................................ 186 
6.1 Summary of thesis objectives ............................................................................ 187 
6.2 Original contributions ........................................................................................ 188 
9 
6.3 Future work ....................................................................................................... 190 
First author publications arising from thesis work and future work to publish ........ 191 
First author conference presentations arising from thesis work .............................. 193 
Other first author publications arising during period of study ................................ 195 
Bibliography .......................................................................................................... 196 
 
10 
Table of figures 
Figure 1-1: A partial wiring diagram of biological circuits for heart failure. .................. 26 
Figure 1-2: Therapeutic algorithm for a patient with symptomatic heart failure with 
reduced ejection fraction. .............................................................................................. 28 
Figure 1-3: Freedom from composite primary endpoint (time to death from any cause, 
≥15% increase in LVESV index or an urgent care visit for heart failure that required 
intravenous therapy) in the BLOCK HF Trial. .................................................................. 44 
Figure 1-4: Prevalence of CRT non-response ................................................................. 50 
Figure 1-5: Causes of CRT non response in a group of 75 patients. ............................... 52 
Figure 2-1: Cardiac CT dyssynchrony analysis ................................................................ 77 
Figure 2-2: Annotated dyssynchrony plots of volume change (Y-axis) over time (X-axis)
 ....................................................................................................................................... 78 
Figure 2-3: Pre-implant CT Guided CRT workflow ......................................................... 81 
Figure 2-4: Occlusive balloon coronary venography ...................................................... 84 
Figure 2-5: Real-time Cardiac CT image overlay guidance ............................................. 85 
Figure 2-6: Late iodine enhancement seen with single energy cardiac CT (protocol B) 89 
Figure 2-7: Cardiac CT scar analysis ............................................................................... 90 
Figure 2-8: CT derived coronary venous anatomy ......................................................... 98 
11 
Figure 2-9: Pre-procedural cardiac CT multi-planar reformat images of the coronary 
sinus indicating: ........................................................................................................... 102 
Figure 3-1: Representative posterior-anterior (A) and lateral (B) chest radiographs one 
day post implantation of a triventricular CRT defibrillator. Maximal left ventricular lead 
separation is best appreciated in the lateral chest radiograph. .................................. 114 
Figure 4-1: Scar texture examples generated from Laplacian filters applied to LGE images 
to extract and augment features of different sizes based on the spatial scaled filter 
values from 2-6mm radius (SSF2-6) corresponding to A) coarse, B) medium and C) fine 
texture scales respectively. D) corresponding unfiltered LGE image. ......................... 141 
Figure 4-2: Separate multivariable Cox regression analyses to determine independent 
predictors of appropriate ICD therapy for the entire cohort (n=114) using different scar 
indices (A: mean entropy, B: T1-native, C: Grayzone-2SD-FWHM, D: Scar-2SD .......... 148 
Figure 4-3: Multivariable Cox regression analysis to determine independent predictors 
of appropriate ICD therapy for patients with ischemic cardiomyopathy (n=70). ........ 151 
Figure 4-4: Multivariable Cox regression analyses to determine independent predictors 
of appropriate ICD therapy for patients with non-ischemic cardiomyopathy (n=44) using 
different scar indices (A: mean entropy, B: T1-native). ............................................... 153 
Figure 4-5: Kaplan-Meier survival analysis showing difference in event-free survival 
when patients are stratified according to mean entropy for the entire cohort. ......... 154 
Figure 4-6: Bland-Altman plot showing absolute difference in mean entropy values 
calculated by histogram analysis of segmented scar regions from 15 randomly selected 
patients (ICM n=8 and NICM n=7) by two independent assessors. ............................. 156 
12 
Figure 4-7: Visual comparison of unfiltered LGE images (left) and medium scar textures 
(right) of a high mean entropy patient (A) who met the primary endpoint and a low mean 
entropy patient (B) who did not receive ICD therapy. ................................................. 161 
Figure 5-1: A specific topology example of fibrosis distribution for an isthmus containing 
10%(A) and 50%(D) fibrosis. ........................................................................................ 172 
Figure 5-2: Univariable(A) and multivariable(B) Cox regression analyses to determine 
predictors of appropriate ICD shock therapy for patients (n=33) receiving appropriate 
ICD therapy (ATP or shock therapy). ............................................................................ 176 
Figure 5-3: Box and whisker plots showing difference in ‘mean entropy’ between 
patients receiving successful ATP (no shock therapy) versus failed ATP (with rescue ICD 
shock). .......................................................................................................................... 177 
13 
Table of tables 
Table 1-1: Definitions of heart failure by left ventricular ejection fraction ................... 23 
Table 1-2: The causes of heart failure ............................................................................ 24 
Table 1-3: Indications for CRT ........................................................................................ 31 
Table 1-4: CRT versus right ventricular pacing trials in patients requiring bradycardia 
pacing ............................................................................................................................. 38 
Table 1-5: Summary of 2016 ESC Guidelines for the Diagnosis and Treatment of Acute 
and Chronic Heart Failure Relating to CRT and RV Pacing in Patients with High Degree 
AV Block ......................................................................................................................... 48 
Table 2-1: Baseline characteristics ................................................................................. 87 
Table 2-2: Baseline pharmacological therapy ................................................................ 88 
Table 2-3: Feasibility and safety of CT guided CRT ........................................................ 92 
Table 2-4: CRT response - echocardiographic and clinical measures at baseline and six-
month follow-up ............................................................................................................ 93 
Table 3-1: Baseline characteristics ............................................................................... 121 
Table 3-2: Baseline pharmacological therapy .............................................................. 122 
Table 3-3: Feasibility and safety of biventricular versus triventricular pacing ............. 124 
14 
Table 3-4: Echocardiographic and clinical measures at baseline and six-month follow-up
 ..................................................................................................................................... 125 
Table 3-5: Reverse remodelling outcome measures in the entire cohort and subgroups 
of atrial fibrillation and heart failure aetiology ............................................................ 127 
Table 3-6: Left ventricular end-systolic volumes at baseline and six-month follow-up for 
heart rhythm and heart failure aetiology subgroups ................................................... 128 
Table 4-1: Patient demographics according to heart failure aetiology ........................ 145 
Table 4-2: Univariable analysis of appropriate ICD therapy for the entire cohort ...... 147 
Table 4-3: Univariable analysis of appropriate ICD therapy for the ICM group ........... 150 
Table 4-4: Univariable analysis of appropriate ICD therapy for the NICM group ........ 152 
Table 5-1: Baseline characteristics of patients receiving appropriate ICD therapy for 





I confirm the work within this thesis is my own and I have appropriately acknowledged 
the work of others. 
 
 
Dr Justin S Gould 
16 
Acknowledgments 
During this PhD, I have had the privilege of working with many talented individuals 
across a wide range of disciplines.  
 
First and foremost, I would like to thank my supervisors, Professor Christopher Aldo 
Rinaldi and Professor Reza Razavi for their guidance, encouragement, patience and 
wisdom. 
 
Special thanks also go to Dr Ronak Rajani, Dr Amedeo Chiribiri, Dr Gerald Carr-White, for 
their patience, knowledge and collaboration in many of the projects undertaken. I would 
also like to thank Dr Orod Razeghi, Dr Angela Lee, Dr Martin Bishop and Dr Steven 
Niederer for their tremendous help, advice and support with many of the projects 
included in this work. 
 
I am very grateful to Dr Bradley Porter, Dr Baldeep Sidhu, Dr Benjamin Sieniewicz and 
Dr Simon Claridge, for their help with patient recruitment and data collection, and who 
were always there for support and as a sounding board of ideas. In addition, I would like 
to thank Dr Bradley Porter for his endless enthusiasm for medical statistics and teaching 
me many of the necessary statistical methods used in this thesis. 
 
I am grateful for the support of St Jude Medical for their ongoing educational support in 
a number of the projects. I am also very grateful to Dr Peter Mountney, Dr Daniel Toth, 
Dr Tanja Kurzendorfer and the team from Siemens Healthineers in the UK, in Erlangen 
Germany and Princetown, USA for their ongoing support, training and guidance.  
17 
 
Last, and by no means least, I would like to thank my incredible wife and my absolutely 
amazing children who help me keep things in perspective. 
18 
Thesis outline  
This thesis aims to explore novel strategies to improve complex cardiac implantable 
electronic device therapy outcomes. 
 
Chapter 1 provides an introduction into the burden, aetiology and pathophysiology of 
heart failure. The use of cardiac resynchronisation therapy and ways to improve 
response rates are explored with a focus on image guidance and multisite left ventricular 
pacing. A detailed review on the evidence of chronic right ventricular pacing in patients 
with heart failure is included. In addition, Chapter 1 discusses the use of ICDs in the heart 
failure population and the importance of ICD risk stratification. 
 
Chapter 2 explores the feasibility and potential benefit of using real-time cardiac CT 
image-overlay guidance to improve CRT response rates through targeting late 
mechanical activation for optimal LV lead delivery. 
 
Chapter 3 assesses the feasibility and outcomes of multisite left ventricular pacing in 
patients with LBBB and an intermediate QRS duration of 120-150ms as a way to improve 
CRT response rates. 
 
Chapter 4 evaluates the benefit of quantifying scar heterogeneity, using cardiac MRI 
texture analysis (mean entropy), as a potential metric to predict appropriate ICD therapy 
and explore its potential role in ICD risk stratification. 
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Chapter 5 builds upon the work in the previous chapter and examines mean entropy, 
calculated using cardiac MRI texture analysis, as a potential metric to predict ATP failure 
and explore its potential role in patient selection for ICD implantation. 
 
Chapter 6 is a synthesis and summary of the findings from the preceding chapters. Final 
conclusions are made including a summary of the new knowledge acquired and 
recommendations for future directions. 
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Chapter 1: Background and literature 
review 
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1.1 Heart failure 
1.1.1 The prevalence of heart failure  
Heart failure is frequently the final common pathway of many cardiovascular 
disorders1,2 which accounts for a significantly large global burden of morbidity and 
mortality. Despite advances in our understanding and treatment of heart failure, it 
remains the commonest cause of death in the developed world and increasingly in the 
developing world. Heart failure is an overarching term used to define the syndrome that 
results from cardiac pump failure and the inability to effectively deliver oxygenated 
blood to organs and tissues, resulting in a series of physiological responses.3–6 Patients 
frequently experience deteriorating breathlessness, exercise capacity and peripheral 
oedema with heart failure progression resulting in a significant deterioration in quality 
of life, although symptoms can sometimes be temporarily improved with heart failure 
treatment.3 The New York Heart Association (NYHA) Functional Classification helps with 
staging of heart failure symptom severity and limitations for patients and are graded 
from Class I (mild) to IV (severe).7 The Minnesota living with heart failure questionnaire 
(MLWHFQ) score further attempts to quantify the impact of heart failure on patient’s 
activities of daily living.8–10  
 
More recently, heart failure has been re-defined into three categories; heart failure with 
preserved (HFpEF), mid-range (HFmrEF) and reduced ejection fraction (HFrEF) as shown 




Table 1-1: Definitions of heart failure by left ventricular ejection fraction 
 
Reproduced with permission from Ponikowski et al 201611 
 
The most common causes of reduced cardiac function are hypertension, ischaemic heart 
diseases, valvular heart disease and non-ischaemic cardiomyopathies which may be 
inherited or acquired. Table 1-2 summarises the aetiologies of heart failure. 
 
Heart failure prognosis is generally very poor with approximately 40% of patients dying 
within 12 months of being diagnosed, and it remains significantly worse compared to 
that of some malignancies.12 Furthermore, only a third of patients with heart failure 
remain alive after heart failure diagnosis.12 
 
Heart failure continues to pose a significant universal health problem with an estimated 
26 million people affected by the condition.13 In the United Kingdom (UK), the 
prevalence of heart failure is estimated to be up to 920,000 with approximately 200,000 
new cases diagnosed each year.14 Heart failure accounts for around 2% of the total 
National Health Service (NHS) budget in the UK and is expected to rise with an 
increasingly older population.15 Even though survival from acute myocardial infarction 
has considerably reduced due to thrombolysis and primary percutaneous coronary 
intervention,1617,18 a significant number of such patients still develop heart failure in 
their later years. Moreover, an increasing number of patients are being diagnosed with 
24 
chemo-induced cardiomyopathy due to certain cardiotoxic chemotherapy treatments 
with a corresponding reduction in cancer mortality rates.19 
Table 1-2: The causes of heart failure 
 
ARVC = arrhythmogenic right ventricular cardiomyopathy; DCM = dilated cardiomyopathy; EMF = 
endomyocardial fibrosis; GH = growth hormone; HCM = hypertrophic cardiomyopathy; HES = 
hypereosinophilic syndrome; HIV/AIDS = human immunodeficiency virus/acquired immune deficiency 
syndrome; LV = left ventricular. 
Reproduced with permission from Ponikowski et al. (2016)11  
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1.1.2 The pathophysiology of heart failure  
The clinical manifestations of heart failure are caused by a cascade of biochemical, 
structural and haemodynamic changes that result in increased wall stress and 
ventricular remodelling initiating hypertrophy and dilatation of the left ventricle.1,4,5,20 
As a result, the failing LV is unable to meet metabolic demands and atrioventricular 
dyssynchrony results in a broadened QRS, frequently left bundle branch block and 
functional mitral regurgitation.4,5,20 
 
These mechanisms lead to impairment of LV filling and/or contractility with subsequent 
activation of neurohormonal pathways, frequently resulting in the clinical 
manifestations of the heart failure syndrome.21 Interestingly, the clinical syndrome of 
heart failure may occur rapidly after acute myocyte injury or develop over weeks, 
months or even years or in some circumstances not at all. Figure 1-1 demonstrates the 




Reproduced with permission from Benjamin and Schneider 200521 
 
Figure 1-1: A partial wiring diagram of biological circuits for heart failure. 
‘Impaired pump function after myocyte death from myocardial infarction or abnormal loading conditions 
such as found in hypertension (white) activate a biomechanical stress-dependent signalling cascade 
(purple). The responsible targets of altered signal transduction cascades in heart failure include 
transcription factors, coactivators, and corepressors for cardiac gene expression (green) as well as the 
effector mechanisms like calcium cycling, metabolism, growth, and apoptosis (yellow) that culminate in 
ventricular dysfunction (orange) and secondary neurohormonal responses (grey) such as adrenergic drive 
and intramyocardial growth factors (not shown). Inherited mutations for cardiomyopathy (blue) affect 
proteins at many of these points and are thought to engage a similar cascade of events in order to elicit 
the full myopathic phenotype. Cell based therapies (red), although often envisioned working chiefly or 
wholly by replacing dead myocytes, probably improve ventricular performance through a combination of 
mechanisms, including angiogenesis, paracrine signals for myocyte protection and conceivably 
augmenting host self-repair.’21 
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Following myocyte injury, initial adaptation to maintain stroke volume occurs as 
described by the Frank-Starling law.22,23 The response to a reduction in blood ejected 
from the left ventricle is two-fold: A rise in the LV end diastolic volume and pressure 
results in an increase in preload. This stimulates greater stretch of the myocytes 
resulting in an increased recoil force of contraction to restore the decrease in stroke 
volume. Neurohormonal responses gradually ensue to help maintain cardiac output by 
increasing the LV end diastolic pressure through sodium and water retention. To begin 
with, these mechanisms are protective but the continuous onslaught of raised filling 
pressures and chronic arterial wall constriction lead to ventricular remodelling and 
eventually LV pump failure.24 When myocyte death occurs through either apoptosis or 
necrosis, an inflammatory soup, mediated by the release of cytokines leads to 
ventricular wall thinning and chamber dilation.25,26 At a cellular level, activation of 
enzymes leads to destruction of the extracellular matrix which may condition the 
progression of the cardiac myopathy.25,26 In addition, myocardial fibrosis occurs from 
proliferation of collagen synthesis.25,26 
 
Continuous interplay and progression of the above pathological processes leads to the 
clinical manifestation of heart failure described above. 
 
1.1.3 Pharmacotherapy options for heart failure with reduced ejection 
fraction 
Treatment goals for patients with heart failure are primarily focussed on improving 
quality of life, functional capacity, clinical status, preventing hospital admissions and 
reducing mortality.11 
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A treatment workflow for treating heart failure with reduced ejection fraction is shown 
in Figure 1-2. 
 
Reproduced with permission from Ponikowski et al 201611 
 
Figure 1-2: Therapeutic algorithm for a patient with symptomatic heart failure with 
reduced ejection fraction. 
 
‘Green indicates a class I recommendation; yellow indicates a class IIa recommendation. ACEI = 
angiotensin-converting enzyme inhibitor; ARB = angiotensin receptor blocker; ARNI = angiotensin 
receptor neprilysin inhibitor; BNP = B-type natriuretic peptide; CRT = cardiac resynchronisation therapy; 
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HF = heart failure; HFrEF = heart failure with reduced ejection fraction; H-ISDN = hydralazine and 
isosorbide dinitrate; HR = heart rate; ICD = implantable cardioverter defibrillator; LBBB = left bundle 
branch block; LVAD = left ventricular assist device; LVEF = left ventricular ejection fraction; MR = 
mineralocorticoid receptor; NT-proBNP = N-terminal pro-B type natriuretic peptide; NYHA = New York 
Heart Association; OMT = optimal medical therapy; VF = ventricular fibrillation; VT = ventricular 
tachycardia. Symptomatic = NYHA Class II-IV. HFrEF = LVEF <40%. If ACE inhibitor not tolerated/contra-
indicated, use ARB. If MR antagonist not tolerated/contra-indicated, use ARB. With a hospital admission 
for HF within the last 6 months or with elevated natriuretic peptides (BNP > 250 pg/ml or NTproBNP > 500 
pg/ml in men and 750 pg/ml in women). With an elevated plasma natriuretic peptide level (BNP ≥ 150 
pg/mL or plasma NT-proBNP ≥ 600 pg/mL, or if HF hospitalization within recent 12 months plasma BNP ≥ 
100 pg/mL or plasma NT-proBNP ≥ 400 pg/mL). In doses equivalent to enalapril 10 mg b.i.d. With a 
hospital admission for HF within the previous year. CRT is recommended if QRS ≥ 130 msec and LBBB (in 
sinus rhythm). CRT should/may be considered if QRS ≥ 130 msec with non-LBBB (in a sinus rhythm) or for 
patients in atrial fibrillation provided a strategy to ensure bi-ventricular capture in place (individualized 
decision). For further details, see Sections 7 and 8 and corresponding web pages.’11 
 
Neuro-hormonal antagonists improve survival in patients with heart failure with 
reduced ejection fraction and are recommended for all patients with the condition 
unless intolerant or contraindicated. These included angiotensin converting enzyme 
inhibitors (ACEIs), mineralocorticoid receptor antagonists (MRAs) and beta-blockers. 
More recently, the PARADIGM-HF trial demonstrated that the combination of an 
angiotensin receptor blocker (valsartan) with a neprilysin inhibitor (sacubitril) is superior 
to an ACEI (enalapril) in reducing the risk of mortality and heart failure 
hospitalisation.11,27 Sacubitril/valsartan is currently recommended to replace ACEIs in 
mobile patients with heart failure with reduced ejection fraction who remain 
symptomatic despite optimal pharmacotherapy and who match the PARADIGM-HF trial 
criteria.11,27 Angiotensin receptor blockers (ARBs) have in the past been reserved for 
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patients who are intolerant to an ACEI but they have not been consistently proven to 
reduce mortality in patients with heart failure with reduced ejection fraction.11 
Ivabradine reduces the raised heart rates seen in patients with heart failure and has also 
been shown to improve outcomes.11 Diuretic medications are used in patients with 
symptoms and/or signs of congestion and in conjunction with the above medications 
that have been shown to improve prognosis.11 
 
In addition to optimal pharmacotherapy, cardiac implantable electronic devices (CIEDs) 
for certain patient groups have shown an incremental mortality reduction at two years 
follow-up.28  
 
1.1.4 Cardiac resynchronisation therapy for heart failure 
In 1995, Cazeau et al. described the first use of biventricular (BiV) pacing for a patient 
with heart failure.29 This rapidly evolved into CRT as a treatment for selected patients 
with heart failure. Delivering continuous electrical impulses to both ventricles has been 
shown to restore electromechanical dyssynchrony and improve cardiac output. In 
certain groups of patients with heart failure (Table 1-3), CRT has been shown to improve 
both symptoms and quality of life,11,30 as well as reduce morbidity and mortality.4,31–33 
It remains unclear whether CRT reduces the arrhythmia burden in heart failure patients, 
thereby reducing the need for an ICD.11 Similarly, it is currently uncertain if CRT offers 
incremental benefit to an ICD by reducing mortality rates from deteriorating heart 




Table 1-3: Indications for CRT 
 
Reproduced with permission from Ponikowski et al 201611 
 
‘SR: sinus rhythm, AF: atrial fibrillation, Sx: symptoms, OMT: optimal medication therapy, LVEF: left 
ventricular ejection fraction, NYHA: New York Heart Association grade of symptoms, BVp: biventricular 
pacing, LBBB: left bundle branch block, IVamb: NYHA class IV ambulatory, RVp: right ventricular pacing, 
PPM: permanent pacemaker, ICD: internal cardiac defibrillator, HF: heart failure. *recent change to 
European heart failure guidelines in August 2016.11 
 
The COMPANION32 and CARE-HF trials4,34 demonstrated the advantages of CRT 
compared to optimised medical therapy alone. However, not all patients respond to CRT 
as well as others.11,30 One of the most important mechanisms of action of CRT is reverse 
remodelling which is likely to underpin the improvements in morbidity and mortality.11 
Ischaemic cardiomyopathy (ICM) is frequently associated with LV scar (myocardial 
fibrosis) which may be subendocardial or transmural and less likely to undergo 
significant reverse remodelling.11,35 
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Patients with true left bundle branch block (LBBB) morphology are more likely to 
respond favourably to CRT, compared to non-LBBB morphology.11 However, this may 
reflect the fact that patients with LBBB morphology typically have longer QRS durations 
and whether this or QRS morphology is the main driver of a favourable response to CRT 
remains to be decided.11 
 
Chronic right ventricular (RV) pacing in the setting of impaired LV systolic function may 
worsen cardiac dyssynchrony and is an important consideration for all patients receiving 
a CIED as well those with pre-existing devices. This may be prevented by CRT and lead 
to improved patient outcomes.36–39 However the evidence remains uncertain and given 
this is an increasingly common conundrum when treating patients with heart failure, 




This section has been adapted from Chronic Right Ventricular Pacing in the Heart Failure 
Population.40 
1.2 Improving the outcomes of chronic right ventricular 
pacing in the heart failure population 
 
1.2.1 Introduction 
Right ventricular (RV) pacing is an important and effective treatment in patients with 
atrioventricular (AV) block. RV pacing restores the heart rate to a pre-determined rate 
however, a high RV apical pacing percentage/burden may promote left ventricular 
systolic dysfunction (LVSD).41–49 Alternative RV pacing sites have been explored to 
combat this problem as well as investigating CRT in patients with AV block with mild to 
severe heart failure. CRT is an effective therapy to improve symptoms and reduce 
mortality in patients with dyssynchronous heart failure.50 CRT has consistently 
demonstrated benefit in treating patients with systolic heart failure and interventricular 
conduction delay, typically with LBBB.4,32,51 However, numerous trials have used 
moderate and high degree AV block in their exclusion criteria to independently evaluate 
the effects of CRT without the potential cofounding detrimental effects of RV pacing.37 
Notwithstanding, several studies have demonstrated the deleterious effects of RV apical 
pacing and therefore alternative RV pacing sites have been explored as well as using CRT 
for patients with narrow QRS and/or mild to moderate heart failure in patients who are 
predicted to require a significant amount of RV pacing.52 In the present review, we 
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review the trials that have demonstrated potentially harmful effects from RV apical 
pacing as well as reviewing the evidence of alternative RV pacing sites and CRT for 
patients who have heart failure and AV bock (Block HF and BioPace trials). 
 
1.2.2 Chronic Right Ventricular Pacing and its Deleterious Effects 
Single or dual chamber RV pacing is the mainstay of treatment for symptomatic AV 
block. However, there is increasing evidence of potential adverse effects with chronic 
RV apical pacing secondary to mechanical and electrical dyssynchrony.53,54 The 
detrimental effects from chronic RV pacing including the manifestation of heart failure, 
adverse LV remodelling and LVSD have repeatedly been reported.41–49 These include a 
wide array of structural changes incorporating left atrial and LV remodelling, LV wall 
thickness and functional mitral regurgitation.55–58 In patients with complete AV block, 
both cellular and intracellular changes have been described including degenerative 
fibrosis.59 The Dual Chamber and Implantable Defibrillator (DAVID) Trial enrolled 
patients undergoing ICD implantation without bradycardia or AV block and randomized 
them to either DDD pacing at 70 beats/min or VVI backup pacing at 40 beats/min. The 
DAVID trial identified significantly more heart failure and cardiovascular events in the 
DDD group with a higher percentage of RV apical pacing.45 Similarly, the Mode Selection 
Trial (MOST) demonstrated that RV apical pacing may lead to heart failure, however, the 
loss of AV synchrony itself was shown to probably be less important. The MOST 
investigators found a significantly increased risk of heart failure events in both single 
and dual chamber pacing modes, with a threshold for adverse outcomes with an RV 
pacing percentage greater than 40%.52,60 The Multicenter Automated Defibrillator 
Implantation Trial (MADIT II) randomized patients with ischemic cardiomyopathy and 
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LVEF ≤30 % to ICD therapy versus (vs.) conventional medical therapy. MADIT II showed 
that ICD therapy reduced total mortality.61 A subsequent subanalysis showed that 
patients with a high RV pacing percentage had a significantly increased risk of new or 
worsening heart failure.61,62 The potentially harmful effects of long-term RV pacing may 
occur in patients with both preserved and reduced LV systolic function, however, they 
are more prominent in patients with a reduced LVEF at baseline. The true incidence of 
LV remodelling secondary to RV apical pacing is not known, however, it is widely 
recognized to occur where RV pacing is >40 % of the time.60 However, there are some 
pacing dependent patients who have 100% RV pacing who do not develop LV 
dysfunction for reasons that are unknown.63 
 
1.2.3 Pathophysiology of the Detrimental Effects of Right Ventricular 
Pacing 
Several clinical studies have established the potential adverse effects of chronic RV 
pacing on LV function. The exact pathophysiological process underpinning the 
deleterious effects from chronic RV pacing is not clear. RV apical pacing may have 
adverse effects on haemodynamics, remodelling, mechanical function, myocardial 
metabolism and perfusion due to mechanical and electrical dyssynchrony.52,64,65 An 
LBBB-type pattern is widely recognised to develop immediately following RV apical 
pacing. Early activation of the RV apex subsequently causes mechanical dyssynchrony as 
well as increasing early systolic shortening which results in pre-stretch of the late-
activated regions and subsequent premature relaxation.52,66,67 As a result, changes in LV 
mechanical and electrical activation due to RV apical pacing may lead to a decrease in 
cardiac output as well as intraventricular and interventricular dyssynchrony resulting in 
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LVSD. This has been demonstrated in a number of studies using doppler and strain 
analysis on two-dimensional (2D) and three-dimensional (3D) transthoracic 
echocardiogram (TTE).48,52,64,65,67–71 In addition, reduced ventricular diastole and 
increased ventricular systole may lead to reduced coronary perfusion.52 Interestingly, 
with chronic RV apical pacing, up to 65% of patients have been found to have myocardial 
perfusion defects in the pacing region in the absence of flow-limiting coronary artery 
disease.72–74 
 
1.2.4 Alternate Right Ventricular Pacing Sites 
The advent and safety of active fixation leads has facilitated the exploration of 
alternatives to the traditional apical RV pacing site. However, using other RV pacing sites 
such as RV outflow tract and septal pacing on their own, may not be sufficient to 
circumvent the detrimental effects of chronic RV pacing. This might be explained by 
technical difficulties with lead placement as well as no clear evidence of superiority of 
RV high septal pacing, not to mention evidence of worsening LVEF with any RV pacing 
site.52 The PROTECT-PACE study randomized 240 patients with high-grade AV block 
requiring >90% ventricular pacing and preserved baseline LVEF >50%, to receive pacing 
at the right ventricular apex (RVA) (n = 120) or right ventricular high septum (RVHS) (n = 
120). At 2 years, LVEF decreased in both the RVA (57 ± 9 to 55 ± 9%, P = 0.047) and the 
RVHS groups (56 ± 10 to 54 ± 10%, P = 0.0003).75 However, there was no significant 
difference in intra-patient change in LVEF between confirmed RVA and RVHS lead 
position (P = 0.43).75 Similarly, there were no significant differences in heart failure 
hospitalization, mortality, burden of atrial fibrillation, or plasma brain natriuretic 
peptide levels between the two groups.75 A significantly greater time was required to 
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place the lead in the RVHS position (70 ± 25 vs. 56 ± 24 min, P < 0.0001) with longer 
fluoroscopy times (11 ± 7 vs. 5 ± 4 min, P < 0.0001). The authors concluded that in 
patients with high-grade AV block and preserved LV function requiring a high percentage 
of ventricular pacing, RVHS pacing does not provide a protective effect on LV function 
over RVA pacing in the first 2 years.75 
 
His bundle pacing (HBP) is an alternative way to perform bradycardia pacing. The His-
Purkinje conduction system allows the impulse generated by the sinoatrial node to 
rapidly propagate into both right and left ventricles which facilitates synchronized 
ventricular contraction. Early studies demonstrated distal HBP was able to normalize 
bundle branch block and QRS morphology.76 The first successful series of permanent 
direct HBP was performed in 18 patients with atrial fibrillation (AF) and dilated 
cardiomyopathy in 2000 where the investigators found improvements in LV dimensions 
and cardiac function.77 HBP may provide physiological activation thereby avoiding 
ventricular dyssynchrony and preserving LV systolic function in patients with a narrow 
QRS duration and several studies have suggested a potential beneficial effect over RV 
pacing.78–82 HBP may therefore be a way to avoid the potential deleterious effects of RV 
pacing, however, further randomized studies including The His Optimised Pacing 
Evaluated for Heart Failure (HOPE-HF) trial will be important in determining this. 
 
38 
Table 1-4: CRT versus right ventricular pacing trials in patients requiring bradycardia 
pacing 
Study n Inclusion Criteria Treatment Follow-up End Point Results 
PAVE 
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Study n Inclusion Criteria Treatment Follow-up End Point Results 
BLOCK HF 
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691 AV block 1st -3rd 
HF NYHA I-III 
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primary end 
point: time to 
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cause, urgent 
care visit for 
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apical & septal lead 
position (P = 0.43). 
 
Reproduced with permission, Gould et al. (2017)88 
 
Abbreviations 
HF = heart failure, LVEDV = left ventricular end-diastolic volume, CRT = cardiac resynchronisation therapy, 
RV = right ventricular, AF = atrial fibrillation, CI = confidence interval, SND = sinus node dysfunction, QoL 
= quality of life, AV = atrioventricular, LVESV = left ventricular end-systolic volume, HR = hazard ratio. 
 
There have been several studies examining CRT-based approaches to avoid the 
detrimental effects of apical RV pacing in patients with AV block and normal, mild or 
moderate LVEF. PACE, PREVENT HF and BLOCK HF have all directly compared CRT with 
RV pacing in patients with an indication for bradycardia pacing who were likely to 
require a high percentage of RV pacing (Table 1-4). These studies recruited patients in 
both sinus rhythm and AF. CRT has been shown to have advantages over RV pacing in 
four randomised clinical trials.36–38,89,90 There have also been smaller trials that have 
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demonstrated an advantage of CRT pacing over RV pacing.70,85,86 However, both BioPace 
and PREVENT HF have not been able to demonstrate a statistically significant benefit of 
CRT pacing over RV pacing in similar cohorts.83,87,91 All other trials included in Table 1-4 
have shown CRT pacing to favour over RV pacing, irrespective of NYHA class, baseline LV 
systolic function, degree of reverse remodelling or QRS duration.63 
 
The Pacing to Avoid Cardiac Enlargement (PACE) trial was a prospective, double-blinded, 
randomized, multicentre study where patients with bradycardia and preserved LVEF 
were randomized to receive CRT (n = 89) or RV apical pacing (n = 88).84 Co-primary 
endpoints were LVEF and left ventricular end-systolic volume (LVESV) measured by 2D 
TTE. Patients were followed-up with a mean duration of 4.8 ± 1.5 years (2.5 – 7.8 years) 
and analyses of the primary endpoint were performed in 146 patients (CRT group n = 
72, RV apical pacing group n = 74). The LVESV and LVEF remained unchanged in the CRT 
group whereas in the RV apical pacing group, not only did the LVEF decrease, the LVESV 
also increased progressively at follow-up.84 The differences in LVEF between the RV 
apical pacing and CRT pacing groups were –6.3% at 1 year, –9.2% at 2 years and –10.7% 
at long-term follow-up (all P < 0.001). The corresponding differences in LVESV were +7.4 
millilitres (mL) at 1 year, +9.9mL at 2 years and +13.1 mL at long-term follow-up 
(all P < 0.001).84 In addition, the detrimental effects of RV apical pacing consistently 
occurred in all pre-defined subgroups (age groups, gender, QRS duration, pre-existing 
LV diastolic dysfunction, as well as pre-existing diabetes, hypertension and coronary 
artery disease). Patients in the PACE trial with RV apical pacing had a significantly higher 
prevalence of heart failure hospitalization than the CRT group (23.9% vs. 14.6%, log-rank 
χ2 = 7.55, P = 0.006).84 The authors concluded that CRT was superior to RV apical pacing 
in the prevention of LV adverse remodelling and reduction of LVEF at 1 and 2 years 
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follow-up. The Homburg Biventricular Pacing Evaluation (HOBIPACE) and the 
Conventional Versus CRT Pacing in Heart Failure and Bradyarrhythmia Therapy 
(COMBAT) studies were both small randomized studies that found CRT pacing superior 
to conventional RV apical pacing in terms of improvement in quality of life, exercise 
capacity and LVEF as well as reduction in LV volumes.49,85,86 HOBIPACE was a prospective, 
randomized crossover study where 30 patients, who had AV block, LVSD defined by an 
left ventricular end-diastolic diameter (LVEDD) ≥60 mm and an LVEF ≤40% with NYHA II-
IV, were randomized to three months of RV pacing then three months of CRT pacing or 
vice-versa.  
  
The COMBAT trial was a prospective, multicentre, randomized, double blind crossover 
study that enrolled 60 patients with pacing indications for AV block with an LVEF <40% 
and NYHA class II-IV for a mean follow-up period of 17.5 ± 10.7 months. All patients 
underwent CRT device implantation and were randomized to two groups and received 
the following for 3 months: Group A received RV pacing-CRT pacing-RV pacing and group 
B received CRT pacing-RV pacing-CRT pacing. There were significant improvements in 
LVEF, LVESV, NYHA class and quality of life questionnaire scores in the CRT group 
compared to the RV pacing group. Death was more frequent with RV pacing, however, 
six-minute walk test (6MWT) distance and VO2max were not significantly different 




1.2.5 BLOCK-HF and BioPace Studies 
To date the most significant study to assess the benefits of CRT over RV pacing is the 
Biventricular versus Right Ventricular Pacing in Heart Failure Patients with 
Atrioventricular Block (BLOCK HF) trial. This was a large, multicentre, double-blind 
randomized study that assessed whether CRT reduced adverse LV remodelling, 
morbidity and mortality in patients with AV block with a standard class I or IIa indication 
for ventricular pacing, NYHA I-III class heart failure and LVEF ≤50%.37 Patients received 
a cardiac resynchronisation therapy pacemaker (CRT-P) unless they had an indication 
for defibrillation therapy in which case they received a CRT implantable cardioverter-
defibrillator (CRT-D) and were randomized to receive either CRT pacing or standard RV 
pacing. Patients with standard indications for CRT, based on the guidelines during the 
recruitment phase, were excluded from recruitment as were patients with recent or 
acute myocardial infarction, unstable angina, percutaneous or surgical coronary 
revascularization within 30 days or severe valvular heart disease with an indication for 
repair or replacement.37,52 The primary outcome was time to death from any cause, 
≥15% increase in LVESV index or an urgent care visit for heart failure that required 
intravenous therapy. 918 patients were enrolled, but only 691 patients underwent 
randomization in a 1:1 ratio. Patients were followed-up every 3 months with a mean 
follow-up duration of 37 months. The primary outcome occurred in 190 of 342 patients 
(55.6 %) in the RV pacing group and 160 of 349 (45.8 %) in the CRT group (hazard ratio, 
0.74; 95% credible interval, 0.60 to 0.90). with a posterior probability of a hazard ratio 
<1 was 0.9978, exceeding the threshold of 0.9775 for a significant different between the 
two groups Figure 1-3.37 Similar findings were noted in patients receiving a CRT-P or CRT-
D. Removing the echocardiographic volumetric indices from the analysis, death from 
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any cause or an urgent care visit for heart failure still showed a significant difference in 
favour of CRT pacing compared to RV pacing with a hazard ratio of 0.73 (95 % credible 
interval, 0.57 to 0.92).37,52 Of note, 6.4% of patients had a complication documented 
secondary to LV lead implantation. A subsequent sub-study of BLOCK HF demonstrated 
reverse remodelling within the CRT group using 2D TTE, where CRT pacing significantly 
reduced intraventricular mechanical delay and LV volume indices along with 
improvement in LVEF compared to RV pacing, all indicating LV revere remodelling. The 
risk of morbidity and mortality was estimated to increase by up to 1% for every 1mL/m2 
increase in LVESV index, suggesting LVESV index may be predictive of morbidity and 
mortality.92 The main limitation of BLOCK HF was a high crossover rate from the RV 
pacing group to CRT group as well a reasonably large amount of missing 2D TTE data.  
 
 
Reproduced with permission, Curtis et al. (2013)37, Copyright Massachusetts Medical Society 
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Figure 1-3: Freedom from composite primary endpoint (time to death from any cause, 
≥15% increase in LVESV index or an urgent care visit for heart failure that required 
intravenous therapy) in the BLOCK HF Trial. 
 
The preliminary results of the Biventricular Pacing for Atrioventricular Block to Prevent 
Cardiac Desynchronisation (BioPace) trial were announced in 2014.87,91 BioPace was a 
multicentre, randomized, single-blind study conducted in Europe and aimed to 
investigate the hypothesis that CRT pacing is superior to RV pacing in patients with AV 
block requiring permanent ventricular pacing. The combined primary end point was first 
hospitalization secondary to heart failure or time to death. Main inclusion criteria were 
patients with an indication for implantation of a ventricular pacemaker according to 
European Society of Cardiology (ESC) guidelines and an anticipated need for frequent 
ventricular pacing with any LVEF as measured by TTE. Patients with first, second and 
third AV block were enrolled. For first degree AV block, the defining PR interval was ≥220 
milliseconds (ms) with an indication for pacing. Patients with permanent AF were also 
included providing their spontaneous ventricular rate was ≤60 beats per min at rest. 
1810 patients were recruited and 902 patients were assigned to the CRT group and 908 
to the RV pacing group. The patient demographics were largely similar to BLOCK HF 
except the average LVEF in BioPace was 55% compared to approximately 40% in Block 
HF. The preliminary results from BioPace showed no statistically significant difference 
between CRT pacing and RV pacing for first hospitalization secondary to heart failure or 
time to death. However, there was a non-significant trend in favour of CRT pacing versus 
RV pacing. Additional analyses might identify subgroups of patients where CRT pacing 
shows a clear and statistically significant benefit. Interestingly, LVEF did not seem to 
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have any influence on the combined primary outcome as the results were similar for 
LVEF ≤50% versus >50%. It is not immediately obvious why the BioPace study results 
differed to BLOCK HF, however, different patient demographics are likely to have played 
a role. Furthermore, patients in the BLOCK HF trial had a greater number of patients 
with LBBB (total 32.6%, CRT pacing group 35.2%, RV pacing group 29.8%) compared to 
BioPace (total 17.2%, CRT group 16.6%, RV group 18.3%) and lower LVEF, possibly 
indicating a cohort with more severe heart failure. Furthermore, AF is a recognised 
marker for underlying morbidity and again more patients in the BLOCK HF trial had AF 
(total 52.8%, CRT group 51.6%, RV group 54.1%) versus BioPace (total 24.9%, CRT group 
24.9%, RV group 24.8%) indicating the higher morbidity in the BLOCK HF cohort. The 
long-awaited final published results from the BioPace investigators may help to better 
understand the results and differences to the BLOCK HF trial. 
 
 
1.2.6 The Role of CRT in Patients with Atrial Fibrillation Undergoing AV 
Node Ablation 
There have been several studies that have demonstrated better outcomes with CRT 
followed by AV node ablation than RV pacing in patients with symptomatic AF with rapid 
ventricular response.36,38,39,93,94 In 2012, a meta-analysis of the aforementioned studies 
as well as two other similar studies found CRT pacing was associated with a significant 
reduction in hospitalizations for heart failure (RR= 0.38, 95%CI = 0.17–0.85; P = 0.02). 
Moreover, they established a non-significant reduction in mortality compared to RV 
pacing (RR= 0.75, 95 % CI = 0.43–1.30; P = 0.30).39 Conversely, there was no significant 
difference in MLWHFQ Score or 6MWT distance between CRT and RV pacing groups. In 
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2010, Orlov et al. randomized 153 patients in a single-blinded trial and revealed a 
significant increase improvement in LVEF in the CRT pacing group, however, in the RV 
pacing group there was a non-significant reduction in LVEF.94 Similarly, Brignole et al. 
conducted a prospective, multicentre study (The Ablate and Pace in AF Trial) and 
randomized 186 patients who had undergone CRT device implantation and AV node 
ablation to receive either CRT (n=97) with V-V interval optimization or RV apical pacing. 
Baseline demographics were similar to the PAVE study and follow-up was a median of 
20 months (interquartile range 11-24). The primary composite endpoint of death from 
heart failure, hospitalization due to heart failure, or worsening heart failure occurred in 
11% patients in the CRT group and 26% patients in the RV group [CRT vs. RV group: sub-
hazard ratio (SHR) 0.37 (95% CI 0.18-0.73), P = 0.005].38 Fewer patients had worsening 
heart failure in the CRT group compared to the RV group [SHR 0.27 (95% CI 0.12-0.58), 
P = 0.001] and fewer hospitalizations for heart failure [SHR 0.20 (95% CI 0.06-0.72), P = 
0.013].38 There was, however, no significant difference in total mortality, although the 
authors concluded that CRT was superior to RV apical pacing in reducing the clinical 
manifestations of heart failure in patients requiring an AV node ablation for 
symptomatic AF.38 The Left Ventricular-Based Cardiac Stimulation Post AV Nodal 
Ablation Evaluation (The PAVE study) was a prospective randomized controlled study 
that compared CRT pacing with RV pacing in 184 patients with NYHA functional class I 
to III heart failure (baseline LVEF 45% ± 15% in the CRT group vs. 47% ± 16% in the RV 
group) undergoing an AV node ablation for AF refractory to pharmacotherapy.36 
Patients undergoing ICD implantation were excluded. The PAVE study showed that 
patients randomized to CRT (n=103) had significant improvements in LVEF and 6MWT 
but not in quality of life parameters compared to the RV paced group. At 6 months post 
ablation, patients treated with CRT had a significant degree of improvement in 6MWT, 
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31% above baseline (82.9 ± 94.7 m), compared to patients receiving RV pacing, 24% 
above baseline (61.2 ± 90.0 m) (P = 0.04).36 At 6 months post ablation, the LVEF in the 
CRT group (46%±13%) was significantly greater in comparison to the RV pacing group 
(41% ± 13%, p = 0.03).36 The LVEF remained stable for patients in the CRT group whereas 
in the RV pacing group, the LVEF deteriorated by 3.1% at 6 weeks (p = 0.04) and 3.7% at 
6 months (p = 0.03).36 He authors concluded that CRT provided a significant 
improvement in 6MWT distance and LVEF compared to RV pacing in patients undergoing 
AV node ablation for AF. Furthermore, patients with LV systolic impairment or 
symptomatic heart failure derived the greatest benefit from CRT pacing.36 
 
BLOCK HF was a landmark United States-based trial that revealed encouraging evidence 
that improved outcomes may be achieved with CRT pacing compared to RV apical pacing 
in patients with LVSD and AV block when a high percentage of RV pacing is anticipated. 
49,52 As a result, in 2014 the United States Food and Drug Administration approved the 
use of CRT in patients with AV block associated with a high percentage of ventricular 
pacing, mild to moderate heart failure and LVEF ≤50%.95 In 2016, the ESC guidelines for 
the diagnosis and treatment of acute and chronic heart failure were updated 
recommending CRT over RV pacing for patients with high degree AV block, heart failure 
with reduced ejection fraction (HFrEF) and NYHA I-IV functional class in order to reduce 
morbidity (1A evidence, Table 1-5).11 Patients with AF were included in this guidance. 
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Table 1-5: Summary of 2016 ESC Guidelines for the Diagnosis and Treatment of Acute 
and Chronic Heart Failure Relating to CRT and RV Pacing in Patients with High Degree 
AV Block 
ESC Recommendation Class Level 
CRT is recommended over RV pacing for patients in sinus rhythm or AF, with 
HFrEF of any NYHA functional class, who have an indication for ventricular 
pacing and high degree AV block, in order to reduce morbidity. 
I A 
CRT is recommended over RV pacing in patients with HFrEF who require pacing 
with a high degree of AV block. 
I A 
Pacing modes that avoid inducing or worsening ventricular dyssynchrony should 
be considered for patients with HFrEF who require ventricular pacing without 
high degree AV block. 
IIa C 
 
Adapted from ESC 2016 Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure 11 
 
Abbreviations 
ESC = European Society of Cardiology, CRT = Cardiac Resynchronisation Therapy, HFrEF = Heart failure 
with reduced ejection fraction, NYHA = New York Heart Association, AV = Atrioventricular, RV = Right 
ventricular 
 
1.2.7 Conclusions on chronic RV pacing in the heart failure population 
The role of CRT pacing in patients with AV block and impaired LV systolic function 
remains an important consideration. The BLOCK HF trial demonstrated better outcomes 
with CRT pacing over RV pacing in patients with LVSD and AV block in patients expected 
to have a high RV pacing burden. However, BLOCK HF failed to demonstrate any 
mortality benefit. The preliminary results of the European-based BioPace trial have not 
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confirmed the same statistically significant benefit, although we are still awaiting the 
full results to be published. In the interim, CRT pacing seems to have a beneficial effect 
on LV reverse remodelling, systolic function and clinical outcomes in patients with NYHA 
functional class I-III heart failure, moderate to severe LVSD and AV block compared to 
RV pacing. However, it is less clear whether there is a similar benefit from CRT in patients 
with a high percentage of RV pacing who have normal or mild LVSD in the treatment of 
AV block.  
  
50 
1.3 Evaluating CRT response 
CRT has been in clinical use now for over 20 years and is an excellent treatment for 
certain groups of patients with heart failure. However, a significant proportion of 
patients still fail to improve,96 which has unfortunately remained static despite 
significant advances in technique and technology. CRT non-response therefore remains 
a significant problem in the treatment of heart failure5,97,98 and its prevalence is 
summarised in Figure 1-4.  
 
 
Reproduced with permission from Daubert et al., 2012.96  
Figure 1-4: Prevalence of CRT non-response 
‘Non-response (y axis, %) amongst clinical studies (x axis, first author, year). Hard outcome measures 
(blue): mortality and heart failure hospitalisation. Remodelling measures (red): use of reductions in LVESV 
on echocardiography. Soft clinical function measures (green): 6-minute walking distance and clinical 
scoring questionnaires. Clinical composite measures (purple): for example, Packer’s clinical scoring 
system.’96 
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There also remains a lack of consensus on how best to define and measure CRT 
response,99 and several approaches have been used including both subjective and 
objective metrics: 
 
• Subjective – patient quality of life questionnaires.8 
• Mixed subjective and objective – clinical composite score 
• Objective - echocardiographic remodelling,100 including reduction in LV end systolic 
volume (LVESV) by >15% compared with baseline. 
• Objective - VO2 max using cardiopulmonary exercise testing. 
• Objective - Heart failure hospitalization, all-cause mortality, cardiovascular mortality 
and the composite endpoint, major adverse cardiovascular events (MACE). 
 
Approximately 30-50% of patients undergoing CRT fail to derive any benefit, depending 
on heart failure aetiology and the metric used to evaluate response.5 In addition, over 
40% of patients undergoing CRT show no objective evidence of ventricular reverse 
remodelling.5,97,101–103 Poor patient selection, suboptimal LV lead positioning and 
insufficient delivery of CRT are important causes of CRT non-response.104–106 In addition, 
disease aetiology107–113; pattern of dyssynchrony 112–115; patient selection5,97,116; site of 
LV stimulation 6,103,117–122; and device programming102,103,123,124 have been identified as 
predisposing factors of CRT non-response. Figure 1-5 summarises some of the important 
causes of CRT non-response. LV scar may also reduce the reverse remodelling potential 
with CRT and patients with ischaemic cardiomyopathy show less improvement in LV 
ejection fraction (LVEF) than those with dilated cardiomyopathy.5 Suboptimal LV lead 
position has been reported to occur in 21% of cases and may be lead to poor patient 
outcomes.103,125,126 The posterolateral and lateral coronary veins have been shown to 
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best correlate with later electrical activation and improvement in echocardiographic 
volumetric measures compared to septal or anterior LV lead positions.6,118,120,121,127,128 
However, due to variations in coronary venous anatomy, using coronary veins to assess 
optimal LV lead placement may not be ideal.103,122 Furthermore, LV scar location and its 
relationship to electromechanical delay also need to be considered.103,122 Patterns of 
electrical activation also differ between ischaemic and non-ischaemic cardiomyopathies 
and therefore, heart failure aetiology may play a role in optimal LV lead positioning.129 
 
 
Reproduced with permission from Mullens et al., 2009.103 
Figure 1-5: Causes of CRT non response in a group of 75 patients. 
 
Left ventricular reverse remodelling has previously been shown to be a robust predictor 
of cardiovascular clinical outcomes in numerous heart failure landmark trials for the use 
of ACEI and beta-blockers.1,130,131 Additionally, mortality reduction is predicted by LV 
reverse remodelling rather than clinical improvement measures and hence 
echocardiographic volumetric assessments are often used in studies evaluating 
53 
techniques to improve CRT response.132 However, quantifying LV reverse remodelling 
using echocardiographic volumetric assessments has a sensitivity and specificity of 
approximately 70% which implies that up to a third are incorrectly classified.133 
However, these limitations have been considered acceptable and have been adopted as 
the benchmark metric for evaluating volumetric response in many important CRT 
trials.4,134–136  
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1.4 Strategies to improve CRT delivery 
In the modern era of advancing medical technology and imaging, it is important to 
ensure that the basics are still considered when assessing patients for CRT and later in 
ensuring maximum CRT capability is achieved once implanted with a CRT device. 
Ensuring patients meet CRT guideline inclusion criteria11,137 is important, although there 
will be cases where clinicians need to deviate from such guidelines when treating 
patients with heart failure. Notably, the EchoCRT trial demonstrated that patients with 
a relatively narrow QRS duration <130ms on surface electrocardiogram (ECG), despite 
having objective evidence of mechanical dyssynchrony on 2D-echocardiography, had 
significantly higher rates of all-cause mortality in those with CRT turned on compared to 
those who had CRT turned off.35,138 In addition, successful deployment of the LV lead to 
a stable and lateral position with a good capture threshold and absence of phrenic nerve 
stimulation is of paramount importance for all CRT procedures. Occasionally, complex 
coronary venous anatomy and/or extensive scar dictate transvenous epicardial LV lead 
positioning and pre-procedural cardiac computed tomography (CT) or magnetic 
resonance imaging (MRI) may help plan for such technical challenges and potentially 
inform a different CRT delivery strategy e.g. surgical epicardial LV lead placement, His 
bundle pacing or endocardial LV lead implantation using the wireless stimulation 
endocardially (WiSE) CRT system (EBR systems, Sunnyvale, CA, USA). These same 
techniques may also be considered for patients that have not responded to conventional 
CRT. Follow-up of CRT patients is equally important to optimise heart failure 
pharmacotherapy as well CRT. Ensuring patients have any causes of suboptimal 
biventricular pacing (<95%) e.g. ventricular ectopy or atrial tachyarrhythmias addressed 
is paramount. Echo and/or ECG guided optimisation of atrioventricular and/or 
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ventriculo-ventricular intervals after CRT implantation remains uncertain but may be 
considered when patients have a poor response to CRT11,139,140 Minimising shocks from 
CRT-defibrillators (CRT-Ds) as well optimizing battery longevity are other important 
areas to address during CRT follow-up assessments. 
 
There are also a number of advanced strategies including multimodality imaging, 
multisite pacing, multipoint pacing, acute haemodynamics, electrical parameters and 
mapping that have been trialled to optimise LV lead delivery and allow operators to 
place transvenous LV leads in locations that aim to optimise mechanical and electrical 
synchrony and ultimately CRT response.141 
 
This thesis will now focus on the potential roles of image guidance and multipoint LV 
pacing in targeting areas of dyssynchrony and avoiding LV scar. 
 
1.4.1 The rationale for targeting dyssynchrony  
The basis for targeting dyssynchrony lies in the electrical disruption and electrical 
slowing of myocardial conduction that occurs in heart failure, leading to interventricular 
delay typically observed as LBBB on a 12-lead surface ECG.142 This frequently results in 
poor interventricular coordination and inefficient contraction culminating in reduced 
cardiac output143 and progressive left ventricular dilatation.50 Re-establishing electrical 
and mechanical synchronous contraction is thought to be the mechanism by which CRT 
works.29 Whilst QRS prolongation on the 12-lead surface ECG reflects electrical 
dyssynchrony, it does not always parallel mechanical dyssynchrony.112,144 Furthermore, 
56 
it is possible to have mechanical dyssynchrony both with a normal QRS duration <120ms 
and preserved LV systolic function.145 
1.4.2 The rational for avoiding left ventricular scar 
It is widely recognised that patients with extensive LV scar have less improvement in LV 
systolic function with CRT, however, this is also true when they are treated with 
pharmacotherapy and does not reliably predict less clinical benefit.11,146 Moreover, 
there is little evidence that they obtain less prognostic benefit from CRT despite having 
an intrinsically worse prognosis.11,33 
 
High lead pacing thresholds occur in scarred myocardium and hence should be avoided 
where possible to preserve battery life and reduce the chance of phrenic nerve 
stimulation.11,125,126 There is also a concern that pacing in scarred regions of the LV may 
promote ventricular tachyarrhythmias and worsen prognosis,147–150 although this may 
be improved with catheter ablation.151 It is therefore this group of patients that are likely 
to gain the most from an image guided approach that may help avoid LV scar and place 
the LV lead in the region of latest mechanical activation outside of scar. 
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1.5 Image guidance for CRT 
Multimodality cardiac imaging has often been used to identify patients most likely to 
respond to CRT.112,113,152 More recently, pre-procedural LV target selection as well as 
real-time image overlay guidance have been explored in order to help operators target 
areas of latest mechanical and/or electrical activation i.e. areas of dyssynchrony and 
avoid regions of LV scar in order to achieve the most optimal LV lead position for the 
delivery of CRT.153–156 
 
1.5.1 Echocardiography to guide LV lead implantation 
Two-dimensional echocardiography has been integral in selecting suitable patients for 
CRT as well as monitoring their progress. It has also been used to predict which patients 
are most likely to respond CRT by evaluating dyssynchrony. Numerous techniques and 
metrics have been the focus of research studies for the last 20 years including 2D 
echocardiography, 3D echocardiography, tissue doppler imaging and speckle 
tracking.104,112,113,152 Speckle tracking echocardiography has been used in two important 
image guided trials; The TARGET125 and STARTER157 trials. These single centre 
randomised controlled studies both identified target segments based on speckle 
tracking indices to identify areas of latest mechanical activation for LV lead delivery. 
Both studies concluded that speckle tracking image guidance leads to significantly 
improved CRT response outcomes compared to standard CRT implantation. However, 
both studies most likely excluded LV scarred segments on the basis of wall thickness 
and/or low amplitude strain curves and therefore the final pacing target was frequently 
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remote from LV scar. It is therefore plausible that targeting late mechanical 
dyssynchrony may represent a surrogate for avoiding myocardial scar. 
 
3D echocardiography potentially allows for a more comprehensive and true 
representative assessment of ventricular dyssynchrony and can account for out of plane 
movement of myocardial segments throughout ventricular systole and diastole. 
However, despite advances in both 2D and 3D echocardiography, a distinct and 
reproducible predictor of dyssynchrony and CRT response has not yet been identified 
which may be related to inter-operator variability and suboptimal echocardiographic 
windows for accurate dyssynchrony quantification. Finally, echocardiography is only 
able to infer scarred regions of the LV using certain criteria including myocardial wall 
thinning (<6mm) on 2D echocardiography158 and absence of contractile reserve during 
dobutamine stress echocardiography159 Whilst these surrogate markers for LV scar may 
help predict CRT response, echocardiography cannot provide direct visualisation and 
quantification of LV scar tissue that is possible with myocardial perfusion imaging, 
cardiac magnetic resonance (CMR), and increasingly with cardiac CT. 
 
1.5.2 Myocardial perfusion imaging to guide LV lead implantation 
Faucheir et al. (2002) described the early assessment of LV contraction timing using 
phase analysis.160 More recently, the integration of single photon emission CT with 
nuclear perfusion imaging has allowed 3D assessment of regional LV motion.161,162 
Myocardial perfusion imaging has been shown to reliably assess regional 
dyssynchrony.163 It also offers robust myocardial substrate imaging, especially in terms 
of LV function and scar burden evaluation, the latter of which has been shown to 
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correlate with less LV reverse remodelling,164 in keeping with that seen with late 
gadolinium enhancement (LGE) imaging with CMR.165 Furthermore, myocardial 
perfusion has been beneficial in predicting CRT response,161,162,166 however, high 
radiation doses are likely to limit its widespread use, including with regards to image 
guidance for CRT compared with other techniques. 
 
1.5.3 Cardiac magnetic resonance to guide LV lead implantation 
Cardiac magnetic resonance is an advanced cross-sectional imaging modality that offers 
superior spatial resolution, accurate endocardial border definition and suffers less from 
operator/analyser variability compared to echocardiography.167 It’s temporal resolution 
is acceptable but inferior to echocardiography. Excellent anatomical and functional 
images are readily achievable in the majority of patients using steady state free 
precession (SSFP) sequences. Functional imaging data can be readily used to quantify 
dyssynchrony using tissue tracking algorithms similar to those used in echocardiography 
and calculate both regional and global dyssynchrony scores.  
 
Simonetti et al (2001)168 described the early use of CMR to detect ventricular scar using 
LGE sequences which has evolved into the current gold standard for assessing 
myocardial fibrosis (scar).169,170 LV scar burden and location relative to LV lead 
placement are important factors in determining CRT response.165,171–173 reported that 
higher scar burdens were associated with inferior LV reverse remodelling rates and 
either no improvement in LVESV or progressive dilatation of the LV cavity was observed 
in patients with a very high scar burden. LV pacing remote to scar identified on CMR has 
been shown to result in more favourable CRT response rates,173 which suggests that 
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using real-time CMR overlay guidance to locate and avoid scar may be beneficial.155 It is 
important to note that LV leads are often empirically deployed in a lateral or 
posterolateral vein as these coronary veins typically subtend to myocardial segments 
that most often correspond to areas of late electrical activation. However, pacing over 
posterolateral scar is associated with poor response to CRT173 and therefore implies an 
image guided approach to avoid LV scar may be important and more sensible than 
empirical LV lead implantation. 
 
Left ventricular mid-wall fibrosis seen in patients with non-ischaemic cardiomyopathy 
also results in suboptimal outcomes with CRT, albeit to a lesser extent than that seen 
with patients with subendocardial or transmural scar.174 Therefore, dedicated real-time 
image guidance studies for patients with non-ischaemic scar may be consider in the 
future. 
 
However, CMR has its limitations as an image guidance tool. Approximately 28% of 
patients undergoing CRT have a pre-existing pacing or ICD system and are often 
unsuitable for CMR.96 Whilst we are starting to MRI patients with non-MRI conditional 
pacing systems, this is not always possible due to abandoned leads and is not entirely 
risk free, particularly in patients that are pacing dependent. Furthermore, patients with 
heart failure awaiting CRT often find CMR scans challenging due to long breath holds 
and a prolonged period of 30-45 minutes supine which often affects image quality 
through respiratory motion artefact. There is also a risk of nephrogenic systemic fibrosis 
with gadolinium contrast agents used in CMR scar imaging, particularly in patients with 
renal impairment which is common in the heart failure population. Additionally, image 
degradation from lead artefact may impede the use of using CMR images for 
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dyssynchrony analysis. Cardiac CT has shown excellent promise in addressing these 
limitations of CMR in imaging patients with pre-existing CIEDs. 
 
1.5.4 Cardiac Computed Tomography to guide LV lead implantation 
Cardiac CT has the potential to guide LV lead placement.153,154,156,175 Rapid acquisition of 
isotropic 3-dimensional whole heart data sets with submillimetre spatial resolution 
allows accurate assessment of coronary venous anatomy175,176 as well as non-invasive 
assessment of regional and global LV systolic function.175,177 Additionally, cardiac CT may 
be used to evaluate LV dyssynchrony and areas of LMA,175,178 and has the potential to 
detect regional hypoperfusion/myocardial scar,179 albeit with varying results and no 
clearly standardized imaging protocols to reliably identify late iodine enhancement.180 
Identification of LV scar through first pass hypoperfusion as well as late iodine 
enhancement which has similar pharmacokinetics as Gadolinium used in CMR have been 
investigated. Gerber et al. (2006) showed that early hypoperfusion may however reflect 
acute myocardial injury from microvascular obstruction whereas late iodine 
enhancement may reflect chronic scar formation/infarction in a porcine model.181 In the 
absence of regional hypokinesis or akinesis, hypoperfusion may not be specific to 
myocardial injury182 and late iodine contrast uptake into the myocardium may also 
reflect hypoperfusion without necessarily infarction.183 Modern dual energy CT scanners 
have the potential to allow better and more reliable scar assessment through late iodine 
enhancement by using two simultaneous sources of energy to identify more subtle 
changes in tissue characterisation.179 
 
62 
Cardiac CT has a few limitations, although through rapid advancements in CT technology 
these are gradually becoming less problematic. Hard-beam artefact from metallic 
objects including mechanical heart valves and pacing wires can lead to image 
degradation. However, there are now excellent algorithms that are able to limit this 
effect184–186 and as such measuring LV dyssynchrony remains possible in most patients 
with pre-existing right atrial and RV pacing leads.175 In addition, whilst the temporal 
resolution of CT has significantly improved (up to 66ms with current dual source 
scanners) this remains inferior to echocardiography (20ms) and CMR (35-50ms obtained 
over multiple heart beats) and therefore cardiac CT may be less sensitive to subtle 
regional motion changes. There is also an ionizing radiation dose to factor in when using 
CT, however the plethora of detailed cardiac information obtainable often outweighs 
the negative impact of using ionizing radiation in the heart failure population, 
particularly in patients unable to undergo a CMR scan. Furthermore, radiation doses 
have dramatically fallen with modern CT scanners making ionizing radiation less 
concerning than with early cardiac CT imaging. Nonetheless, a radiation assessment 
should always be taken into account when considering using CT. Additionally, use of 
cardiac CT may not be feasible in all patients because of significant renal impairment 
and given the small risks of ionising radiation this may not be an appropriate imaging 
modality for all groups of patients. An in-depth feasibility analysis of using cardiac CT for 
real-time image overlay guided LV lead implantation is covered in Chapter 2. 
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1.6 Left ventricular multisite pacing  
An alternative strategy to improve CRT response rates has focused on increasing the 
number of LV stimulation sites using multisite pacing which may improve CRT response 
by increasing the probability of pacing at an optimal site. In addition, by capturing more 
LV myocardium, a greater number of sites may provide faster and more physiological LV 
activation. Multisite LV pacing has the potential advantage over multipoint pacing using 
a quadripolar lead in that it allows a theoretical larger separation of the two LV 
electrodes. Multisite LV pacing with two LV leads may allow simultaneous recruitment 
of a larger volume of viable LV myocardium compared to single or multipoint LV pacing 
and therefore be more effective in reversing dyssynchrony.187 Stimulating the LV using 
multisite LV pacing may capture the myocardium around areas of scar more effectively 
resulting in an improvement in CRT response. Previous studies have shown the 
feasibility of multisite LV pacing and it has been shown to improve clinical parameters 
and ventricular reverse remodelling compared to biventricular pacing.98,187–189 
 
Whilst experimental data has suggested that patients with a high probability of a good 
response to BiV pacing (i.e. patients with a broad LBBB) are unlikely to obtain 
incremental benefit from implanting an additional LV pacing lead, there remains a 
clinical need to try to improve response rates in patients with less clear indications for 
BiV pacing and multisite LV pacing offers a possible way for this to be achieved.187,190,191  
 
The STRIVE HF (Standard care versus TRIVEntricular pacing in Heart Failure) trial is 
currently underway to examine whether LV multisite pacing (two LV leads and one RV 
lead) in patients with LBBB with a moderately prolonged QRS duration of 120-150 ms is 
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feasible and superior in terms of the proportion of patients who successfully reverse 
remodel compared to standard BiV pacing. An in-depth interim review and analysis of 
the STRIVE HF trial is covered in Chapter 3. In addition, a detailed review of previous 
multisite trials is explored in the discussion section 3.4. 
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1.7 Implantable cardioverter-defibrillators in the heart 
failure population 
A large proportion of deaths among patients with heart failure occur suddenly and are 
frequently due to electrical disturbances.11 Importantly, sudden death often occurs in 
patients with milder heart failure symptoms and many are due to ventricular 
tachyarrhythmias, bradyarrhythmias and asystole. Whilst certain antiarrhythmic agents 
may reduce the burden of tachyarrhythmias and sudden death, major trials have failed 
to demonstrate a reduction in overall mortality and may even increase it.11 Importantly, 
ICDs have been shown to be effective in preventing bradycardia and correcting 
potentially fatal VAs.11 ICDs have been shown to reduce mortality from VAs but are 
associated with complications including inappropriate shocks, lead/device malfunction 
and infection.61 Mortality rates are higher in patients receiving ICD shock therapy192,193 
which may lead to heart failure progression.194  
 
1.7.1 Improving ICD risk stratification 
The vast majority of sudden cardiac deaths are due to malignant ventricular 
tachyarrhythmias and are responsible for the deaths of over 70,000 people in the UK 
and approximately 300,000 people in the United States each year.195,196 
 
Pharmacotherapy for the prevention of sudden cardiac death has been largely negative 
with only beta-blockers exhibiting benefit in randomised clinical trials.197 The SWORD198 
and CAST199 trials were both terminated prematurely following an interim analysis that 
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revealed an excess of deaths in patients randomised to receive antiarrhythmic therapy 
compared to placebo. Additionally, the SCD-HeFT (Sudden Cardiac Death in Heart 
Failure) trial showed that amiodarone was inferior to ICD therapy and equivalent to 
placebo in preventing deaths for patients with heart failure.200  
 
Contrastingly, electrical therapy in the form of direct current cardioversion remains very 
effective in the treatment of ventricular tachyarrhythmias by restoring a stable heart 
rhythm. The development of ICDs in the last 30 years was a significant landmark in 
modern medicine.61,201–203 However, whilst ICDs reduce mortality from VAs, they are 
associated with complications including infection, lead malfunction and inappropriate 
shocks.61,204–206 Notably, mortality rates are higher in patients receiving ICD shock 
therapy192,193 and may lead to heart failure progression.194 A recent large meta-analysis 
including almost 200,000 patients demonstrated mortality was greater for appropriate 
compared to inappropriate shock therapy but both were associated with reduced 
survival with multiple shocks predicting worse outcomes.193,207 Furthermore, 
appropriate ICD therapy only occurs in one third of patients implanted with an ICD 
indicating better risk stratification of VA is needed.208 Identifying VAs may also play an 
important role in identifying patients who may benefit from prophylactic ventricular 
tachycardia (VT) ablation. 
 
Despite considerable research into potential indicators, risk stratification of arrhythmic 
sudden cardiac death remains complex.209 This is compounded by the fact that 
approximately 50% of sudden cardiac deaths occur in individuals living with 
undiagnosed ischaemic heart disease.210 This has led to a significant drive in improving 
public health through the use of cardiac risk scores with a focus on improving patient 
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education and the modification of risk factors associated with the development of 
ischaemic heart disease.211,212 
 
Over the last 20 years, there has also been a vast array of research into identifying 
suitable metrics to predict fatal arrhythmias. Multiple information from historical 
factors, biomarkers, autonomic parameters (heart rate variability, baroreflex 
sensitivity), surface ECG abnormalities (QT variability, T-wave alternans, T-wave 
oscillations), invasive electrophysiology (EP) studies, intracardiac electrograms, 
provocation testing and cardiac imaging (LVEF, ventricular scar assessment) have proven 
important although none offer 100% sensitivity.213,214 
 
Current guidelines base risk stratification of patients at risk of malignant VAs using 
transthoracic echocardiographic LVEF £35% as a surrogate for severely impaired cardiac 
function in order to guide which patients should be considered for an ICD in the primary 
prevention of arrhythmic sudden death.61,200,201 However, LVEF £35% as a sole metric 
for ICD risk stratification appears to be suboptimal given patients with normal or mild-
moderate LV systolic impairment still have either aborted or fatal VAs. In addition, the 
recent Danish Study to Assess the Efficacy of ICDs in Patients with Non-ischemic Systolic 
Heart Failure on Mortality (DANISH) has demonstrated the need for additional risk 
stratification metrics.209 Moving forwards, it is likely that formal risk stratification tools 
will need to incorporate multiple modalities as it is unlikely any single measure will have 
sufficient discrimination to be used in isolation and individual risk can markedly change 




Non-invasive LV scar analysis using CMR and LGE sequences is one modality that has 
shown promise in the prediction of VAs and has potential as an ICD risk stratification 
metric in the primary prevention of arrhythmic sudden cardiac death. This thesis will 
therefore focus on the quantification of scar heterogeneity using cardiac MRI texture 
analysis to calculate entropy as a potential ICD risk stratification tool in chapters 4 and 
5.
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1.8 Summary and hypotheses 
Cardiac resynchronisation therapy is an effective treatment for certain patients with 
heart failure. However, a significant proportion of patients fail to respond to CRT and 
there is potential to improve CIED outcomes through improving CRT response rates. 
There are several advanced strategies that have been trialled to improve LV lead delivery 
by allowing operators to place transvenous LV leads in locations that aim to optimise 
mechanical and electrical synchrony with the aim of improving CRT response.  
 
Initially, this thesis explores two distinct and important strategies to improve CRT 
response by targeting areas of dyssynchrony and avoiding LV scar tissue: 
 
1. Image guidance using cardiac CT in patients undergoing an LV lead upgrade to 
CRT procedure. Chapter 2 addresses the hypothesis that using cardiac CT will 
lead to an improvement in CRT response rates and patient outcomes. 
2. Multisite LV pacing in patients undergoing de novo CRT-D implantation. Chapter 
3 addresses the hypothesis that multisite LV pacing will lead to an improvement 
in CRT response rates and patient outcomes. 
 
ICD risk stratification represents another important area to target in order to improve 
CIED outcomes. A large proportion of deaths among patients with heart failure occur 
suddenly and are frequently due to electrical disturbances. However, ICD risk 
stratification is complex and currently sole use of LVEF £35% is insufficient.  
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Finally, this thesis explores quantifying scar heterogeneity using cardiac MRI texture 
analysis to calculate entropy from LGE imaging as a potential ICD risk stratification tool. 
Specifically: 
 
1. Scar heterogeneity, quantified by mean entropy, to predict appropriate ICD 
therapy. Chapter 4 addresses the hypothesis that high mean entropy, calculated 
from CMR-TA, will predict appropriate ICD therapy in patients undergoing de 
novo ICD implantation. 
2. Scar heterogeneity, quantified by mean entropy, to predict anti-tachycardia 
pacing (ATP) failure. Chapter 5 addresses the hypothesis that high mean entropy, 
calculated from CMR-TA, will be higher in patients with failed ATP compared to 
those receiving successful ATP. 
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Chapter 2: Real-time cardiac CT image 
overlay to guide optimal left ventricular 
lead implantation for CRT upgrades 
72 
2.1 Introduction 
Patients with moderate to severe LV systolic dysfunction and a pre-existing pacing or ICD system 
may benefit from an upgrade to CRT for pacing induced cardiomyopathy as well as other 
aetiologies.37,88 Non-response to CRT occurs in up to 30-50% of patients depending on heart failure 
aetiology and whether CRT response is assessed as an improvement in patient symptoms or the 
percentage of reverse remodelling using echocardiography volume and LVEF quantification. 
Suboptimal LV lead positioning is an important cause of CRT non-response and most likely occurs 
because of LV lead placement in myocardial scar with persistent dyssynchrony.215,216 Cardiac 
magnetic resonance imaging can guide LV lead placement by targeting LMA and avoiding LV 
scar,155,217 however, 28% of patients undergoing CRT have a pre-existing pacing or ICD system and 
may be unsuitable for CMR.96 Imaging patients with non-MRI conditional pacing systems is not 
always possible due to abandoned leads and is not entirely risk free, particularly in patients that are 
pacing dependent. Furthermore, patients with heart failure often find CMR scans challenging due 
to long breath holds and a prolonged period 30-45 minutes supine which often affects image quality 
through respiratory motion artefact. Additionally, CMR image degradation from lead artefact 
frequently impedes the use of using CMR images for dyssynchrony analysis in our experience.  
 
Cardiac CT has the potential to guide LV lead placement.153,154,156,175 Rapid acquisition of isotropic 3-
dimensional whole heart data sets with submillimetre spatial resolution allows accurate assessment 
of coronary venous anatomy175,176 as well as non-invasive assessment of regional and global LV 
systolic function.175,177 Additionally, cardiac CT may be used to evaluate LV dyssynchrony and areas 
of LMA,175,178 and has the potential to detect regional hypoperfusion/myocardial scar,179 albeit with 




We have previously shown that offline pre-procedural cardiac CT dyssynchrony analysis produces 
functional data sets with sufficient temporal resolution to differentiate the region of LMA in a 
separate cohort of 18 patients and that CT target selection correlates well with an acute 
haemodynamic response (AHR) >10%.175 This study sought to test the feasibility of a purpose-built, 
integrated software platform to process, analyse and overlay CT data in real-time within a cardiac 
catheter laboratory to guide LV lead implantation.
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2.2 Methods 
Between September 2017 and August 2019, 18 patients undergoing an LV lead upgrade 
to CRT procedure from either a pre-existing pacemaker or ICD were prospectively 
enrolled. All patients provided written informed consent. The study protocol was 
approved by the West Midlands Research Ethics Committee (Research Ethics Committee 
approval number 14/WM/1069) and conducted in accordance with the Declaration of 
Helsinki. 
 
2.2.1 Recruitment and follow-up 
Consecutive patients with heart failure and an LVEF <45% undergoing an LV lead 
upgrade to CRT from either a pre-existing pacemaker or ICD were screened for their 
eligibility. Patients of any gender, at least 18 years of age could participate in the study 
if they were able and willing to comply with all study requirements and provide informed 
consent. Patients were required to be stable on optimal heart failure pharmacotherapy 
for at least 3 months prior to enrolment. All aetiologies of heart failure were eligible for 
this feasibility study and patients with sinus rhythm or AF were included. Patients were 
ineligible if they had insufficient capacity to consent to the study, a life expectancy of 
less than a year, an eGFR of less than 30mL/min/1.73m2, previous iodine contrast allergy 
or any contraindication to CRT or transvenous LV lead implantation via the coronary 
sinus. In addition, patients were not eligible if they had any other significant disease or 
disorder which, in the opinion of the investigator, may either put the participants at risk 
because of participation in the study, or may influence the result of the study, or the 
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participant's ability to participate in the study. Female participants who were pregnant, 
lactating or planning pregnancy during the course of the study were not eligible for 
enrolment.  
 
All study participants underwent a dedicated cardiac CT research protocol prior to the 
CRT upgrade procedure. Eligible patients underwent the following tests at baseline and 
six-month follow-up visits: NYHA functional class assessment; physical examination; 12-
lead resting ECG; 2D TTE including Simpson’s biplane assessment for left-ventricular 
end-diastolic volume (LVEDV), LVESV and LVEF; MLWHFQ score; and 6MWT. In addition, 
patients underwent a full CRT device and pacing check at the six-month follow-up visit. 
 
2.2.2 Pre-procedural Cardiac CT dyssynchrony imaging protocol 
Cardiac CT examinations were performed using a 3rd generation dual source scanner 
(SOMATOM Force, Siemens Healthineers, Forchheim, Germany). Intravenous 
metoprolol was used to achieve a heart rate of <65 beats/min in sinus rhythm and <100 
beats/min in AF. A topogram was scanned as localizer and for the automatic exposure 
control. Following an injection of 120 mL iodinated contrast material (Omnipaque 350 
mg/ml iodine, GE Healthcare, Princeton, NJ) at 5 mL/s via the antecubital vein, a 
retrospective ECG gated cardiac computed tomography angiogram (CTA) was 
performed with reference dose settings of 100 kV and 288 mAs/rot. Contrast monitoring 
triggered the scan with 14 s delay after reaching 100 HU (at 100kV) in the descending 
aorta. The cardiac CT scan provided the full cardiac function for motion analysis over the 
entire cardiac cycle (0-100% every 5%) and coronary venous anatomy imaging for 
identifying a target vein in the target segment.  
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2.2.3 Pre-procedural cardiac CT scar imaging and dyssynchrony analysis 
For the first 8 patients (protocol A), at 7 minutes after contrast injection completion, 
patients underwent end-systolic prospectively ECG triggered late enhancement 
scanning with a dual energy scan for patients in sinus rhythm with a heart rate <65 
beats/min. The dual energy scan was performed at 90/Sn150 kV with 165 and 127 
reference mAs respectively with a full 250ms reconstruction. A single energy shuttle 
mode (dynamic scan) was used for patients in AF and/or a heart rate >65 beats/min. The 
scanner alternates rapidly between two table positions and acquires prospectively ECG-
triggered axial images in these two positions for 15 seconds. The trigger was set end-
systole at 250ms. The shuttle mode was scanned for 15 seconds (4-5 cycles) at 80 kV/300 
mAs reference dose settings. For the last 10 patients (protocol B), at 12 minutes and 30 
seconds after contrast injection completion, all patients underwent shuttle mode 
dynamic scanning as described above, regardless of cardiac rhythm or heart rate. The 
reference dose was also increased by 30% to ref kV 80 and ref mAs 390.
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Figure 2-1: Cardiac CT dyssynchrony analysis 
Our Cardiac CT Dyssynchrony analysis platform is based on the open-source software medical imaging 
interaction toolkit (MITK) and provides a simple stepwise approach for tracking wall motion from cardiac 
CT datasets.  
 
A) Interactive image rendering for visualising 3D images and surface meshes 
B) 16-segment bullseye plot for visualisation of myocardial strain at every phase throughout the cardiac 
cycle. 
C) Individual volume (Y-axis) over time (X-axis) strain curves for each of the 16 endocardial segments. 
The apical cap is not included as a segment. 
 
Our comprehensive cardiac CT dyssynchrony assessment methodologies are adapted 
from Behar et al (2017).175 In brief, LV dyssynchrony was calculated using an opensource 
clinician-focused platform (Figure 2-1) by applying an image registration warping field 
to a triangulated mesh of the LV endocardium from the retrospective ECG gated cardiac 
CT angiogram (0-100% phase, incrementing every 5%). Two registration methods were 





automated segmentation of the left ventricle cavity at end-diastolic phase. The motion 
was characterised by the circumferential and longitudinal strains as well as local area 
change throughout the cardiac cycle. The derived motion was validated against 
manually annotated anatomical landmarks and the calculation of strains were verified 




Figure 2-2: Annotated dyssynchrony plots of volume change (Y-axis) over time (X-axis) 
a Time to 10% represents the time taken for the area of each AHA segment to reduce in size to 90%.  
 
b Retrospective analysis of historical cases showed that a 15% threshold of time to 10% could be used to 
distinguish between LV lead pacing locations which correspond with response and non-response to CRT. 
 
Late iodine enhancement images were reconstructed with a slice thickness of 2mm and 
an increment of 1mm with a medium smooth kernel (Qr36) and iterative correction of 
iodine beam hardening. The time points of the dynamic scans were averaged after non-
rigid registration. The resulting average volume was then loaded into a DICOM viewer 
and displayed in cardiac planes and qualitatively evaluated in apical, mid, and basal 
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views of the short axis orientation in a narrow window. For comparison, a systolic phase 
of the retrospective cardiac CTA was loaded in synchronized orientation. 
 
2.2.4 Image overlay using the Guide CRT platform prototype 
Our image overlay methods using the Guide CRT platform (Siemens Healthineers, 
Forchheim, Germany) for cardiac MRI have been previously described.175,218–221 In brief, 
the Guide CRT platform is a custom-built software prototype developed by the 
Department of Imaging Sciences & Biomedical Engineering and Siemens Healthineers 
and is integrated into our Artis Q biplane Angiography system (Siemens Magnetom Artis 
Combi Suite, Siemens Healthcare GmbH, Erlangen, Germany). The Guide CRT platform 
was installed on a dedicated prototype workstation connected to the biplane 
fluoroscopic system. Rapid, automatic data processing enables information to be 
extracted from either cardiac CT or MRI.  
 
The Guide CRT platform incorporates an automatic protocol for slice registration and LV 
segmentation. Additional features not used in this study include semiautomatic LV scar 
segmentation, transmurality and overall scar burden (%). Manual adjustment of the 
segmentation process is possible and final verification by the clinical operator is required 
to confirm the registration process. 
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2.2.5 Real-time CT guided CRT workflow 
The ECG gated cardiac CT angiography images (0-100% phase, incrementing every 5%) 
together with the CT dyssynchrony values (plots) were uploaded to the Guide CRT 
platform and processed as follows (Figure 2-3):  
 
1. Automatic segmentation of the LV epicardium and endocardium with manual 
adjustment of the segmentation where required to create a 3D mesh of the LV 
(Figure 2-3A). 
2. Semi-automatic segmentation of the coronary sinus was performed by adding 
intermittent markers along the coronary sinus and coronary veins (Figure 2-3B). 
3. Integration of the CT derived dyssynchrony values (plots) acquired as described 
above (Figure 2-3C). 
4. Following review of the regional dyssynchrony curves to identify the latest 
mechanically activating segments (latest time to peak contraction), the optimal 
target myocardial segment(s) for LV delivery were selected on a corresponding 16-
segment American Heart Association (AHA) bull’s-eye plot (Figure 2-3D) according 
to the target segment selection protocol outlined in detail below. LV scar (whether 
inferred or directly visualised on CT) was avoided where possible when choosing the 
target LMA segment. Scar burden and transmurality were not incorporated into the 
workflow due to inconsistencies of identifying scar on CT. 
5. Fusion of the target AHA segment with the coronary sinus segmentation was 






Figure 2-3: Pre-implant CT Guided CRT workflow 
A) Automatic segmentation generates a 3D mesh of the left ventricle. 
B) Semi-automatic segmentation of the coronary venous anatomy using 3D markers (red circles) 
generates a 3D reconstruction of the coronary sinus and tributary veins. 
C) Integration of the CT-derived dyssynchrony plots allows for choosing the latest mechanically 
activating segment. 
D) Target selection is then made on the AHA 16 segment Bull’s eye plot using the dyssynchrony 
plots. 
E) 3D fusion of the coronary venous anatomy in relation to the chosen target segment(s) is 
performed showing a target vein leading to the target segment(s). In this case a large 
posterolateral vein is seen to subtend the basal and mid inferior segments. 
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2.2.6   Target segment selection protocol 
During the above steps, a guidance screen is displayed from which the clinician selects 
the target segments targeting areas of latest mechanical dyssynchrony (latest time to 
peak contraction i.e. minimum volume) in line with our previously published 
work.155,175,222,223 All septal segments were excluded since epicardial LV stimulation in 
this region does not achieve effective cardiac resynchronisation. Segments with minimal 
volume change i.e. reduced endocardial strain were also excluded for selection given 
they likely represent regions of nonviability and is supported by previously published 
work linking LV placement in such regions with poor CRT outcomes.125,155 
 
2.2.7   Intra-procedural CT Guided CRT workflow 
1. Co-registration (image fusion) of the 3D LV endocardial mesh with fluoroscopic cine 
images was performed using three fluoroscopic projections: right anterior oblique 
(RAO) 30 degrees, posterior-anterior (PA) and left anterior oblique (LAO) 30 degrees. 
Bony landmarks, existing pacing wires +/- sternotomy wires were used to facilitate 
accurate image fusion as well as motion compensation. The co-registration 
algorithm has previously undergone validation using both cardiac models and 
patients undergoing CRT implantation.218–220 
 
2. After CS cannulation was established, occlusive balloon venography was performed 
in three fluoroscopic projections (RAO 30 degrees, PA, LAO 30 degrees). These were 
then fused with the CT derived 3D shell (Figure 2-4A) and CS venogram (Figure 2-4B) 
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to confirm target vein locations as segmented by Cardiac CT and ensure a target vein 
ran through the target segment. 
 
3. The RADI pressure wire protocol was performed as previously described.175,224 The 
LV lead was temporarily placed in one or more non-target veins and the RADI 
pressure wire protocol was followed for each of these prior to attempting to deliver 
the LV lead  
 
4. Finally, LV lead deployment was performed (in the usual fashion aiming to place the 
lead in the CT derived target segment (Figure 2-5) when coronary venous anatomy 
allowed and a target threshold of <2.5V @ 0.5 ms without phrenic nerve stimulation 
at 10V was achieved. A quadripolar LV lead was used in all cases ensuring the 
cathode was within the target segment where possible. Where a target vein did not 
exist in the target segment(s), the next adjacent and closest vein to the target 
segment was used. The RADI pressure wire protocol was also performed in the final 







Figure 2-4: Occlusive balloon coronary venography 
A) Fused with CT derived 3D mesh with 16 AHA segments 








Figure 2-5: Real-time Cardiac CT image overlay guidance 
Final LV lead position with the LV lead deployed in the mid-anterolateral AHA target segment 12 
represented in:  
A) Posterior-anterior projection 






2.2.8   RADI pressure wire protocol 
Invasive dP/dtmax measurements were performed using a 0.014-inch high-fidelity 
‘wireless’ Pressure Wire X (St. Jude Medical, St. Paul, MN) in the LV cavity via a 
retrograde arterial approach as previously described.175,224 Invasive dP/dtmax 
measurements were recorded using CoroFlow (Coroventis, Uppsala, Sweden) Patients 
with moderate to severe aortic valve stenosis, artificial aortic valves, aortopathy, aortic 
stent grafts or congenital aortic valve or sub-aortic valve pathology were not recruited 
to the study. Atrial pacing (AAI) 10 beats/min above the intrinsic rate or RV pacing (DDD) 
for patients with AF or no underlying rhythm was used for baseline dP/dtmax 
measurements. Atrioventricular delays were fixed at 100 ms and ventriculo-ventricular 
delay at 0 ms. The AHR for each venous site compared biventricular pacing with baseline 
(% change, dP/dtmax, mmHg/s). The AHR was retrospectively compared for those 
measured within CT target segments versus non-target segments. An AHR >10% was 
considered a positive result. 
 
2.2.9   Statistical analysis 
Discrete data are presented as n values with corresponding percentages in parentheses 
and continuous data as mean±1SD or median [interquartile range]. Discrete variables 
were compared using Fisher’s exact test. Normally distributed data were compared with 
a paired samples t-test. Non-normally distributed data were compared using Wilcoxon 
signed-rank testing. For all tests, p≤0.05 was considered statistically significant. 
Statistical analysis was performed using Statistical Package for Social Sciences, 
Macintosh V 24.0.0.1 (2017). Armonk, NY, IBM Corporation.
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2.3 Results 
A total of 18 patients underwent the dedicated Cardiac CT research protocol for LV 
dyssynchrony and scar assessment. Baseline characteristics and pharmacological 
therapy are summarised in Table 2-1 and Table 2-2 respectively. Patients were 
predominantly male (n=17, 94.4%), had a moderately high percentage of RV pacing 60.0 
± 43.7% with a mean QRS duration of 154 ± 30 ms and just over half of the patients had 
ischemic cardiomyopathy (n=10, 55.6%).  
 
Table 2-1: Baseline characteristics 
Characteristic Value 
Age (years) 67.0 ± 9.9 
Male gender 17 (94.4) 
Ischaemic cardiomyopathy 10 (55.6) 
NYHA III/IV 7 (38.9) 
MLWHF questionnaire score 36.6 ± 23.5 
6MWT distance (m) 316 ± 128 
NT-proBNP (ng/mL) 1108.1 ± 767.3 
Haemoglobin (g/L) 139.4 ± 13.8 
Renal function (eGFR 60 mL/min/1.73m2) 69.1 ± 21.0 
QRS duration (ms) 154 ± 30 
Left bundle branch block 15 (83.3) 
CT Dose Length Product (mGycm) 1536 ± 701  
Atrial fibrillation 9 (50) 
Right ventricular pacing burden (%) 60.0 ± 43.7 
 
Values are presented as mean ± SD or as n (%). 
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Table 2-2: Baseline pharmacological therapy 
Pharmacological treatment Value 
ACE inhibitor/ARB/Sacubitril and Valsartan 18 (100) 
Beta-blocker 16 (88.9) 
Aldosterone antagonist 12 (66.7) 
Loop diuretic 9 (50) 
Anti-arrhythmic 4 (22.2) 
Antiplatelet 7 (38.9) 
 
Values are presented as n (%). 
 
2.3.1 Cardiac CT planning outcomes 
All 18 CT scans were completed successfully with a mean radiation dose length product 
(DLP) of 119.6 [IQR 106.9-204.9]cGycm2 and mean supine CT scan time of 14.3 ± 2.0 
minutes. CT post-processing (scar and dyssynchrony assessment to identify the optimal 
target segment) time was 23.9 ± 7.4 minutes giving a combined CT scan and processing 
time of 38.2 ± 6.0 minutes. Although we only observed late iodine enhancement in two 
patients in this study (Figure 2-6), we did identify clear regional hypoperfusion which 
was observed as hypoattenuation in keeping with scar tissue from previous myocardial 
infarction (Figure 2-7) in two further patients which correlated with regional LGE from 
historical CMR imaging where available. A further six patients had evidence of LV scar 
inferred by myocardial wall thinning and hypokinesis/akinesis but did not have visible 
late iodine enhancement or visible hypoperfusion. CT scar protocol B had superior 
reliability of visualising regional hypoattenuation compared to CT scar protocol A. Late 
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iodine enhancement was seen using both protocols but was not detected when 
expected to be visualised based on historical CMR imaging in some patients. Post-
processing CT analysis identified the proposed target AHA segment subtended by a 




Figure 2-6: Late iodine enhancement seen with single energy cardiac CT (protocol B) 
Images acquired with dynamic single energy cardiac computed tomography 12.5 minutes post contrast 
administration. 
 
A) Series of short axis slices showing late iodine enhancement in the mid to apical anterior segments, 
extending into the mid anterolateral segment in keeping with prior left anterior descending (LAD) 
artery territory infarction. 
B) Single 2 chamber slice showing transmural late iodine enhancement in the mid anterior segment.
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Figure 2-7: Cardiac CT scar analysis 
Images acquired with dynamic single energy cardiac computed tomography 12.5 minutes post contrast 
administration. 
 
A) 3-chamber acquisition showing hypoattenuation (white arrow) in the basal anteroseptal, mid 
anteroseptal and apical anterior segments 
B) Short axis slice showing hypoattenuation (white arrow) in the mid anterior and anteroseptal segments. 
C) 2-chamber acquisition slice showing hypoattenuation (white arrow) in the basal to apical anterior 
segments 
D) AHA 17 segment polar plot of the left ventricle for first pass enhancement mapping (75% phase). 
E) AHA 17 segment polar plot of the left ventricle for enhancement mask mapping (75% phase). 
F) Hybrid view of volume rendered cardiac CT angiography images with colour coded first pass 
enhancement projected on the epicardial model of the left ventricle. 
 
The fully retrospective scan showed a corresponding area of dyssynchrony and myocardial wall thinning. 
Hypoperfusion on the resting scan was observed and reduced wall motion compatible with scar tissue. 
Using dynamic perfusion at 12.5 minutes post 120mL iodinated contrast injection, although there was no 
delayed iodine enhancement, we did identify hypoperfusion which was observed as hypoattenuation 
(white arrows) over the infarcted LAD territory in keeping with scar tissue. This raises an interesting 
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question as to whether all scar actually hyper-enhances and in fact may be seen as hypoattenuating areas 
in patients with advanced scar formation. 
 
To better assess the contrast in the myocardium CT data can be displayed with a colour coded overlay 
based on the HU values or an enhancement mask only colour coding the relatively low contrasted regions 
on top of the left ventricular myocardium, based on the first pass enhancement data. 
 
2.3.2 CT guided CRT implant outcomes 
A total of 17/18 (94%) patients underwent successful LV lead implantation with delivery 
to the CT derived target vein subtending the target AHA segment in 16/18 (89%) of 
patients (Table 2-3) and the LV lead was deployed in the CT derived target AHA segment 
in 15/18 (83%) of patients (Table 2-3). In the three patients where the LV lead was not 
deployed within the target AHA segment, one patient had phrenic nerve stimulation 
with all available vectors, one patient did not have a target vein of suitable calibre to 
pass a lead which had been anticipated on the pre-procedural CT scan and one patient 
had an unsuccessful LV lead implantation due to an acute angle from the right atrium 
(RA) into the coronary sinus (CS) preventing intubation with a catheter or guide sheath 
that was not apparent on the pre-procedural cardiac CT. Mean time from CS intubation 
to final LV lead deployment was 59 ± 26 minutes and complete implant procedural time 
(skin incision to closure) was 142 ± 47 minutes. Mean fluoroscopy run time was 28.2 ± 
13.4 minutes with a median fluoroscopy radiation dose area product (DAP) of 1444 [IQR 
947-2170] cGycm2 and a mean implant contrast dose was 86.1 ± 49.4mL.
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Table 2-3: Feasibility and safety of CT guided CRT 
Variable Value 
Feasibility of CT guided LV lead placement in target vein 16/18 (89) 
Feasibility of CT guided LV lead placement in target AHA segment 15/18 (83) 
All-cause mortality 0 
Heart failure hospitalisation 0 
Other cardiovascular hospitalisation 2/18 (11)a 
Intra-procedural related complications 1/18 (5.6)b 
 
Values are presented as n (%). Feasibility of using real-time cardiac CT image overlay guidance, placing 
the LV lead in the CT-derived target vein and target segment and maintaining CRT pacing at 6 months. 
 
a  One patient was admitted for angina which was treated with optimisation of anti-anginal medication. 
The second represents the patient with unsuccessful LV lead implantation who went on to have a leadless 
LV endocardial pacing system (WiSE CRT, EBR systems, Sunnyvale, CA, USA). 
 
b  One patient became hypotensive with evidence of cardiac tamponade upon removal an externalized RV 
lead at the end of procedure and therefore was deemed not to be related to the image guidance element 
of the procedure. The patient was managed with a pericardial drain without the need to progress to 
emergency thoracotomy. The patient previously had a device implanted that became infected and had 
undergone transvenous lead extraction two weeks prior. 
 
2.3.3 CT planning and CT guided outcomes 
Total CT guided procedure time including CT scan, post-processing and implant time was 
172.7 ± 59.6 minutes. Total CT and implant contrast dose were 201.3. ± 52.1mL. 
Echocardiographic and clinical measures at baseline and six-months follow-up are 
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shown in Table 2-4. LVESV was improved at six months compared to baseline (133.8 ± 
67.7 vs. 103.5 ± 53.9mL, p=0.003). Furthermore, LVEDV, NYHA functional class and 
paced QRS duration were significantly lower at six months compared to baseline (Table 
2-4). MLWHFQ scores, 6MWT distance and NT-proBNP were similar at six months 
follow-up compared to baseline (Table 2-4). 
 
Table 2-4: CRT response - echocardiographic and clinical measures at baseline and six-
month follow-up 
Variable Baseline 6-month follow-up p value 
LVEDV (mL) 200.8 ± 75.8 178.0 ± 63.2 0.028 
LVESV (mL) 133.8 ± 67.7 103.5 ± 53.9 0.003 
LVEF (%) 36.2 ± 9.4 44.2 ± 11.2 0.038 
NYHA functional class 2.1 ± 0.6 1.5 ± 0.7 0.031 
MLWHFQ score 30.9 ± 23.6 27.3 ± 24.2 0.266 
6MWT distance (m) 341.8 ± 124.5 383.8 ± 138.1 0.178 
NT-proBNP (pg/mL) 1161.6 ± 903.9 1163.4 ± 1435.9 0.997 
Paced QRS duration (ms)  168.9 ± 29.8 134.2 ± 21.4 0.008 
All comers QRS duration (ms) 154.6 ± 34.8 134.2 ± 21.4 0.082 
 
All values are presented as mean ± SD. Absolute and percentage change values are the difference between 
values obtained from baseline pre-assessment visit and 6-month follow-up measures. Paced QRS duration 
excludes patients with recorded intrinsic QRS durations at baseline i.e. those that had a low RV pacing 
burden. All comers QRS duration reflects the change in QRS duration regardless whether paced or not at 
baseline and 6/12 follow-up. 
 
2.3.4 Validation of CT target with the acute hemodynamic response 
Of the 17 patients that underwent successful LV lead implantation, acute hemodynamic 
data was achievable in 14 patients. In the three patients that did not have acute 
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hemodynamic data collected, this was due to poor patient compliance during the initial 
part of the LV lead upgrade procedure in one patient and therefore a pressure wire was 
deemed inappropriate. In the other two patients, there was malfunction of the RADI 
analysing equipment at the start of the procedure and therefore neither patient 
received a RADI pressure wire study. 
 
CT dyssynchrony analysis identifying the target coronary vein subtending the area of 
LMA outside of scarred regions was compared with all sites where the AHR was 
measured (2 ± 1 coronary veins per patient). An average AHR >10% was considered a 
positive result and was achieved in 9/11 (81.8%) patients with an LV lead delivered to 
the CT targets segments compared to 3/11 (27.3%) patients with LV leads placed in the 
non-target segments (p=0.030). In two patients that had dP/dtmax (mmHg/s) data 
recorded, only a single AHR was recorded within the target segment with no 
comparative AHR in a non-target segment due to unfavourable coronary anatomy and 
in one of these cases a limited dissection of the CS occurred and therefore these were 
not be included in this specific comparative AHR analysis.
95 
2.4 Discussion 
The current study demonstrates for the first time the safety and feasibility of real-time 
dedicated CT-defined scar and dyssynchrony to successfully guide LV lead implantation 
for CRT delivery. Furthermore, pacing within CT-defined segments showed more 
favourable acute haemodynamics confirming the validity of this approach. The results 
of the present study builds upon our previous pilot CT work,175 where we validated the 
use of offline pre-procedure CT dyssynchrony analysis to identify LMA segments as 
potential target segments for LV lead placement. Our previous work found that cardiac 
CT derived target segments correlated well with invasive AHR data during biventricular 
pacing when compared offline.175 In the present prospective study, we have 
demonstrated that using real-time CT image overlay guidance to target the latest 
mechanically activating segment outside of scar in patients undergoing an LV upgrade 
to CRT procedure is feasible. Furthermore, real-time CT image overlay guidance led to 
an improvement in outcomes at 6-months post LV lead upgrade to CRT. In addition, LV 
leads placed in the CT target segments were more likely to have an AHR >10% compared 
to those placed in non-target segments (p=0.030) which has previously been 
demonstrated to predict chronic reverse remodelling.224 
 
2.4.1 Feasibility of using real-time CT image overlay guidance for left 
ventricular lead placement 
CT image overlay guidance was performed with acceptable implant procedural times, 
contrast volumes and radiation doses. Mean time from CS intubation to final LV lead 
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deployment was 58 ± 26 minutes allowing for invasive acute hemodynamic data to be 
acquired whilst pacing in multiple coronary veins which would have artificially 
lengthened the implant procedure time as well as increased the risk of coronary vein 
complications including CS dissection and/or cardiac tamponade. The DAP for CT guided 
LV lead upgrade procedures were similar to historical de novo CRT implant controls from 
our centre 1757.9 ± 982.9 cGycm2 vs. 1893 ± 1965 cGycm2 (p=NS). The combined CT scan 
and CT data processing time to generate dyssynchrony curves was lengthy at 38.2 ± 6.0 
minutes mainly due to large CT data sets, however, this is something that can be greatly 
improved upon in future software iterations with full-automation of the process. More 
research into reliable LV scar detection using cardiac CT is required and there is a great 
need for standardization of CT scar imaging protocols. 
 
The majority of patients undergoing an LV lead upgrade procedure to CRT had a 
successfully guided LV lead placement into the CT derived target segment (83%) 
representing the area of latest mechanical activation outside of ischaemic scar. 
Echocardiographic and clinical outcome measures at 6 months were favourable using a 
real-time CT image overlay approach and in particular there was a significant 
improvement in mean LVESV, LVEDV and LVEF compared to baseline volumetric 
measurements. The overall volumetric CRT response rate using CT guidance was 70% 
which is high given over half of the patients had ischaemic cardiomyopathy who have 
been reported to have much lower non-guided CRT response rates around 50-
60%132,215,225–228 In addition, volumetric response rates are considered hard end-points 
for measuring CRT response outcomes and are usually lower than clinical composite 
score derived CRT response rates. We did not perform a statistical analysis on outcomes 
in patients receiving an LV lead delivered into the target segment versus non-target 
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segment due to small numbers of patients receiving an LV lead in the non-target 
segment (n=2). However, the results presented suggest that a CT-guided approach may 
improve CRT response outcomes in patients undergoing an LV lead upgrade to CRT and 
therefore an appropriately powered, larger randomised controlled study of real-time CT 
image overlay guidance versus standard (non-guided) CT guidance is warranted. 
 
2.4.2 Safety of using a CT guided approach  
The main risk of using a CT guided approach is from additional ionising radiation from 
the retrospective CT scan required for the dyssynchrony assessment. However, this may 
be partially offset by potentially quicker implant procedure times and lower fluoroscopy 
radiation doses in the future due to improved pre-procedural planning of the optimal 
target vein subtending the optimal target AHA segment as well as intra-procedural real-
time image overlay guidance of the CS ostium location and coronary anatomy (Figure 
2-4) and (Figure 2-8). The use of a RADI pressure wire in the LV cavity in this study was 
to further validate the CT target segments with the AHR. Invasive AHR measurements 
carry a small risk of arterial injury and stroke as well as increasing procedural complexity 
including the use of heparin whilst the pressure wire is in vivo. Future CT guided LV lead 
implants will not require an invasive pressure wire for validation as this has now been 







Figure 2-8: CT derived coronary venous anatomy 
A) Overlaid onto fluoroscopy to aid operator with coronary sinus cannulation. CS guide (arrowed) is seen 
to enter the CS ostium and main CS body. 
B) Volume rendered cardiac CT angiography images delineating the course of the coronary sinus 
(arrowed) and coronary venous anatomy.  
A 
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2.4.3 Comparison with similar studies 
Zhou et al. (2014) showed that reconstructing 3D LV venous anatomy from dual-view 
fluoroscopic venograms and fusing it with the LV epicardial surface on single photon 
emission computed tomography (SPECT) myocardial perfusion imaging (MPI) is feasible 
and technically accurate for guiding LV lead placement using a 17 segment AHA 
model.229 Similarly, Sommer et al. (2013 and 2016) undertook a double-blind single 
centre randomised controlled trial to evaluate the clinical benefit of multimodality 
imaging-guided LV lead placement in CRT.230,231 The study integrated CT derived CS 
anatomy, 99mTechnetium myocardial perfusion imaging and speckle-tracking 
echocardiography radial strain to target the optimal coronary vein closest to the non-
scarred myocardial segment with latest mechanical activation in the image guided group 
(n=89). The control arm involved routine LV lead implantation in the posterolateral 
region with late electrical activation (n=93). In the image guided group significantly 
fewer patients met the primary endpoint of clinical non-response to CRT (26% vs. 42%, 
P= 0.02).231 The study defined non-response to CRT as one or more of the following: (1) 
death, (2) heart failure hospitalisation or (3) no improvement in NYHA functional class 
and <10% increase in 6MWT distance.231 Whilst the image guided group demonstrated 
greater improvement in absolute change in 6MWT at 6 months, there was no significant 
difference between groups for NYHA functional class or echocardiographic volumetric 
parameters.231 This is in contrast to the findings in the present study and whilst there 
are no standardised ways to measure CRT response, we believe that volumetric 
response either on its own or as part of composite endpoint should be included when 
assessing techniques to improve CRT response outcomes. 
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Truong et al (2018) reported their findings using dual source cardiac CT to predict clinical 
outcomes in 54 patients scheduled for CRT in the DIRECT study.154 This study did not use 
image guidance but interestingly 1:1 randomisation was performed and the implanting 
physician was given preimplant knowledge of coronary venous anatomy in half the 
patients. In the other half of patients, operators were blinded to the CT coronary venous 
anatomy and measurements were made of time to maximal wall thickness and inward 
wall motion to determine both CT global and segmental dyssynchrony as well as 
concordance of lead location to regional LV mechanical contraction.154 The study 
identified that 72% of patients were clinical responders at 6-months follow-up using the 
heart failure clinical composite score and 17% had MACE at 2 years follow-up.154 The 
study also found that both global wall motion and opposing anteroseptal-inferolateral 
wall motion individually predicted MACE. Furthermore, they identified that lead location 
concordant to regions of maximal wall thickness was associated with less MACE 
(p<0.01).154 However, the DIRECT study failed to show that CT dyssynchrony metrics 
predicted 6-month CRT response and that myocardial scar (43%), posterolateral wall 
scar (28%), and total scar burden did not predict outcomes either. Furthermore, the 
study found that prior knowledge of coronary venous anatomy by CT did not reduce 
implant or fluoroscopy time.154 These findings are in contrast to our previous 
retrospective CT work,175 as well as the current study which uses real-time CT image 
overlay to guidance based on CT dyssynchrony indices and appears to have favourable 
volumetric outcomes when using real-time CT guidance.  
 
More recently, Nguyên et al. (2019) successfully integrated a CS roadmap acquired from 
cardiac CT angiography, LGE imaging from Cardiac MRI and electrocardiographic 
imaging (ECGI) into a 3D CRT roadmap in 14 patients undergoing CRT implantation.156 
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Two further patients had CT and EGCI integration due to unusable MRI data in one 
patient and one patient did not undergo cardiac MRI due to a pre-existing device.156 The 
LV lead was positioned outside scar in late-activated myocardium determined from ECGI 
in 11/14 patients that were implanted.156 In the remaining three patients LV scar could 
not be avoided and in two patients cannulation of the initial target vein was not possible 
due to limited coronary venous anatomy.156 The results of this feasibility study certainly 
show promise in targeting optimal LV lead placement, however, this is potentially a time 
and resource heavy pre-procedural planning exercise requiring two cardiac imaging 
modalities as well as ECGI analysis and integration. Nguyên et al. did not report the pre-
procedural imaging and data processing/planning time which is likely to be reasonably 
long and may limit its clinical utility in real-world clinical practice. However, whilst LV 
scar imaging acquired from CMR is more reliable and reproducible than Cardiac CT at 
present,180 if this were to change then CT and ECGI integration would certainly be a 
viable and potentially robust option for guiding LV lead implantation into the latest 





Figure 2-9: Pre-procedural cardiac CT multi-planar reformat images of the coronary 
sinus indicating: 
A) Presence of a Thebesian valve (arrowed) 
B) Large left-sided superior vena cava (white arrow) draining into the coronary sinus (orange arrow) with 




2.4.4 Real-time Cardiac CT versus Cardiac MRI Guidance for CRT and 
Future Directions 
We have previously demonstrated the feasibility of real-time CMR image guidance in a 
similar manner.155 However, the advantage of cardiac CT over cardiac MRI in patients 
undergoing a device upgrade procedure is that there are no concerns around imaging 
CIEDs. Despite recent encouragement to image more patients with non-MRI conditional 
devices, this is not without risk in pacing dependent patients (44% were pacing 
dependent in the present study) and remains an absolute contraindication in patients 
with abandoned leads. Moreover, significant image degradation with pre-existing CIEDs 
limits the usefulness of CMR-based guidance platforms. There is also very little risk of 
claustrophobia with Cardiac CT and scans times are significantly quicker. Minimal breath 
holding is required with cardiac CT which is an important aspect to consider in the heart 
failure population who often struggle when supine for extended periods with repeated 
breath holds during multiple CMR acquisitions which may lead to image degradation. 
Cardiac CT also has the advantage over CMR as it can easily and rapidly image the 
coronary venous anatomy with submillimetre resolution which significantly helps with 
planning whether a target vein subtends the target AHA segment prior to the implant 
procedure. Additionally, preprocedural cardiac CT can identify potential complex 
anatomical challenges to aid with preprocedural planning and treatment decisions 
(Figure 2-9). Cardiac CT is also more widely available than CMR imaging in the majority 
of hospitals in the UK. However, LGE imaging with CMR remains superior to late iodine 
enhancement with cardiac CT, although there is a risk of nephrogenic systemic fibrosis 
with gadolinium contrast agents used in CMR, particularly in patients with renal 
impairment which is common in the heart failure population. In the present study, 
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cardiac CT did not reliably identify late iodine enhancement but instead, regional 
hypoperfusion, seen as hypoattenuating areas was observed and therefore more 
research into reliable LV scar detection using cardiac CT is required with standardization 
of CT scar imaging protocols. Additionally, use of cardiac CT may not be feasible in all 
patients because of significant renal impairment and given the small risks of ionising 
radiation this may not be an appropriate imaging modality for all groups of patients.  
 
Integration of both modalities has recently been trialled by Nguyên et al.156 however, 
using multiple imaging modalities adds significant cost and time which may limit its 
application to clinical care. Currently, we believe CMR guided LV lead implants are best 
suited to patients undergoing de novo image guided CRT implantation and CT guidance 
is more appropriate for patients with pre-existing devices undergoing LV lead upgrade 
to CRT. The TACTIC CRT study (A prospective randomised multi-centre Trial comparing 
cArdiac MRI guided CRT versus conventional CRT implantation in patients with 
Ischaemic Cardiomyopathy) is currently underway and is expected to complete 
recruitment of 218 patients by 2022 and will advise whether real-time CMR image 
overlay guidance is superior to standard care in patients with ischaemic cardiomyopathy 
undergoing de novo CRT implantation.  
 
If late iodine enhancement protocols for cardiac CT improve and match the reliability of 
scar imaging obtained from CMR imaging, then cardiac CT may in the future become the 
imaging modality of choice for both de novo and upgrade image guided CRT procedures. 
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2.4.5 Study limitations 
Our findings are subject to the inherent limitations of single centre, non-randomized 
controlled studies. However, this is a small proof of principle study and a larger 
multicentre, randomised controlled study would be necessary to evaluate whether real-
time CT image overlay guidance is superior to standard care in patients undergoing an 
LV lead upgrade to CRT and is something we plan to undertake. Specifically, CRT 
response outcomes could not be compared for the ‘out of CT target’ group versus ‘in CT 
target’ group in the present study due to the small numbers of patients with LV leads 
delivered outside the target AHA segment (n=2) versus those delivered within the AHA 
target segment (n=8). Larger randomised controlled studies are therefore needed to 
investigate this further. In addition, although the co-registration algorithm has 
previously undergone validation using both cardiac models and patients undergoing CRT 
implantation,218–220 there may still be a small margin of error unaccounted for in this 
study. 
 
Left ventricular dyssynchrony was computed using motion tracking of the endocardial 
surface on retrospective cine imaging and volume over time curves were used to identify 
the latest mechanical activating segments as opposed to calculating pure strain with 
myocardial tagging. This could potentially neglect passive wall motion when only 
tracking the endocardial surface, however, similar tracking algorithms using both 
cardiac CT and CMR have shown good agreement with strain derived from myocardial 
tagging.175,232,233 In addition, whilst the temporal resolution of cardiac CT in this study 
(up to 66ms) is greatly improved upon previous generations of CT scanners, this remains 
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inferior to echocardiography (20ms) and CMR (35-50ms obtained over multiple heart 
beats) and therefore cardiac CT may be less sensitive to subtle regional motion changes.  
 
Given the expense of performing cardiac CT as well postprocessing of CT data to 
generate the target segments, this may not be feasible or cost-effective in some centres; 
however the data could be processed offsite and image-linked to the implanting site 
with the dyssynchrony assessment results and even target segment selection 
completed. 
 
A large proportion of patients in this study had successful LV lead delivery to the CT 
derived target vein (89%) and AHA target segment (83%). Whilst we believe these 
numbers are acceptable for an image guidance approach, this remains a limitation of 
using a transvenous approach via the CS for LV lead delivery. Conversely, this may also 
be seen as an advantage of cardiac CT in preprocedural planning as we were able to 
reliably determine whether a target coronary vein subtended the target AHA segment. 
If preprocedural cardiac CT is able to reliably predetermine whether there is a suitable 
calibre vein subtending the target segment, then it could also be used to identify 
patients who are less likely to respond to conventional CRT and may be more suited to 
first-line endocardial LV lead implantation in order to reach the target segment. Left 
ventricular endocardial pacing may be useful in non-responders to conventional CRT.234 
However, the optimal site of stimulation varies greatly between patients.235–237 The 
image guidance system may therefore help identify which patients are more suited to 
CT guided conventional CRT versus CT guided endocardial LV lead implantation which 
we have recently demonstrated using the WiSE CRT system (EBR systems, Sunnyvale, 
CA, USA).238 We have also previously shown that such a targeted approach for 
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Real-time cardiac CT image overlay guidance for optimal LV lead placement in delivering 
CRT is safe and feasible. There was significant improvement in echocardiographic 
volumetric response outcomes at 6-months follow-up compared to baseline and the 
overall CRT response rate was high given the large number of patients with ischaemic 
cardiomyopathy and use of volumetric response as a hard endpoint. Larger, multicentre, 
randomised controlled studies are needed to evaluate whether real-time CT image 
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Cardiac resynchronisation therapy has be shown to improve symptoms and prognosis in 
selected patients with dyssynchronous heart failure. 4,31,32,240,241 However, a significant 
proportion of patients do not derive clinical benefit and/or show evidence of reverse 
remodelling assessed by 2D TTE.103,241 There is a 30-50% non-response rate depending 
on heart failure aetiology and whether CRT response is assessed as an improvement in 
patient symptoms or the percentage of reverse remodelling using echocardiography 
volume and LVEF quantification. Poor patient selection, suboptimal LV lead positioning 
and insufficient delivery of cardiac resynchronisation are important causes of CRT non-
response.104–106  
 
One strategy to improve CRT response rates has focused on increasing the number of 
LV stimulation sites using multisite pacing which may improve CRT response by 
increasing the probability of pacing at an optimal site. In addition, by capturing more LV 
myocardium, a greater number of sites may provide faster and more physiological LV 
activation. Multisite LV pacing has the potential advantage over multipoint pacing using 
a quadripolar lead in that it allows a theoretical larger separation of the two LV 
electrodes. Multisite LV pacing with two LV leads may allow simultaneous recruitment 
of a larger volume of viable LV myocardium compared to single or multipoint LV pacing 
and therefore be more effective in reversing dyssynchrony.187 Stimulating the LV using 
multisite LV pacing may capture the myocardium around areas of scar more effectively 
resulting in an improvement in CRT response. Previous studies have shown the 
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feasibility of multisite LV pacing and it has been shown to improve clinical parameters 
and ventricular reverse remodelling compared to biventricular pacing.98,187–189 
 
Previous pathophysiological work has demonstrated a negligible benefit with increasing 
the number of LV pacing sites when an adequate response is achieved with BiV pacing, 
however this is also experimental data demonstrating that patients with scar and 
without functional block may benefit from novel pacing strategies such as multisite LV 
pacing.187,190,191 Therefore patients with a high probability of a good response to BiV 
pacing (i.e. patients with a broad LBBB) are unlikely to obtain further benefit from 
implanting an additional LV pacing lead, however, there is a clinical need to try to 
improve response rates in patients with less clear indications for BiV pacing and multisite 
LV pacing offers a possible way for this to be achieved. The STRIVE HF (Standard care 
versus TRIVEntricular pacing in Heart Failure) trial was therefore designed to examine 
whether triventricular (TriV) pacing (two LV leads and one RV lead) in patients with LBBB 
with a moderately prolonged QRS duration of 120-150 ms was feasible and superior in 
terms of the proportion of patients who successfully reverse remodel (defined as a >15% 
reduction in LVESV on 2D TTE) compared to standard BiV pacing. 
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3.2 Methods 
The STRIVE HF study currently has recruited 59 patients out of a target of 100 patients 
between 08 October 2015 and 04 October 2018 from 11 UK centres. All participants 
provided written informed consent. The study protocol was approved by the South East 
Coast Research Ethics Committee (Research Ethics Committee approval number 
15/LO/0183) and conducted in accordance with the Declaration of Helsinki. This 
manuscript serves as an interim analysis of the STRIVE HF trial data. 
 
3.2.1 Recruitment and follow-up 
Consecutive patients undergoing CRT-D implantation for heart failure were screened for 
their eligibility. Patients who had class 1b indication for CRT (LBBB QRS 120-150ms) as 
per ESC guidelines 2013137 were eligible for enrolment. Patients of any gender who were 
at least 18 years of age could participate in the study if they were able and willing to 
comply with all study requirements and able to give informed consent. Female 
participants of child bearing potential were allowed to participate in the study providing 
they ensured effective contraception was used during the study and for three months 
thereafter. Patients were not eligible if they had any other significant disease or disorder 
which, in the opinion of the investigator, may either put the participants at risk because 
of participation in the study, or may influence the result of the study, or the participant's 
ability to participate in the study. In addition, patients were not eligible if they had 
insufficient capacity to consent to the study, a QRS duration >150ms and non-LBBB 
morphology QRS duration 120-150ms. Female participants who were pregnant, 
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lactating or planning pregnancy during the course of the study were not eligible for 
enrolment. 
 
All study participants were on optimal heart failure and/or antiarrhythmic therapy prior 
to device implantation. Eligible patients underwent the following tests at baseline and 
six-month follow-up visits: NYHA functional class assessment; physical examination; 12-
lead resting ECG; 2D TTE (including Simpson’s biplane assessment for LVEDV, LVESV and 
LVEF); MLWHFQ score (MLWHFQ); and 6MWT. In addition, patients underwent a full 
CRT device and pacing check at the six-month follow-up visit. 
 
3.2.2 Randomisation 
Enrolled patients were randomly assigned using the minimisation method in a 1:1 ratio 
to receive either a triventricular CRT-D (using one RV shock lead, two LV leads with 
maximal possible lead separation +/- RA lead as shown in Figure 3-1) or a conventional 
biventricular CRT-D (one RV shock lead, one LV lead and/or RA lead) and were stratified 
according to clinical centre, heart failure aetiology (ischaemic or non-ischaemic 






Figure 3-1: Representative posterior-anterior (A) and lateral (B) chest radiographs one 
day post implantation of a triventricular CRT defibrillator. Maximal left ventricular 
lead separation is best appreciated in the lateral chest radiograph. 
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3.2.3 Two-dimensional transthoracic echocardiographic studies 
Left ventricular volumes (LVEDV and LVESV) were estimated by averaging those derived 
from the two-chamber and four-chamber windows according to Simpson's biplane 
method and the LV ejection fraction (LVEF) was calculated in the usual fashion. 
Transthoracic echocardiogram analysis was performed by experienced 
echocardiographers and consultant cardiologists competent at assessing LV volumes 
and LVEF using Simpsons biplane method who were both blinded to patient 
randomisation identifiers and study endpoints. 
 
3.2.4 Implant procedure 
An active fixation RV lead was positioned in the septum or RV apex according to operator 
preference and optimal lead parameters for both arms of the study. For patients 
randomised to triventricular device implantation, two LV leads were subsequently 
attempted to be implanted transvenously via the CS. Most operators performed two LV 
lead implantation using two of their preferred guide sheathes. Some operators elected 
to use the WorleyTM Advance Coronary Sinus Guide and LV lead delivery system (Merit 
Medical, South Jordan, UT, USA) and were able to successfully deliver two LV leads down 
a single guide sheath. Operators were instructed to aim for maximal LV lead separation 
as permitted by optimal lead parameters and absence of phrenic nerve stimulation e.g. 
The first LV lead (LV1) was inserted, where possible, into a posterolateral or true lateral 
vein and the second LV lead (LV2) as far as possible form LV1, in an anterior, high 
anterolateral or middle cardiac vein as governed by individual coronary venous 
anatomy. The two LV leads were connected to a triventricular capable device with an 
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integrated parallel Y port (Paradym TriV SonR CRT-D, ICV1231, MicroPort CRM, Clarmart, 
France, formerly Sorin and LivaNova CRM). A single LV output was programmed for all 
patients and acceptable thresholds were required for both LV pacing leads given 
individual LV outputs were not programable. Bipolar LV leads were used to connect to 
the IS-1 port on the triventricular device. For patients randomised to the biventricular 
control arm, quadripolar LV leads were used and connected to an IS-4 port. An active 
fixation right atrial (RA) lead was positioned in the RA appendage or RA free wall 
according to optimal lead parameters and absence of phrenic nerve stimulation for both 
arms of the study in patients deemed appropriate for RA lead implantation (i.e. those in 
sinus rhythm or expected to have a reasonable chance of maintaining sinus rhythm). 
The SonR (MicroPort CRM, Clarmart, France) auto-optimising RA lead was permitted to 
be used in both arms of the study. Once all the leads were sutured in place, electrical 
latency (Q-LV) was measured individually for each LV lead implanted during RV sensing 
and RV pacing but the results did not guide the final LV lead position. 
 
Following CRT implantation, all devices were programmed with an AV delay of 100ms 
and simultaneous RV-LV pacing. Patients implanted with a SonR leads were allowed to 
have automatic AV optimisation switched on. All CRT implants had a company 
representative present for advice regarding lead and device implantation, equipment or 
device interrogation, however, they did not take part in the study design, data 
collection, analysis, interpretation of results, manuscript writing or in the decision to 




Ischaemic cardiomyopathy was defined by standard criteria (prior myocardial infarction, 
presence of any epicardial coronary artery stenosis >75% or coronary revascularization 
with a scar pattern consistent with myocardial infarction on CMR imaging). Absence of 
the above criteria were defined as non-ischaemic cardiomyopathy (NICM). Triventricular 
pacing was defined as CRT with one RV lead and two LV leads and/or an RA lead. 
Biventricular pacing refers to CRT with one RV lead, one lead and/or an RA lead. LV 
pacing thresholds were defined as the first loss of capture on the LV channel. 
 
3.2.6 Endpoints 
The primary endpoint was feasibility of achieving and maintaining triventricular pacing 
at 6 months, calculated as the percentage of surviving patients still triventricular pacing 
at 6 months based on their pacing check. The exact percentage of triventricular pacing 
recorded by the device was not deemed to be important for assessing the feasibility of 
triventricular pacing as any reduction in RV-LV pacing would likely have occurred if the 
patient was implanted with either one or two left ventricular leads.  
 
Secondary endpoints were as follows:  
1. Proportionate effect of TriV vs. BiV pacing on reverse remodelling (comparison of % 
reduction in LVEDV) 
2. Proportion of patients who successfully reverse remodel (defined as a reduction in 
end systolic volume >15% derived from 2D echocardiogram) 
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3. Proportionate effect of TriV vs. BiV pacing on reverse remodelling (comparison of % 
reduction in LVESV) in patients with prespecified subgroups of AF and heart failure 
aetiology 
4. Proportion of patients who successfully reverse remodel (defined as a reduction in 
end systolic volume >15% derived from 2D echocardiogram) in patients with 
prespecified subgroups of AF and heart failure aetiology 
5. Mean change in NTpro-BNP in patients with triventricular devices compared with 
biventricular devices (pg/mL) 
6. Percentage change in NTpro-BNP in patients with triventricular devices compared 
with biventricular devices 
7. Comparison of effect of biventricular and triventricular pacing on scores in MLWHFQ 
scores 
8. Comparison of effect of biventricular and triventricular pacing on change in 6-minute 
walk test (metres) 
9. Comparison of percentage of shocks delivered in triventricular arm vs biventricular 
arm. 
 
Time to first heart failure hospitalisation, rate of adverse events and mortality rates 
during the study period were also recorded for both groups. All adverse events were 
reported to and adjudicated by the chief investigator and sponsor of the study (Guy’s 
and St Thomas’ NHS Foundation Trust) who reviewed the event type, severity and 
relatedness to an additional LV lead implant. 
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3.2.7 Statistical analysis 
Data analysis was performed according to the intention-to-treat principle; patients who 
crossed over were analysed in their original treatment assignment. Discrete data are 
presented as n values with corresponding percentages in parentheses and continuous 
data as mean±1SD. Discrete variables were compared using Fisher’s exact test. 
Continuous data were assessed for normality with the Shapiro-Wilk test where p³0.05 
was considered normally distributed data. Normally distributed data were compared 
with an independent samples t-test. Non-normally distributed data were compared 
using the Wilcoxon signed-rank test. All statistical tests were 2-sided and p<0.05 was 
considered statistically significant. Statistical analysis was performed using Statistical 
Package for Social Sciences, Macintosh V24.0.0.1(2017). Armonk, NY:IBM Corporation.
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3.3 Results 
A total of 59 patients were randomised (TriV group n=30; control BiV group n=29) during 
the interim analysis study period. In the TriV group, a total of 27/30 patients were 
successfully implanted with a TriV system; a second LV lead was not able to be implanted 
in three patients who therefore received a BiV system but remained in their TriV group 
for the intention-to-treat analysis. In the BiV group, all 29 patients were successfully 
implanted with a BiV system. There were no deaths and no patients lost to follow-up in 
either group for the interim analysis period.  
 
Baseline characteristics (Table 3-1) and pharmacological therapy (Table 3-2) were 
balanced between both groups. 
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Table 3-1: Baseline characteristics 







Age (years) 68.0 ± 11.1 66.5 ± 10.2 67.2 ± 10.6 0.623 
Male gender 21 (72.4) 23 (76.7) 44 (74.6) 0.771 
Coronary artery disease 9 (31.0) 11 (36.7) 20 (33.9) 0.785 
Ischaemic cardiomyopathy 19 (65.5) 20 (66.7) 39 (66.1) 1.000 
Previous CABG 4 (13.8) 3 (10.0) 7 (11.9) 0.706 
Previous valve surgery 4(13.8) 1 (3.3) 5 (8.5) 0.195 
Hypercholesterolaemia 6 (20.7) 4 (13.3) 10 (16.9) 0.506 
Current tobacco smoking 1 (3.4) 5 (16.7) 6 (10.2) 0.195 
Previous history of tobacco 
smoking 
7 (24.1) 4 (13.3) 11 (18.6) 0.333 
Diabetes mellitus 14 (48.3) 12 (40.0) 26 (44.1) 0.604 
Hypertension 11 (37.9) 11 (36.7) 22 (37.3) 1.000 
Atrial fibrillation 8 (27.6) 5 (16.7) 13 (22.0) 0.360 
Atrial flutter 2 (6.9) 1 (3.3) 3 (5.1) 0.612 
QRS duration (ms) 138.2 ± 7.9 136.2 ± 9.0 137.2 ± 8.5 0.418 
LVEF (%) 29.5 ± 5.4 25.9 ± 7.3 27.7 ± 6.6 0.115 
LVEDV (mL) 174.5 ± 43.1 180.8 ± 82.6 177.7 ± 65.7 0.515 
LVESV (mL) 125.6 ± 38.9 136.3 ± 70.9 131.1 ± 57.2 0.883 
Impaired RV systolic function 8 (29.6) 8 (28.6) 16 (29.1) 1.000 
Systolic blood pressure 123.8 ± 16.0 120.1 ± 12.5 121.8 ± 14.1 0.360 
6MWT distance (m) 295.0 ± 140.7 313.6 ± 175.5 305.2 ± 159.5 0.520 
MLWHFQ score 34.8 ± 22.6 44.9 ± 22.9 40.0 ± 23.1 0.110 
NT-proBNP (pg/mL) 1865.8 ± 2128.0 1439.7 ± 1676.3 1648.0 ± 1900.7 0.723 
NYHA functional class III/IV  7 (24.1) 10 (33.3) 17 (28.8) 0.567 
Values are presented as mean ± SD or as n (%). 
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Table 3-2: Baseline pharmacological therapy 







ACE inhibitor or ARB 27 (93.1) 27 (90) 54 (91.5) 1.000 
Beta-blocker 25 (86.2) 28 (93.3) 53 (89.8) 0.424 
Aldosterone antagonist 18 (62.1) 25 (83.3) 43 (72.9) 0.084 
Loop diuretic 19 (65.5) 19 (63.3) 38 (64.4) 1.000 
Aspirin 15 (51.7) 15 (50.0) 30 (50.8) 1.000 
Clopidogrel 2 (6.9) 4 (13.8) 6 (10.3) 0.670 
Oral anticoagulant 14 (48.3) 10 (34.5) 24 (41.4) 0.424 
Statin 18 (62.1) 16 (55.2) 34 (58.6) 0.790 
 
Values are presented as n (%). 
 
In the BiV group, the LV lead was positioned in the anterior vein in 2 patients (%), an 
anterolateral vein in 3 patients (%), a lateral vein for 11 patients (%), a posterolateral 
vein in 10 patients (%), a middle cardiac vein in 1 patient (%) and 2 final LV locations 
were unknown. In the TriV group, the LV leads were positioned in the anterior and 
anterolateral veins in 1 patient (3%), the anterior and lateral veins in 3 patients (10%), 
the anterior and posterolateral veins in 4 patients (13%), the anterior and middle cardiac 
veins in 1 patient (3%), the anterolateral and posterolateral veins in 7 patients (23%), 
the anterolateral and lateral veins in 4 patients (13%), the lateral and middle cardiac 
veins in 2 patients (7%) and in the lateral and posterolateral veins in 5 patients (17%). In 
the 3 patients that had an unsuccessful 2nd LV lead implants, a single LV lead was 
implanted in the posterolateral vein in 2 patients (7%) and in the anterolateral vein in 1 
patient (3%). 
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Mean procedure duration was significantly higher in the TriV group (183.9 ± 77.1 vs. 
132.7 ± 49.0 minutes, p=0.007) as was the mean duration from CS intubation to final LV 
lead placement (76.8 ± 40.5 vs. 45.4 ± 31.6, p=0.001). Mean fluoroscopy times were 
significantly longer in the TriV compared to BiV group (41.4 ± 19.9 vs. 28.5 ± 17.8 
minutes, p=0.005). Radiation doses were non-significantly higher in the TriV group (3335 
± 2930 vs. 2361 ± 1990 cGycm2, p=0.386). Mean contrast volume was non-significantly 
higher in the TriV vs. BiV groups (80.7 ± 56.3 vs 63.40 ± 37.9 mL, p=0.372). Mean LV 
pacing thresholds at implant were significantly higher in the TriV group (1.65 ± 0.70 vs. 
1.01 ± 0.54 V, p=0.001), with similar LV lead pulse widths (0.57 ± 0.25 vs. 0.45 ± 0.13 ms, 
p=0.135) and similar LV lead impendences between TriV and BiV groups (757.4 ± 304.7 
vs. 846.6 ± 293.8 W, p=0.222). There were no significant differences in all-cause 
mortality, heart failure hospitalisation, other cardiovascular hospitalisation or a 
composite of all three of these endpoints (Table 3-3). 
124 
Table 3-3: Feasibility and safety of biventricular versus triventricular pacing 







Feasibility of CRT 29 (100) 23/28 (82.1%)a 52/57 (91.2%) 0.023 
All-cause mortality 0 0 0  
HF hospitalisation 1 (3.4) 0 1 (1.7) 0.492 
Other CV hospitalisation 1 (3.4) 4 (13.3) 5 (8.5) 0.353 
Composite of all-cause mortality, HF and 
other CV hospitalisation 
2 (6.9) 4 (13.3) 6 (10.2) 0.671 
Percentage of appropriate ICD shock 
therapy (%) 
1 (3.4) 1 (3.3) 2 (3.4) 1.000 
 
Values are presented as n (%). Feasibility of achieving and maintaining triventricular pacing at 6 months 
is calculated as the percentage of surviving patients still triventricular pacing at 6 months based on their 
6-month pacing check. 
 
aTwo patients in the TriV group did not have sufficient data documented to determine whether they were 
TriV pacing or not and were therefore excluded from this calculation. 
 
3.3.1 Primary endpoint 
Feasibility of achieving and maintaining CRT at 6 months was significantly lower in the 
TriV versus BiV group (82.1%, n=23 vs 100%, n=29, p=0.023) (Table 3-3).
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Table 3-4: Echocardiographic and clinical measures at baseline and six-month follow-
up 






Baseline 174.5 ± 43.0 180.8 ± 82.6  
Follow-up 156.0 ± 59.3 175.3 ± 84.8  
Absolute change (mL) -18.6 ± 56.1 -5.5 ± 51.2 0.101 
Percentage change (%) -8.6 ± 31.2 -2.3 ± 22.4 0.377 
LVESV (mL) 
Baseline 125.6 ± 38.9 136.3 ± 70.9  
Follow-up 106.4 ± 51.4 121.1 ± 73.7  
Absolute change (mL) -19.3 ± 55.3 -15.2 ± 40.8 0.500 
Percentage change (%) -11.2 ± 40.3 -11.6 ± 25.9 0.959 
LVEF (%)    
Baseline 29.5 ± 5.4 25.9 ± 7.3  
Follow-up 35.6 ± 9.3 33.0 ± 9.0  
Absolute change (%) 6.1 ± 9.9 8.0 ± 10.8 0.499 
NT-proBNP (pg/mL) 
 Baseline 1865.8 ± 2128.0 1439.7 ± 1676.3  
 Follow-up 1937.0 ± 2559.8 1801.4 ± 2608.7  
 Absolute change (pg/mL) 296.5 ± 2085.2 600.5 ± 2464.2 0.354 
 Percentage change (%) 131.2 ± 546.2 70.1 ± 152.5 0.248 
MLWHFQ score 
 Baseline 34.8 ± 22.6 44.9 ± 22.9  
 Follow-up 28.5 ± 21.4 32.5 ± 23.5  
 Absolute change -4.2 ± 21.1 -13.7 ± 24.7 0.136 
 Percentage change (%) 57.8 ± 221.7 -16.9 ± 70.9 0.180 
6MWT distance (m) 
 Baseline 295.0 ± 140.7 313.6 ± 175.5  
 Follow-up 271.0 ± 146.7 319.2 ± 170.5  
 Absolute change (m) -35.8 ± 84.6 23.0 ± 72.9 0.016 
 Percentage change (%) -6.6 ± 34.0 31.1 ± 95.2 0.133 
NYHA functional class 
 Baseline 2.3 ± 0.5 2.3 ± 0.5  
 Follow-up 1.9 ± 0.7 2.0 ± 0.8  
 Absolute change -0.4 ± 0.8 -0.3 ± 0.7 0.839 
 Percentage change (%) -18.4 ± 34.9 -14.4 ± 31.2 0.714 
 
All values are presented as mean ± SD. Absolute and percentage change values are the difference between 
values obtained from baseline pre-assessment and 6-month follow-up measures. 
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3.3.2 Secondary endpoints 
1. There was no significant difference in absolute change or percentage change of 
LVESV (mL) from baseline to 6-month follow-up between TriV and BiV groups (Table 
3-4). 
2. There was no significant difference in the number of patients that reverse 
remodelled (i.e. the number of volumetric responders defined by a reduction in 
LVESV >15% on TTE) between TriV and BiV groups (40% vs. 51.7%, p=0.438) (Table 
3-5). 
3. There was no significant difference in absolute change or percentage change of 
LVESV (mL) from baseline to 6-month follow-up between TriV and BiV groups in 
patients with sinus rhythm, AF, ICM or NICM (Table 3-6). 
4. There was no significant difference in the number of patients that reverse 
remodelled between TriV and BiV groups in patients with sinus rhythm, AF, ICM or 
NICM (Table 3-5). 
5. There was no significant difference in absolute change of NTpro-BNP (pg/mL) from 
baseline to 6-month follow-up between TriV and BiV groups (Table 3-4). 
6. There was no significant difference in percentage change of NTpro-BNP from 
baseline to 6-month follow-up between TriV and BiV groups (Table 3-4). 
7. There was no significant difference in absolute change or percentage change of 
MLWHFQ scores from baseline to 6-month follow-up between TriV and BiV groups 
(Table 3-4). 
8. There was no significant difference in percentage change of 6MWT distance (m) 
from baseline to 6-month follow-up between TriV and BiV groups, although absolute 
change in 6MWT distance was significantly higher in the BiV group (Table 3-4). 
127 
9. The mean number of recorded ICD shocks was similar between TriV versus BiV 
groups (3.4%, n=1 vs. 3.3%, n=1, p=1.000) (Table 3-3). 
 
In addition, there was no significant difference in absolute change or percentage change 
of LVEDV and LVEF values from baseline to 6-month follow-up between TriV and BiV 
groups (Table 3-4). Battery longevity (defined as the elective replacement index on the 
device) was significantly lower in the TriV group (6.0 ± 2.4 vs. 8.6 ± 3.1 years, p=0.005). 
 
Table 3-5: Reverse remodelling outcome measures in the entire cohort and subgroups 
of atrial fibrillation and heart failure aetiology 
Number of volumetric responders for the 








Entire cohort 15 (51.7) 12 (40.0) 27 (45.8) 0.438 
Atrial fibrillation 5 (62.5) 3 (60.0) 8 (61.5) 1.000 
Sinus rhythm 9 (47.4) 9 (37.5) 18 (41.9) 0.550 
Ischaemic cardiomyopathy 8 (42.1) 5 (25.0) 13 (33.3) 0.320 
Non-ischaemic cardiomyopathy 7 (70.0) 7 (70.0) 14 (70) 1.000 
 
Values are presented as n (%). Volumetric response was defined as LVESV >15% reduction on two-
dimensional transthoracic echocardiography.
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Table 3-6: Left ventricular end-systolic volumes at baseline and six-month follow-up 
for heart rhythm and heart failure aetiology subgroups 





LVESV (mL) for SR subgroup 
Baseline 130.1 ± 44.1 131.3 ± 70.2  
Follow-up 112.6 ± 54.6 122.9 ± 79.5  
Absolute change (mL) -17.5 ± 61.2 -8.4 ± 30.3 0.529 
Percentage change (%) -7.4 ± 42.6 -8.8 ± 26.3 0.900 
LVESV (mL) for AF subgroup    
Baseline 124.0 ± 24.5 162.3 ± 84.3  
Follow-up 92.9 ± 45.3 114 ± 54.3  
Absolute change (mL) -31.1 ± 43.2 -48.3 ± 71.6 0.596 
Percentage change (%) -25.0 ± 33.2 -25.9 ± 24.0 0.959 
LVESV (mL) for ICM subgroup 
Baseline 122.1 ± 32.3 135.6 ± 74.7  
Follow-up 113.3 ± 56.1 134.2 ± 82.3  
Absolute change (mL) -8.7 ± 59.6 -1.4 ± 24.5 0.613 
Percentage change (%) -3.8 ± 44.4 -3.2 ± 23.1 0.956 
LVESV (mL) for NICM subgroup 
Baseline 132.4 ± 50.5 137.8 ± 66.5  
Follow-up 93.1 ± 40.3 94.9 ± 45.3  
Absolute change (mL) -39.3 ± 41.6 -42.9 ± 53.1 0.956 
Percentage change (%) -25.2 ± 27.7 -28.5 ± 23.6 0.774 
 
Values are presented as mean ± SD. Absolute and percentage change values are the difference between 




The STRIVE HF study was a randomised multicentre study designed to evaluate the 
feasibility, safety and clinical value in improving CRT response of TriV compared to 
standard BiV pacing in patients undergoing CRT-D implantation who had class 1b 
indications for CRT (LBBB QRS 120-150ms) as per ESC guidelines 2013.137  
 
Implanting two LV leads and maintaining triventricular pacing at 6 months was feasible 
in 82.1% of patients which we considered satisfactory, however, this was significantly 
lower compared to the feasibility of maintaining BiV pacing in 100% of the control group. 
Two LV leads were successfully implanted in 27/30 (90%) patients randomised to the 
TriV group. In three patients in the TriV group where addition of a second LV lead was 
not technically possible, these patients received a biventricular pacing system with a 
single LV lead instead; in one patient, this was due to a combination of poor pacing 
parameters with high LV thresholds and presence of phrenic nerve stimulation in the 
remaining available coronary veins for a second LV lead; in the other two patients, the 
attempt at adding a second LV lead was abandoned due to difficult CS cannulation in 
both patients, with a limited CS dissection occurring in one of these patients with no 
evidence of cardiac tamponade or any long-term sequalae. Whilst there were no 
reported lead displacements in the 6-month follow-up period in either, there were 
several reports from multiple sites of technical difficulties with lead stabilities, 
suboptimal pacing parameters and difficulties in avoiding phrenic nerve stimulation. 
Furthermore, there was an additional report of CS dissection in one patient who did 
receive and maintain TriV pacing at 6-months. The study protocol required maximal LV 
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lead separation. Not infrequently, placing a single LV lead in the coronary venous system 
can be technically challenging, often governed by either complicated coronary venous 
anatomy, poor lead stability, suboptimal LV pacing thresholds or presence of phrenic 
nerve stimulation. Unsurprisingly, this was even more challenging when attempting to 
place two LV leads in the coronary venous circulation with even more limitations, 
therefore resulting in the second LV lead being implanted where was feasible rather 
than where was desirable. 
 
3.4.1 Safety of triventricular pacing 
The short-term safety profile of triventricular pacing was satisfactory with no recorded 
deaths or procedure related major complications for the interim study period. There 
were no reports of device related infection during the 6-month study period in either of 
the two groups. The use of an internal Y-connector as opposed to an external Y-
connector made implantation of the TriV system more straightforward for operators. 
However, assessing both LV lead thresholds was not always straightforward at the 
pacing check follow ups and in some cases difficult to ascertain whether the two LV lead 
thresholds were identical or whether there was no capture from one of the LV leads to 
explain why we only saw one change in morphology during LV lead testing. Threshold 
rises were observed in 16/30 patients in the TriV group at the 6-month follow-up and in 
5 of these patients, TriV pacing was deactivated by lowering the LV lead output to a 
threshold below the highest LV whilst still remaining high enough for the other LV lead 
in an attempt to preserve battery longevity and provide the patient with BiV instead of 
TriV pacing for their ongoing clinical care outside of the study. A few cases of phrenic 
nerve stimulation were reported following implant during the study period which were 
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resolved by reprogramming the LV output channel. Furthermore, TriV pacing with two 
LV leads was associated with significantly shorter battery longevity compared to 
biventricular pacing with a single LV lead.  
 
All primary and secondary and secondary endpoints were negative in the STRIVE HF 
interim analysis, apart from absolute change in 6MWT distance which was significantly 
higher in the BiV group (Table 3-4). However, we do not feel this statistically significant 
finding is clinically relevant, not least due the fact that patients in the BiV group walked 
on average 35.8 metres less at 6-month follow-up compared to their baseline scores and 
patients in the TriV group walked 23.0 metres more compared to their baseline scores. 
This statistical finding is not supported by the percentage change in 6MWT scores (Table 
3-4) at baseline compared to 6-months which was not significantly different between 
TriV and BiV groups. Importantly, there was no evidence of superior remodelling benefit 
in the TriV group compared to BiV group and in fact the CRT response rate using 
LVESV>15% to define CRT response, was lower in the TriV group (40%) versus the BiV 
group (51.7%). Taking this together with the fact that mean battery longevity was 
significantly shorter (due to higher mean LV pacing thresholds) with longer procedure 
durations (driven by longer time spent deploying LV leads in the coronary venous 
system) and longer mean fluoroscopy times in the TriV group, we did not find any 
evidence to support the use of Triventricular pacing in patients with a class 1B indication 
for CRT (LBBB QRS 120-150ms) as per the ESC guidelines 2013.137 This remained the case 
in pre-specified subgroups of patients with sinus rhythm, AF and ischaemic and non-
ischaemic heart failure aetiology. However, this is an interim analysis of the study results 
and therefore the results are not sufficiently powered to make any firm conclusions at 
this stage and therefore we eagerly await the final STRIVE HF analysis once recruitment 
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is completed. We did not find any major concerns in terms of safety endpoints and 
therefore believe the STRIVE HF study continue to recruit to the target number of 
patients (n=100). 
 
3.4.2 Comparison with similar studies 
Initial studies of multisite pacing were for the most part undertaken in single centres 
and offered positive results compared to the present trial. Rogers et al demonstrated a 
significant improvement in 6MWT distance, MLWHFQ scores, peak VO2, and LV ejection 
fraction at 6 months when comparing conventional de novo biventricular stimulation 
with de novo triventricular stimulation.98 This study had two TriV groups: group A had 
two LV and one RV lead implanted and Group B had two RV and one LV leads implanted. 
Notably, the improvement in echocardiographic parameters was powered by Group A 
rather than Group B which is in contrast to the findings in the present interim analysis 
of STRIVE HF. Similarly in patients with AF and a pre-existing indication for bradycardia 
pacing, Leclercq et al. compared TriV pacing with BiV pacing in 34 patients who were 
implanted using two LV leads and one RV lead.188 After a 3-month run-in period of BiV 
pacing, patients were then randomised to receive either three months of TriV pacing 
followed by three months of BiV pacing or three months of BiV pacing followed by three 
months of TriV stimulation and found a significant improvement in LV remodelling 
compared with conventional BiV pacing which is again in contrast to the findings of the 
present study.188 Ginks et al. (2012) reported that multisite LV pacing increased the 
acute response rate to CRT in 16% of patients versus single-site pacing which was 
particularly beneficial in patients with posterolateral scar identified on CMR.187 More 
recently, the V3 trial randomised 84 patients deemed to be CRT non-responders 
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according to their clinical composite scores to continue with conventional BiV pacing or 
to receive an upgrade to TriV pacing with the addition of a second LV lead.242 Although 
the V3 trial reported that TriV pacing was feasible with a high implant success rate, the 
addition of a second LV lead in the CRT non-responder population did not result in any 
significant clinical benefit or any significant volumetric improvement on 2D 
echocardiography and was in fact associated with a significantly higher perioperative 
complication rate for procedure or system-related complications (infection, system 
explant, pneumothorax and hematoma) in 9/44 patients(20.4%).242 The feasibility of 
TriV pacing was 82.1% in the present study which is similar to that reported in the V3 
trial of 80%,242 confirming that TriV pacing is technically feasible in terms of both 
implanting and maintaining TriV pacing. The V3 trial had a longer follow-up period (two 
years) compared to the present study (six months) and therefore was able to identify 
and report significantly higher complication rates in patients with triventricular pacing 
which was not found in the present study. However, this cannot be directly extrapolated 
to the present trial which involved de novo CRT-D or upgrade to CRT-D implantation 
compared to the V3 trial which recruited a sicker cohort of CRT non-responders involving 
addition of an LV lead. 
 
3.4.3 Limitations 
The objective of STRIVE HF was to determine whether patients with LBBB and 
intermediate QRS prolongation 120-150ms (Class 1B indications for CRT) would benefit 
from TriV pacing. Therefore patients with LBBB and QRS duration >150ms (Class 1A 
indications for CRT) were excluded from the study based on previous work that 
suggested such patients with a high probability of a good response to BiV pacing (i.e. 
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patients with a broad LBBB) are unlikely to obtain further benefit from implanting an 
additional LV pacing lead.187,190,191 It is unlikely that the study outcomes would have 
differed given this was a randomised control study with the control arm receiving 
conventional CRT with a single LV lead, however this was not evaluated in the present 
study given the trial design. In addition, only patients referred for CRT-D were included 
in the study as the TriV device with an internal Y-connector used in the study is not 
manufactured in a CRT-P version and therefore may have led to selection bias. Similarly, 
patients with pre-existing ICD devices undergoing upgrade to a CRT-D were not recruited 
unless they had a pre-existing and working DF-1 shock lead as required by the TriV 
device used in the study. Contrastingly, patients with a pre-existing bradycardia pacing 
system were able to be recruited providing they were planned for an upgrade to a CRT-
D which may also have contributed to selection bias. The difficulties that were 
sometimes encountered with identifying two LV lead thresholds at the 6-month pacing 
check means that the number of patients TriV pacing at 6 months could in-fact have 
been higher, however, this would not have affected the volumetric or other clinical 
outcome results. There was no echocardiographic core laboratory used in STRIVE HF 
trial due to limited funding, therefore volumetric interrater and intrarater agreements 
were unable to be standardised, however, we do not believe this would have affected 
the study outcomes given all outcomes were negative with no trends towards 
significance apart from absolute change in 6MWT distance.
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3.5 Conclusion 
STRIVE HF was a prospective, multicentre randomised controlled trial specifically 
designed to assess feasibility and outcome benefits of TriV pacing in patients with LBBB 
and an intermediate QRS duration 120-150ms. This interim analysis shows that 
implantation of two LV leads carries a high success rate and TriV pacing appears to be 
feasible without significant complications at 6-month follow-up. However, there was no 
evidence that TriV pacing improves CRT response or has any clinical benefit to patients 
with LBBB and intermediate QRS prolongation. The completion of the STRIVE HF study 






Chapter 4: Mean entropy predicts 
implantable cardioverter-defibrillator 
therapy using cardiac magnetic resonance 
texture analysis of scar heterogeneity
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This chapter has been adapted from Mean entropy predicts implantable cardioverter-
defibrillator therapy using cardiac magnetic resonance texture analysis of scar 
heterogeneity. 40 
4.1 Introduction 
Appropriate therapy occurs in one third of patients implanted with an ICD indicating 
better risk stratification of VA is needed.208 Identifying VAs may also play an important 
role in identifying patients who may benefit from prophylactic VT ablation. 
 
Cardiac magnetic resonance imaging with LGE is considered the non-invasive imaging 
reference standard for identifying ventricular scar with the presence and extent of LV 
scar predicting VA.243,244 Small areas of ventricular scar that do not necessarily cause 
significant LV systolic dysfunction, may result in life-threatening VAs with CMR tissue 
characterization of scar core and grayzone tissue (scar penumbra) predicting VA in 
patients with ischemic cardiomyopathy (ICM).245–248 In non-ischemic cardiomyopathy 
(NICM), diffuse myocardial fibrosis acts as a potential substrate for VA and we have 
previously shown that T1-native values predict appropriate ICD therapy 246,247 These 
techniques require a learning curve with specialized protocols for T1 mapping and signal 
intensity derived values for grayzone analysis. Furthermore, these scar assessment 
methods do not fully quantify tissue heterogeneity as they do not examine the entire 
array of pixels available from LGE imaging. Additionally, numerical simulation studies 
have shown spatial heterogeneity of fibrosis correlates directly with VA risk and is more 
evident as spatial size and degree of heterogeneity both increase.249 
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Quantitative texture analysis is a new technique that uses software formerly used and 
validated for the assessment and stratification of solid tumours.250–252 Cardiac Magnetic 
Resonance Texture Analysis quantifies the entire distribution of pixel intensities within 
a region of ventricular scar from LGE imaging. The filtration-histogram technique 
highlights image features of a specified size, followed by histogram analysis of the 
filtered LGE image,251 from which statistical parameters are derived including image 
entropy, a measure of disorder that characterizes image complexity by evaluating 
fibrosis heterogeneity. In essence, a set of completely white pixels would have an 
entropy value of zero but as the scar image becomes more complex, numerous different 
pixel values are detected and the entropy value increases enabling scar complexity 
evaluation. Our institution recently reported the use of CMR-TA in post-myocardial 
infarction patients with greater tissue heterogeneity being associated with a greater 
incidence of adverse outcomes.253 
 
The study objective was therefore to determine whether scar heterogeneity, quantified 
by mean entropy, predicts appropriate ICD therapy. We hypothesized that higher mean 




4.2.1 Study population 
Consecutive patients undergoing primary and secondary prevention ICD implantation 
between May 2011-January 2013 were prospectively enrolled from two centers. We 
have previously assessed grayzone and T1 mapping indices to assess VAs in patients 
included in this cohort.246 All study participants were on optimal heart failure and/or 
antiarrhythmic therapy and underwent coronary angiography and CMR assessment 
prior to device implantation. ICM was defined by standard criteria (prior myocardial 
infarction, presence of any epicardial coronary artery stenosis >75% or coronary 
revascularization with a scar pattern consistent with myocardial infarction on CMR 
imaging). Absence of the above criteria were defined as NICM. Primary prevention was 
defined as ICD implantation to reduce sudden cardiac death (SCD) in at-risk individuals 
who had not yet experienced an aborted cardiac arrest or life-threatening arrhythmia. 
Secondary prevention was defined as ICD implantation in patients who already had 
experienced an aborted cardiac arrest or life-threatening arrhythmia. The study 
protocol was approved by the South East London Research Ethics Committee and 
conducted in accordance with the Declaration of Helsinki. 
 
4.2.2 CMR protocol and analysis 
We have previously described the CMR protocol.246,247 In summary, CMR imaging was 
performed using a 1.5 Tesla (T) scanner with a 32-channel cardiac phased array surface 
coil (Philips Healthcare, Best, The Netherlands). Following a Look-Locker acquisition to 
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identify optimum inversion time, an inversion-recovery gradient-echo pulse sequence 
was used to acquire a stack of short axis slices 10-15 minutes after Gadobutrol 
0.2mmol/kg body weight contrast injection (Bayer-Schering Pharma, Berlin, Germany) 
for LGE assessment from which scar indices were calculated. CMR-derived scar indices 
for 2 standard deviation (SD) method (Scar-2SD), full-width half-maximum (FWHM) 
method (Grayzone-2SD-FWHM) and T1 mapping have been described.246,247,254 Scar and 
grayzone indices were indexed as percentage of the LV mass. Two independent CMR 
experts blinded to the study endpoint evaluated the LGE images separately and resolved 
any discrepancies mutually. 
 
4.2.3 Cardiac Magnetic Resonance Tissue Analysis (CMR-TA) 
Patients without visible scar were excluded from the study. All areas of visible scar 
throughout the short axis LV stack were manually segmented and analysed using 
TexRAD research software (TexRAD Ltd., Feedback PLC, Cambridge, UK). Manual 
segmentation was performed by a CMR-trained cardiologist blinded to patient 
identifiers and study endpoints. For interrater agreement, a second CMR-trained 
cardiologist performed manual segmentation blinded to the initial assessors’ results. 
CMR-TA was performed as previously described with regions of interest drawn around 
all visible LGE, carefully incorporating the scar border and excluding surrounding 
myocardium.253 A Laplacian of Gaussian band-pass filter was subsequently used to 
extract and augment features of different sizes based on the spatial scale filter (SSF) 
values from 2-6mm radius (SSF2-6) corresponding to fine, medium and coarse texture 
scales respectively (Figure 4-1) as previously described.251,253 Quantification of scar 
texture with histogram analysis of pixel intensity was then performed, generating 
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statistical parameters including entropy. In this study, we evaluated whether mean 
entropy, calculated from a medium scar texture (SSF4), predicts appropriate ICD therapy 
in patients undergoing ICD implantation and compared the results to T1-native, 
Grayzone2SD-FWHM and scar-2SD. 
 
 
Figure 4-1: Scar texture examples generated from Laplacian filters applied to LGE 
images to extract and augment features of different sizes based on the spatial scaled 
filter values from 2-6mm radius (SSF2-6) corresponding to A) coarse, B) medium and 





4.2.4 Follow-up and endpoint 
All patients received an ICD or CRT-D. A standardized program for appropriate VA 
detection and ICD therapy with ATP or shock therapy was used as previously 
described.246 VAs >170 beats/minute (detection count >16 intervals) were treated with 
ATP initially, then shock therapy for unsuccessful ATP. First-line shock therapy was used 
for VAs >210 beats/min (detection count 24/30 intervals). Patients were followed up at 
three-month intervals by experienced device physiologists who evaluated recorded 
events with an electrophysiologist, both blinded to the CMR data. The primary endpoint 
was delivery of appropriate ICD therapy for VT or ventricular fibrillation (VF) 
documented by the device. 
 
4.2.5 Statistical analysis 
Discrete data are presented as n values with corresponding percentages in parentheses 
and continuous data as mean±1SD. Time to events are shown as median[interquartile 
range (IQR)]. Discrete demographic variables were compared using Fisher’s exact test. 
Normally distributed data were compared with an independent samples t-test. Non-
normally distributed data were compared using the Wilcoxon signed-rank test. The first 
episode of appropriate ICD therapy was considered the index event. Interrater 
agreement was evaluated using a Bland-Altman plot and linear regression analysis. 
Univariable and multivariable Cox proportional hazard regression models were 
performed to determine predictors of ICD therapy. Separate multivariable models were 
used to avoid multicollinearity where variables correlated. To avoid overfitting, 
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multivariable models were restricted to five variables for the entire cohort analysis and 
three variables when assessing cardiomyopathy groups independently. Statistically 
significant variables at univariable analysis and important clinical covariates were used 
as the basis for multivariable analysis (p≤0.05 was considered statistically significant). 
Hazard ratios for continuous variables represent the relative increased risk of endpoint 
per unit increase (e.g. per one unit increase in mean entropy and per 10 millisecond 
increase in T1-native value). Receiver operating characteristic (ROC) curves for mean 
entropy were plotted to identify optimal threshold values determined by Youden’s index 
and retrospectively used to dichotomize patients into high and low mean entropy 
groups determined by whether they had met the primary endpoint. Kaplan–Meier 
survival curves were subsequently plotted to evaluate cumulative event rates and 
survival distributions. Statistical analysis was performed using Statistical Package for 
Social Sciences, Macintosh V24.0.0.1(2017). Armonk, NY:IBM Corporation.
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4.3 Results 
A total of 114 patients underwent CMR-TA, 70 (61.4%) with ICM and 44 (38.6%) with 
NICM. In the NICM cohort, aetiologies were 41/44 (93.2%) idiopathic dilated 
cardiomyopathy (DCM), 2/44 (4.5%) hypertrophic cardiomyopathy and 1/44 (2.3%) 
sarcoidosis. Primary prevention ICD implantation occurred in 78/114 (68.4%) patients. 
Demographics are presented in Table 4-1. Patients with ICM were older (67.1±10.2 vs. 
58.6±15.3 years, P=0.005) with a significantly greater number of patients with LV 
ejection fractions (LVEF) £35% (84.3% vs. 63.6%, P=0.014). Mean entropy was 
significantly higher in the ICM group (5.7±0.7 vs. 5.5±0.7, P=0.045). The ICM group also 
had significantly higher scar index values of regional fibrosis with grayzone and scar core 
compared to the NICM group (Grayzone-2SD-FWHM 10.1±4.9 vs. 7.1±6.0, P=0.002; Scar-2SD 
25.0±9.1 vs. 16.2±13.3, P<0.001; Scar-FWHM 15.0±6.5 vs. 9.0±8.6, P<0.001). Both groups 
were balanced for gender and other comorbidities (Table 4-1). 
 
4.3.1 Primary endpoint 
During median follow-up of 955[IQR 691-1185] days, 33 (28.9%) patients met the 
primary endpoint. Median time to first appropriate ICD therapy was 329[116-529] days 
for the entire cohort and similar between ICM and NICM groups (340[101-515] vs. 
329[204-532], P=0.824). Of the 33 patients meeting the primary endpoint, 15/33 
(45.5%) were treated for VF and 18/33 (54.5%) were treated for VT. A total of 16/33 
(48.5%) received successful ATP and 17/33 (51.5%) patients received appropriate and 
successful shock therapy. The cumulative event rate for the primary endpoint was 
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similar between ICM and NICM groups (18/70, 25.7% vs. 15/44, 34.1%, P=0.398). A 
greater proportion of appropriate ICD therapy occurred in the secondary vs. primary 
prevention indication group (15/36, 41.7% vs. 18/78, 23.1%, P=0.049). 
 








Mean age (years±SD) 67.1±10.2 58.6±15.3 63.9±13.1 0.005 
Male 56(80.0%) 34(77.3%) 90(78.9%) 0.815 
Diabetes mellitus 13(18.6%) 6(13.6%) 19(16.7%) 0.609 
Hypertension 25(35.7%) 14(31.8%) 39(34.2%) 0.691 
Atrial fibrillation 14(20.0%) 14(31.8%) 28(24.6%) 0.183 
Renal function (eGFR mL/min/1.73m2) 66.8±20.4 69.9±17.0 68.0±19.1 0.406 
Secondary prevention 23(32.9%) 13(29.5%) 36(31.6%) 0.837 
CRT device 37(52.9%) 25(56.8%) 62(54.4%) 0.704 
QRS>120ms 27(42.9%) 22(55.0%) 49(47.6%) 0.312 
CMR LVEF£35% 59(84.3%) 28(63.6%) 87(76.3%) 0.014 
Mean Entropy 5.7±0.7 5.5±0.7 5.6±0.7 0.045 
T1-native 1051±73.1 1079±76.7 1062±75.3 0.079 
Grayzone-2SD-FWHM 10.1±4.9 7.1±6.0 8.9±5.5 0.002 
Scar-2SD 25.0±9.1 16.2±13.3 21.6±11.7 <0.001 
Scar-FWHM 15.0±6.5 9.0±8.6 12.7±7.9 <0.001 
 
Patients were dichotomized into ischemic (n=70) and non-ischemic (n=44) cardiomyopathy groups. 
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4.3.2 Predictors of appropriate ICD therapy in the entire cohort 
Univariable analysis showed secondary prevention, mean entropy, T1-native, Grayzone-
2SD-FWHM and Scar-2SD were associated with appropriate ICD therapy (Table 4-2). Avoiding 
multicollinearity, separate multivariable analyses showed mean entropy, T1-native, 
Grayzone-2SD-FWHM and Scar-2SD remained independent predictors of appropriate ICD 
therapy (Figure 4-2). An interaction term of ‘mean entropy x cardiomyopathy group’ was 
added to the multivariable Cox proportional hazard regression model, however this was 
not statistically significant (HR 1.219, 95% CI 0.390-3.803, P=0.734) indicating no 
interaction between these co-variates.
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Table 4-2: Univariable analysis of appropriate ICD therapy for the entire cohort 
Variable Hazard Ratio 95% CI P value 
Age 0.977 0.953-1.001 0.061 
Male gender 2.046 0.719-5.822 0.180 
Hypertension 0.565 0.285-1.123 0.103 
Atrial fibrillation 0.658 0.313-1.382 0.269 
Secondary prevention 2.207 1.109-4.391 0.024 
QRS>120 milliseconds 1.075 0.518-2.229 0.847 
CMR LVEF £ 35% 1.508 0.623-3.654 0.363 
Renal function (eGFR 60 mL/min/1.73m2) 1.010 0.993-1.027 0.254 
CRT device 1.011 0.509-2.006 0.976 
History of myocardial infarction 0.808 0.402-1.625 0.550 
ICM 0.724 0.364-1.437 0.355 
Bystander CAD 1.021 0.311-3.347 0.973 
Mean Entropy 1.687 1.028-2.769 0.038 
T1-native 1.008 1.003-1.013 0.002 
Grayzone-2SD-FWHM 1.100 1.039-1.165 0.001 
Scar-2SD 1.039 1.008-1.072 0.013 
Scar-FWHM 1.034 0.991-1.077 0.121 
 
Univariable Cox proportional hazard regression to determine variables associated with appropriate ICD 
therapy for the entire cohort (n=114). Mean entropy is presented as a continuous variable. Variables 
found to be statistically significant at univariable analysis as well as important clinical covariates were 
used as the basis for multivariable analysis. A value of p≤0.05 was considered to be statistically significant. 
All reported associations are presented as hazard ratios with corresponding 95% confidence intervals. 
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Figure 4-2: Separate multivariable Cox regression analyses to determine independent 
predictors of appropriate ICD therapy for the entire cohort (n=114) using different scar 
indices (A: mean entropy, B: T1-native, C: Grayzone-2SD-FWHM, D: Scar-2SD 
 
Separate multivariable models were used to avoid multicollinearity. All reported associations are 
presented as hazard ratios with corresponding 95% confidence intervals. Hazard ratios for continuous 
variables represent the relative increased risk of endpoint per unit increase (e.g. per one unit increase in 
mean entropy and per 10 millisecond increase in T1-native value). P≤0.05 was considered statistically 
significant. 
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4.3.3 Predictors of appropriate ICD therapy in the ICM and NICM groups 
For the ICM group, univariable analysis showed mean entropy was associated with the 
primary endpoint (Table 4-3) and remained an independent predictor of appropriate ICD 
therapy when tested in a multivariable model including age and LVEF£35% (Figure 4-3). 
For the NICM group, univariable analysis showed only T1-native was associated with the 
primary endpoint (Table 4-4) and remained an independent predictor of appropriate ICD 
therapy when tested in a multivariable model including age and LVEF£ 35% (Figure 4-4). 
Mean entropy was not associated with the primary outcome in the NICM group at 
univariable analysis (Figure 4-3). 
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Table 4-3: Univariable analysis of appropriate ICD therapy for the ICM group 
Variable Hazard Ratio 95% C.I. P value 
Age 0.974 0.929-1.022 0.282 
Male gender 1.984 0.456-8.633 0.361 
Hypertension 0.431 0.170-1.094 0.076 
Atrial fibrillation 0.550 0.196-1.545 0.257 
Secondary prevention 2.090 0.817-5.346 0.124 
QRS>120 milliseconds 0.876 0.317-2.419 0.799 
CMR LVEF £ 35% 1.520 0.349-6.616 0.577 
Renal function (eGFR 60 mL/min/1.73m2) 1.004 0.982-1.026 0.724 
CRT device 0.893 0.354-2.252 0.811 
Mean Entropy 2.143 1.088-4.221 0.027 
T1-native 1.008 1.001-1.015 0.025 
Grayzone-2SD-FWHM 1.125 1.047-1.208 0.001 
Scar-2SD 1.096 1.037-1.157 0.001 
Scar-FWHM 1.088 1.015-1.165 0.017 
 
Univariable Cox proportional hazard regression to determine variables associated with appropriate ICD 
therapy for all patients with ischaemic cardiomyopathy (n=70). Mean entropy is presented as a 
continuous variable. Variables found to be statistically significant at univariable analysis as well as 
important clinical covariates were used as the basis for multivariable analysis. A value of p≤0.05 was 
considered to be statistically significant. All reported associations are presented as hazard ratios with 






Figure 4-3: Multivariable Cox regression analysis to determine independent predictors 
of appropriate ICD therapy for patients with ischemic cardiomyopathy (n=70). 
All reported associations are presented as hazard ratios with corresponding 95% confidence intervals. 
Hazard ratios for continuous variables represent the relative increased risk of endpoint per unit increase 
(e.g. per one unit increase in mean entropy). P≤0.05 was considered statistically significant. 
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Table 4-4: Univariable analysis of appropriate ICD therapy for the NICM group 
Variable Hazard Ratio 95% C.I. P value 
Age 0.980 0.949-1.013 0.238 
Male gender 2.274 0.512-10.093 0.280 
Hypertension 0.714 0.243-2.098 0.540 
Atrial fibrillation 0.851 0.291-2.491 0.768 
Secondary prevention 2.427 0.876-6.724 0.088 
QRS>120 milliseconds 1.245 0.407-3.810 0.700 
CMR LVEF £ 35% 1.865 0.593-5.867 0.286 
Renal function (eGFR 60 mL/min/1.73m2) 1.018 0.990-1.046 0.212 
CRT device 1.163 0.414-3.271 0.774 
Bystander CAD 0.932 0.263-3.308 0.914 
Mean Entropy 1.434 0.637-3.226 0.384 
T1-native 1.009 1.001-1.017 0.033 
Grayzone-2SD-FWHM 1.075 1.000-1.155 0.051 
Scar-2SD 1.023 0.988-1.059 0.195 
Scar-FWHM 1.017 0.965-1.072 0.523 
 
Univariable Cox proportional hazard regression to determine variables associated with appropriate ICD 
therapy for all patients with non-ischaemic cardiomyopathy (n=44). Mean entropy and T1-native values are 
presented as a continuous variable. Variables found to be statistically significant at univariable analysis as well 
as important clinical covariates were used as the basis for multivariable analysis. A value of p≤0.05 was 
considered to be statistically significant. All reported associations are presented as hazard ratios with 
corresponding 95% confidence intervals.
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Figure 4-4: Multivariable Cox regression analyses to determine independent predictors 
of appropriate ICD therapy for patients with non-ischemic cardiomyopathy (n=44) 
using different scar indices (A: mean entropy, B: T1-native). 
Hazard ratios for continuous variables represent the relative increased risk of endpoint per unit increase (e.g. 
per one unit increase in mean entropy and per 10 millisecond increase in T1-native value). P≤0.05 was 
considered statistically significant. All reported associations are presented as hazard ratios with corresponding 
95% confidence intervals. 
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4.3.4 Survival analysis 
Kaplan-Meier survival analysis (Figure 4-5) demonstrated that the time until first 
appropriate ICD therapy was significantly shorter in the high mean entropy group with 
an optimized cut off of >5.465 (Log rank 8.9, P=0.003). Furthermore, in the high mean 
entropy group there were significantly higher rates of appropriate ICD therapy over time 
with more than 40% having appropriate ICD therapy compared to the low mean entropy 
group with <20% appropriate ICD therapy.  
 
 
Figure 4-5: Kaplan-Meier survival analysis showing difference in event-free survival 
when patients are stratified according to mean entropy for the entire cohort. 
Thresholds used to stratify patients are optimized cut-off values derived from Youden’s index (high mean 
entropy >5.465, low mean entropy ≤5.465). 
155 
4.3.5 Reproducibility of mean entropy 
The Bland-Altman plot in Figure 4-6 shows the absolute difference in mean entropy 
values calculated by histogram analysis of the segmented scar regions of 15 randomly 
selected patients (8 with ICM and 7 with NICM) by two independent assessors. For each 
patient, both CMR-trained cardiologists segmented total visible scar throughout the left 
ventricle. CMR-TA software automatically generated scar textures of each segmented 
scar region from which histogram analysis was performed to calculate entropy values 
for each segmented region. The mean of the entropy values from each segmented scar 
region were taken as the mean entropy value for each patient. The mean interrater 
difference for mean entropy was 0.0067 (limits of agreement -1.89 to 1.90) and 
displayed on a Bland-Altman plot (Figure 4-6). Linear regression also showed no 
statistical interrater difference (P=0.516, 95%CI -0.614-1.162). We have previously 





Figure 4-6: Bland-Altman plot showing absolute difference in mean entropy values 
calculated by histogram analysis of segmented scar regions from 15 randomly selected 
patients (ICM n=8 and NICM n=7) by two independent assessors. 
For each patient, both CMR-trained cardiologists segmented total visible scar throughout the left 
ventricle. CMR texture analysis software automatically generated scar textures of each of the segmented 
scar regions from which histogram analysis was performed to calculate entropy values for each 
segmented region. The mean of the entropy values from each segmented scar region were taken as the 
mean entropy for each patient. The mean interrater difference for mean entropy was 0.0067 (limits of 
agreement -1.89 to 1.90).
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4.4 Discussion 
4.4.1 CMR Texture Analysis 
Our novel findings demonstrate scar heterogeneity, quantified by mean entropy, is an 
independent predictor of appropriate ICD therapy in a mixed cardiomyopathy cohort 
(HR 1.882, 95% CI 1.083-3.271, P=0.025). In addition, T1-native, Scar-2SD and Grayzone-2SD-
FWHM were independent predictors of appropriate ICD therapy in the mixed cohort when 
tested in separate multivariable models. 
 
4.4.2 CMR Texture Analysis in the ICM and NICM groups 
In the ICM group, mean entropy remained an independent predictor of appropriate ICD 
therapy. The key strength of CMR-TA is in identifying subtle tissue heterogeneity by 
filtering out image noise and accentuating key features of LGE, thereby adding a layer 
of reproducibility and robustness in calculating mean entropy. Mean entropy is likely to 
be more reproducible than T1 mapping as T1 indices vary between different CMR 
scanners and magnet strengths. Only a standard white blood LGE sequence is required 
for CMR-TA and segmenting total visible scar has a short learning curve which could be 
automated in the future. 
 
In the NICM group, there was no significant association between mean entropy and 
appropriate ICD therapy. This may be due to mechanistic differences in 
arrhythmogenesis between patients with regional ischemic scar in the ICM group versus 
patchy mid-wall fibrosis in the NICM group. Patients with NICM typically have a much 
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more diffuse pattern of fibrosis that is sometimes clearly visible as patchy mid-wall LGE. 
Only patients with visible scar were included in the study for both ICM and NICM groups 
to allow for this type of scar segmentation and evaluation. The fact that T1-native values 
outside of visible scar predict appropriate ICD therapy in the NICM group and mean 
entropy calculated from scar textures does not, suggests that diffuse interstitial fibrosis 
is likely to be more important in SCD risk stratification than focal patchy scar in the NICM 
population.247,255 It therefore may be that performing entropy calculations in the NICM 
group is better served by not using a post-processing filtration method to generate scar 
textures and that using a total myocardium segmentation approach of unfiltered/raw 
LGE images is more appropriate as suggested by Muthalaly et al.256 This alternative 
assessment of entropy in NICM patients by Muthalaly et al. may therefore be measuring 
diffuse scar burden compared to our technique that measures focal scar complexity and 
may also reflect that diffuse fibrosis in the NICM group is too small and interspersed to 
be detected using the filtration-histogram CMR-TA method. However, larger 
randomised multicentre trials are needed to evaluate this hypothesis further and 
correlate to histopathologic specimens. 
 
4.4.3 Comparison with previous studies 
Muthalaly et al. (2018) recently reported their findings of LV entropy as a measure of 
heterogeneity and found it was a predictor of arrhythmic events in 130 patients with 
DCM undergoing ICD implantation.256 This is in contrast with the findings from the 
present study which did not identify mean entropy as a predictor of ICD events in the 
NICM group and may be explained by several methodological differences and differing 
baseline characteristics. Only 14% of patients experienced arrhythmic events in their 
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study compared to the NICM group in the present study where 34% of patients had 
appropriate ICD therapy indicating a higher risk NICM cohort over a shorter median 
follow-up (955[IQR 691-1185] days vs. 1168 days[IQR 1898 days]). Compared to our 
NICM group of 44 patients (n=41/44 with DCM) all with visible mid-wall fibrosis, only 
56.9% of patients had visible LGE in Muthalaly et al.’s study. Furthermore, whilst 
Muthalaly et al. used the same formula to calculate entropy, they did not perform CMR-
TA to filter out image noise and accentuate key image features of a specified size prior 
to entropy calculation and thus calculated entropy on raw unfiltered LGE images. In 
addition, they employed manual segmentation of total LV myocardium compared to our 
technique of total scar segmentation. It is therefore difficult to draw direct comparisons 
due to significantly different segmentation and entropy assessment methods even 
though mean LV entropy values were similar in Muthalaly et al. vs. the present study 
(5.6±0.7 vs. 5.5±0.7). There is no standardized method for scar segmentation to derive 
entropy, although in the ICM population, segmenting all visible scar or a selection of 
visible scar seems appropriate. The main challenge lies in quantifying heterogeneity of 
diffuse scar seen in NICM cohorts. We have demonstrated in this and previous 
studies,246,247 that T1-native values derived from the mid septum outside of visible scar are 
predictive of appropriate ICD therapy in NICM supporting the use of T1-native values as an 
inherent tissue-specific index that is effective in differentiating healthy myocardium 
from diffusely diseased tissue. 
 
4.4.4 Predictors of appropriate ICD therapy and clinical translation  
We performed CMR-TA by segmenting visible scar and applying a spatial scale filter to 
identify subtle scar features, particularly in the ICM population, and should therefore 
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have greater robustness and stronger predictive value than other quantitative 
assessment methods of LV scar heterogeneity. We included patients with secondary 
prevention ICD indication and only patients with visible scar, and the predictive value of 
mean entropy is therefore likely to be robust in this already high-risk group. Mean 
entropy provides a more sophisticated method of quantifying scar heterogeneity than 
T1-native, scar core and grayzone indices, and is reproducible and easier to perform, 
particularly for the ICM group. Additionally, our technique of careful scar segmentation 
included the scar border, allowing the filtration step to enhance scar texture 
heterogeneity by filtering out image noise and avoid inadvertent inclusion of ‘healthy’ 
myocardium thereby strengthening the reproducibility and robustness of the CMR-TA 
technique. Figure 4-7 compares the scar textures and unfiltered LGE images of a high 
mean entropy patient (A) who met the primary endpoint and a low mean entropy 
patient (B) who did not have ICD therapy. Moreover, CMR-TA has potential use in 
identifying patients that remain at high risk of VA and may guide prophylactic VT 
ablation in the ICM cohort. Its use in the NICM population is less clear and further larger 
multicentre studies are warranted. 
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Figure 4-7: Visual comparison of unfiltered LGE images (left) and medium scar textures 
(right) of a high mean entropy patient (A) who met the primary endpoint and a low 
mean entropy patient (B) who did not receive ICD therapy. 
 
A) Patient with ICM, LVEF£35%, primary prevention ICD, transmural scar and high mean entropy (6.32) 
who received appropriate ICD therapy 319 days post ICD implantation. 
 
B) Patient with ICM, LVEF£35%, primary prevention ICD, transmural scar and low mean entropy (4.39) 




Risk stratification of arrhythmic SCD is complex and multiple information from historical 
factors, biomarkers, autonomic parameters, surface ECG abnormalities (QT variability, 
T-wave alternans, T-wave oscillations), invasive EP studies, intracardiac electrograms, 
provocation testing and cardiac imaging (LVEF, ventricular scar assessment) have proven 
important although none offer 100% sensitivity.213 Formal risk stratification tools will 
inevitably need to incorporate multiple modalities as it is unlikely any single measure 
will have sufficient discrimination to be used in isolation and the individual risk can 
markedly change over time suggesting static assessment is insufficient for accurate long-
term risk stratification. 
 
Scar texture analysis in the present study is the key distinguishing technique compared 
to other risk stratification tools which is considered more sensitive in identifying subtle 
tissue heterogeneity by filtering out image noise and accentuating key features of LGE, 
thereby adding a layer of reproducibility and robustness when calculating mean 
entropy. However, it differs from non-imaging risk stratification tools since scar is 
considered relatively ‘fixed’ and the electrical properties of scar undoubtedly evolve 
over time which may be more readily assessed using non-imaging modalities. LVEF as a 
single risk stratification tool is inadequate, mainly because it is a potent predictor of 
overall mortality and non-SCD and this significantly limits its specificity as a predictor for 
arrhythmic SCD.213 Combining CMR-TA with LVEF<35% would almost certainly improve 
the specificity of using global LV systolic function, which on its own is only a crude 




Our findings are subject to the inherent limitations of non-randomized controlled 
studies. The rate or morphology of VT in those receiving appropriate ICD therapy was 
not captured in the database which may have provided scope for a subanalysis to 
evaluate the differences in the type of VT requiring ATP or shock therapy. Additionally, 
use of appropriate ICD therapy as a surrogate endpoint does not necessarily parallel 
sudden arrhythmic death. Right ventricular scar was not evaluated which may 
contribute to the overall scar burden and arrhythmic substrate. Patients without scar 
were excluded to assess the predictive value of CMR-TA in a higher-risk population and 
is therefore not entirely representative of all cardiomyopathy patients. A potential 
limitation of our method in segmenting visible patchy scar for the NICM group is 
reproducibility. Furthermore, we recognize that inversion times, timing of LGE 
acquisition and additional imaging factors are unknown and require assessment. We 
used a standardized device therapy protocol mirroring our institutions guidelines when 
the study commenced. The Reduction in Inappropriate Therapy and Mortality through 
ICD Programming (MADIT-RIT) study later demonstrated optimized ICD programming by 
reducing ICD therapy which may potentially have reduced the event rate of this study.192 
Nevertheless, by standardizing ICD programming in our cohort, it is unlikely that device 
programming would have introduced any systemic bias in the associations studied.
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4.5 Conclusion 
Our novel findings demonstrate that scar heterogeneity, quantified by mean entropy 
using CMR-TA, was an independent predictor of appropriate ICD therapy in the mixed 
cardiomyopathy cohort as well as in the ICM group, suggesting a potential role for CMR-




Chapter 5: High mean entropy is 
associated with anti-tachycardia pacing 
failure in patients receiving ICD therapy: 
Insights using cardiac magnetic resonance 
texture analysis of scar heterogeneity and 
in silico computer modelling 
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This chapter has recently been submitted for publication in a peer reviewed journal 
5.1 Introduction  
Implantable cardioverter-defibrillators reduce mortality from VAs but are associated 
with complications including inappropriate shocks.61,200 Mortality rates are higher in 
patients receiving ICD shock therapy192,193,257,258 and may lead to heart failure 
progression.194 A recent large meta-analysis including almost 200,000 patients 
demonstrated mortality was greater for appropriate compared to inappropriate shock 
therapy but both were associated with reduced survival with multiple shocks predicting 
worse outcomes.193,207 Anti-tachycardia pacing may terminate VT avoiding shock 
therapy and represents an effective treatment of some but not all VA.259 ATP has been 
shown to reduce unnecessary shocks and inappropriate shocks192 and is therefore 
important in preserving ICD battery longevity and reducing the psychological impact of 
ICD shocks.260 Furthermore, Sweeney et al. demonstrated ATP failure with subsequent 
ICD shocks was 18 times higher in patients who died at follow-up suggesting failed ATP 
therapy may be a marker of substrate severity.207,261 Predicting patients more likely to 
have failed ATP and require shock therapy may therefore be of significant benefit in pre-
counselling patients, ICD selection and programming. Quantifying microchannels within 
surviving areas of scar tissue (responsible for re-entrant VA) may be possible using 
cardiac magnetic resonance texture analysis (CMR-TA) to quantify scar heterogeneity 
from LGE imaging.40 We previously demonstrated mean entropy, calculated using CMR-
TA, predicts appropriate ICD therapy in patients undergoing ICD implantation.40 In this 
current work, we hypothesized that scar heterogeneity (mean entropy) would be higher 
in patients that received appropriate ICD shock therapy compared to those that received 
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successful ATP. We used scar heterogeneity analysis to predict ICD shock therapy by 
performing a sub-analysis on patients with mixed aetiology cardiomyopathy that 
received appropriate ICD therapy (ATP or shock therapy). Additionally, we hypothesized 
that scar heterogeneity would be higher in patients with failed ATP compared to those 
receiving successful ATP and used in silico modelling based on CMR-derived scar 
geometry to explore potential mechanisms why ATP might fail. 
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5.2 Methods 
5.2.1 Study population 
Between May 2011-January 2013, consecutive patients undergoing primary and 
secondary prevention ICD implantation were prospectively enrolled from two tertiary 
centers. We previously reported the utility of mean entropy to predict appropriate ICD 
therapy (combined ATP/shock therapy) in this cohort.40 All patients had heart failure 
and/or antiarrhythmic therapies optimized and underwent coronary angiography and 
CMR assessment prior to device implantation. Standard criteria defined ischemic 
cardiomyopathy (ICM); prior myocardial infarction; epicardial coronary artery stenosis 
>75%; or coronary revascularization with a scar pattern consistent with myocardial 
infarction on CMR. Absence of these criteria defined non-ischemic cardiomyopathy 
NICM. Primary prevention was defined as ICD implantation to reduce SCD in at-risk 
individuals who had not yet experienced a life-threatening VA or aborted cardiac arrest. 
Secondary prevention implants were in those patients who had already experienced a 
life-threatening VA or aborted cardiac arrest. The study protocol was approved by the 
South East London Research Ethics Committee and conducted in accordance with the 
Declaration of Helsinki. 
 
5.2.2 CMR protocol and analysis 
Our CMR protocol has been previously detailed.40,246,247 CMR imaging was performed 
using a 1.5 Tesla (T) scanner with a 32-channel cardiac phased array surface coil (Philips 
Healthcare, Best, The Netherlands). Following a look-locker acquisition to identify 
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optimum inversion time, an inversion-recovery gradient-echo pulse sequence was used 
to acquire a stack of short axis slices 10-15 minutes after Gadobutrol 0.2mmol/kg body 
weight contrast injection (Bayer-Schering Pharma, Berlin, Germany) for LGE assessment 
from which CMR-TA was performed. Two independent CMR experts blinded to the study 
endpoint evaluated the LGE images separately and resolved any discrepancies mutually. 
 
5.2.3 Cardiac Magnetic Resonance Tissue Analysis (CMR-TA) 
We have previously described our CMR-TA methodology.40,253 Patients without visible 
scar were excluded from analysis. All areas of visible scar throughout the short axis LV 
stack were manually segmented and analysed using TexRAD research software 
(Feedback Medical LTD, Cambridge, UK). Manual segmentation was performed by a 
CMR-trained cardiologist blinded to patient identifiers and study endpoints. CMR-TA 
was performed as previously described with regions of interest drawn around all visible 
LGE, carefully incorporating scar borders and excluding surrounding myocardium.40,253 
CMR-TA was performed using a Laplacian of Gaussian band-pass filter to extract and 
augment image features corresponding to a medium scar texture (spatial scale filter of 
4mm radius), from which histogram analysis of pixel intensity calculated mean entropy 
as previously described.40,251,253 
 
5.2.4 Follow-up and primary endpoint 
All patients underwent implantation of an ICD or CRT-D. A standardized program for 
appropriate VA detection and ICD therapy with ATP or shock therapy was used as 
previously described.40,246,247 VAs >170 beats/minute (detection count >16 intervals) 
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were treated with ATP initially, then shock therapy for unsuccessful ATP. First-line shock 
therapy was used for VAs >210 beats/min (detection count 24/30 intervals). Patients 
were followed up at three-month intervals by experienced cardiac physiologists who 
evaluated recorded events with an electrophysiologist, both blinded to the CMR data.  
 
A total of 114 patients underwent CMR-TA in the original study where the primary 
endpoint was delivery of appropriate ICD therapy. In the present study, we performed 
a retrospective sub-analysis of the 33 patients receiving appropriate ICD therapy and 
dichotomized patients into those that received appropriate ICD shock therapy versus 
successful ATP (without shock therapy) and evaluated whether mean entropy predicted 
ICD shock therapy. We also evaluated whether mean entropy values were higher in 
patients that received unsuccessful ATP (and required rescue shock therapy) versus 
those that received successful ATP. 
 
5.2.5 Computer modelling of left ventricular scar 
In silico computer modelling was performed to explore potential mechanistic 
explanations underlying the clinical findings using a simplified 2D finite element 
geometry representing an idealized scar with a protected diastolic isthmus with mesh 
resolution 200um (Figure 5-1A and D). The infarct region comprised two semi-circular 
segments representing necrotic scar, transcended by a 4mm wide conducting isthmus. 
The necrotic scar was set to be insulating with no-flux boundary conditions on the 
intracellular potential. Patchy fibrosis, of variable density, was included in the protected 
isthmus by randomly replacing myocytes by non-conducting fibrotic tissue. For each 
density (dFib), 10 different topologies, with slightly different (random) fibrosis 
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distributions were generated. Figure 5-1 shows one specific topology of fibrosis 
distribution for an isthmus containing 10%(A) and 50%(D) fibrosis. Tissue 
electrophysiology was represented by the monodomain model, with cellular dynamics 
represented by the ten Tusscher ventricular cell model.262 Additional simulations with 
impaired excitability in the isthmus were conducted by reducing the maximum channel 
conductance of the fast sodium current (INa). Simulations were conducted using Cardiac 
Arrhythmia Research Package.263 Tissue was stimulated in silico at a site proximal to the 
isthmus mouth (entry site of potential VT re-entry circuit), as shown in Figure 5-1B. 
Three steady-state stimuli were delivered at a basic cycle length of 500ms; followed by 
a premature stimulus at a coupling interval of 320ms delivered at the same location. The 
standard definition of Shannon entropy was used to define an effective entropy score 
within the isthmus region for the cases of differing fibrosis densities. 
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Figure 5-1: A specific topology example of fibrosis distribution for an isthmus 
containing 10%(A) and 50%(D) fibrosis. 
The tissue was stimulated at a lower site proximal to the isthmus mouth(B, C, E & F). With 10% 
fibrosis within the isthmus, the paced activation wavefront is able to penetrate the isthmus at 
both slow(B) and fast(C) pacing rates. With 50% patchy fibrosis within the diastolic isthmus, 
activation at slow pacing rates is able to successfully penetrate the isthmus(E). At more rapid 
pacing rates, similar to VT cycle lengths, activation fails to penetrate the isthmus, blocking at its 
mouth(F). The probability of conduction blocking at the mouth of the isthmus was also seen to 
be a function of both the fibrosis density and also the excitability of the surviving tissue within 





5.2.6 Statistical analysis 
Discrete data are presented as n values with corresponding percentages in parentheses 
and continuous data as mean±1SD. Time to events are shown as median[interquartile 
range]. Discrete demographic variables were compared using Fisher’s exact test. 
Normally distributed data were compared with an independent samples t-test. Non-
normally distributed data were compared using Wilcoxon signed-rank testing. The first 
episode of appropriate ICD therapy defined the index event. Univariable and 
multivariable Cox proportional hazard regression models were performed to determine 
predictors of ICD shock therapy in patients receiving appropriate ICD therapy. 
Statistically significant variables at univariable analysis and important clinical covariates 
were used as the basis for multivariable analysis. To avoid overfitting, multivariable 
analysis was restricted to four variables. Hazard ratios for continuous variables 
represent the relative increased risk of endpoint per unit increase (e.g. per one unit 
increase in mean entropy). For all tests, p≤0.05 was considered statistically significant. 
Statistical analysis was performed using Statistical Package for Social Sciences, 
Macintosh V 24.0.0.1 (2017). Armonk, NY, IBM Corporation. 
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5.3 Results 
Of the 33 patients receiving appropriate ICD therapy, 17/33 (51.5%) received successful 
ICD shock therapy and 16/33 (48.5%) had successful ATP without requiring shocks. 
Median time to first appropriate ICD therapy was 329[116-529] days and was similar 
between those that received shock therapy vs. successful ATP therapy (290[89-357] vs. 
388[143-593], p=0.154). Patients receiving appropriate ICD shock therapy had a 
significantly higher mean entropy value compared to those that had successful ATP only 
(6.1±0.5 vs. 5.5±0.7, p=0.037). Otherwise, patient characteristics were balanced 
between groups (Table 5-1). In the group that received successful shock therapy (n=17), 
11 patients were treated for VF, 4 patients had failed ATP during charging for fast VT in 
the VF zone and a further 2 patients had failed ATP for VT at 190bpm and 210 bpm 
respectively. In the successful ATP group (n=16), VAs fell within the device VT zone. 
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Table 5-1: Baseline characteristics of patients receiving appropriate ICD therapy for 
VT/VF 











Mean age (years±SD) 58.8±15.4 61.3±13.3 60.0±14.2 0.615 
Male 14 (82.4%) 15 (93.8%) 29 (87.9%) 0.601 
Diabetes mellitus 6 (35.3%) 2 (12.5%) 8 (24.2%) 0.225 
Hypertension 9 (52.9%) 6 (37.5%) 15 (45.5%) 0.491 
Atrial fibrillation 3 (17.6%) 7 (43.8%) 10 (30.3%) 0.141 
Renal function (eGFR mL/min/1.73m2 )±SD 70.7±15.0 71.4±16.5 71.1±15.5 0.895 
Ischemic cardiomyopathy 9 (52.9%) 9 (56.3%) 18 (54.5%) 1.000 
Secondary prevention 10 (58.8%) 5 (31.3%) 15 (45.5%) 0.166 
CRT device 9 (52.9%) 9 (56.3%) 18 (54.5%) 1.000 
QRS>120ms 6 (46.2%) 8 (50.0%) 14 (48.3%) 1.000 
CMR LVEF£35% 13 (76.5%) 14 (87.5%) 27 (81.8%) 0.656 
Mean Entropy 6.1±0.5 5.5±0.7 5.8±0.7 0.037 
 
Patients receiving appropriate ICD therapy were divided into ‘Required Shock Therapy’ vs. ‘Successful ATP’ 
(no shock therapy) groups. 
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5.3.1 Predictors of ICD shock therapy 
Univariable analysis showed only secondary prevention and mean entropy were 
associated with ICD shock therapy (Figure 5-2A). In a multivariable Cox proportional 
hazard regression model adjusting for significant and important clinical covariates (LV 
ejection fraction£35%, ICM and secondary prevention), mean entropy was an 
independent predictor of ICD shock therapy (HR 3.50, 95% CI 1.29-9.54, p=0.014) as was 
secondary prevention (Figure 5-2B). 
 
 
Figure 5-2: Univariable(A) and multivariable(B) Cox regression analyses to determine 
predictors of appropriate ICD shock therapy for patients (n=33) receiving appropriate 




5.3.2 Analysis of patients receiving ATP therapy 
A total of 22 patients received initial ATP for their index event with 16/22 of these 
patients receiving successful ATP without requiring shock therapy. In the remaining 6 
patients receiving failed ATP prior to the delivery of a successful ICD shock, mean 
entropy values were significantly higher compared to the successful ATP therapy group 
(6.3 ± 0.7 vs. 5.5 ± 0.7, p = 0.048) (Figure 5-3). 
 
 
Figure 5-3: Box and whisker plots showing difference in ‘mean entropy’ between 
patients receiving successful ATP (no shock therapy) versus failed ATP (with rescue ICD 
shock). 
+ = mean values of ‘mean entropy’ 
Whiskers represent minimum and maximum absolute values of ‘mean entropy 
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5.3.3 In silico modelling results 
Computational simulations using the idealized infarct model were used to explore the 
clinical findings reported in Figure 5-3. We modelled how penetration of the re-entrant 
circuit was affected by the fibrotic tissue texture forming the protected isthmus. With a 
high degree of patchy fibrosis (50%) at slower pacing rates, the ATP pacing stimulus was 
able to successfully penetrate the isthmus (Figure 5-1E) albeit with reduced conduction 
velocity due to the tortuous course taken around the fibrotic regions.264 At more rapid 
pacing rates (similar to VT cycle lengths) activation failed to penetrate the isthmus 
blocking at its mouth (Figure 5-1F). Notably with lower degrees of fibrosis (10% fibrosis 
within the isthmus) the paced activation wavefront was able to penetrate the isthmus 
at both slow (Figure 5-1B) and fast (Figure 5-1C) pacing rates. Shannon entropy was seen 
to peak at a level of 50% fibrosis (0.35) and fall to 0.21 for 10% fibrosis. The probability 
of conduction blocking at the mouth of the isthmus (corresponding with the entry site 
of VA) was also seen to be a function of excitability of the surviving tissue within the 
isthmus itself as well as fibrosis density, evidenced by the fact that as excitability was 
further impaired (by blocking INa) the probability of rate-dependent conduction block 
increased for all levels of fibrosis (Figure 5-1G).
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5.4 Discussion 
The results of the present study build upon our previous findings that mean entropy 
predicts appropriate ICD therapy (ATP or shock therapy) in patients with ICM or mixed 
aetiology cardiomyopathy undergoing ICD implantation.40 To the best of our knowledge, 
this is the first analysis demonstrating the novel finding that scar heterogeneity, 
quantified by mean entropy, predicts ICD shock therapy compared to those receiving 
successful ATP. Furthermore, patients receiving unsuccessful ATP prior to the delivery 
of a successful ICD shock had significantly higher mean entropy values compared to 
those receiving successful ATP. This may be of particular clinical importance as it implies 
that a higher degree of scar heterogeneity (quantified by a higher mean entropy) may 
be associated with a more aggressive VA requiring shock therapy to terminate. Our in 
silico computer modelling provides a physiologically plausible mechanism to explain our 
results i.e. ATP failure in the presence of greater scar heterogeneity/fibrosis due to 
inability of the paced wavefront to propagate into the critical VT isthmus especially at 
more rapid pacing rates that are generally required for pace termination of VAs. 
 
5.4.1 Potential mechanistic explanations for ATP failure 
The reasons why higher mean entropy values predict a more aggressive VA requiring 
shock therapy may lie in the mechanistic differences in arrhythmogenesis between 
varying scar heterogeneity. A higher degree of myocardial scar tissue heterogeneity 
(higher mean entropy) may support a greater number of microchannels within scar 
facilitating micro re-entry circuits stable enough to form sustained VT or VF that do not 
180 
spontaneously abort and are more difficult to terminate with ATP requiring shock 
therapy to restore a stable heart rhythm. For ATP to be successful, the stimulus from 
the pacing electrode must successfully reach and penetrate the re-entrant circuit, 
closing-down the excitable gap.265 The re-entrant circuit in sustained monomorphic VT 
often contains regions of patchy fibrosis, particularly in the diastolic isthmuses through 
which conduction is known to be impaired and which directly contribute to the 
arrhythmogenic substrate within the infarcted region. Thus, an important aspect of ATP 
success may be the ability of the paced wavefront to successfully propagate through 
patchy fibrosis within the isthmus, rendering it unexcitable when the re-entrant wave 
subsequently arrives. It has been shown that activation propagating through patchy 
fibrotic regions is susceptible to rate-dependent conduction block264,266,267 with the 
wavefronts forced to take convoluted and tortuous pathways as they attempt to 
navigate their way through the patchy fibrotic regions, undergoing frequent rapid tissue 
expansions and experiencing significant electrotonic source-sink mismatches. Under 
steady-state conditions, tissue is sufficiently excitable to allow propagation to traverse 
such regions, albeit with a modulated conduction velocity.268 However, during rapid 
pacing, tissue has impairing excitability, and thus electrotonic current source-sink 
mismatches may reach a threshold to prevent downstream activation, causing 
unidirectional block. Our computer modelling confirms that high levels of patchy fibrosis 
within the diastolic isthmus may be susceptible to rate-dependent unidirectional 
conduction block, which may play an important role in preventing an ATP-paced 
wavefront from penetrating the critical re-entrant channels within the infarct. Such a 
mechanism, driven by the electronic source-sink mismatch within the patchy fibrotic 
areas, may be exacerbated during compromised excitability at more rapid pacing rates. 
This is further supported by the augmentation of unidirectional block seen in situations 
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where excitability (via INa) was further directly compromised (Figure 5-1G). The amount 
of patchy fibrosis in a given region, as detected on an LGE image, is related to the level 
of entropy i.e. quantifying the degree of disorder, or how dissimilar a particular voxel is 
from its neighbour. Our in silico results suggest that regions with moderate patchy 
fibrosis levels (approximately 50%) have correspondingly higher entropy scores, 
compared to areas with lower fibrosis levels and provides a physiologically plausible 
mechanism for how infarcts with lower entropy scores may be more susceptible to 
successful ATP therapy whereas higher entropy regions may be more susceptible to ATP 
failure due to rate-dependent block. 
 
5.4.2 Comparison with previous studies 
Previous work on entropy and LGE is limited and has focussed on predicting appropriate 
ICD therapy (combined ATP or shock therapy). Androulakis et al. (2019) recently 
reported LV entropy as a measure of scar heterogeneity in post myocardial infarction 
patients and found that high entropy within scar was associated with ICD therapy (ATP 
or shock therapy for monomorphic VT or VF),269 and in keeping with our previous 
findings.40 Androulakis et al. found entropy of the entire LV myocardium was not a 
predictor of appropriate ICD therapy269 in contrast to the findings of Muthalaly et al. 
(2018) who found it was a predictor of ICD therapy in 130 patients with DCM.256 There 
is no standardized method for scar segmentation to derive entropy, although in the ICM 
population, segmenting all visible scar or a selection of visible scar seems appropriate. 
The findings from these recent studies suggest entropy of LV scar is useful in predicting 
ICD therapy in patients with ICM and entropy of the entire LV myocardium is useful in 
predicting ICD therapy in patients with NICM. Notably, Androulakis et al. identified that 
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high entropy of the entire LV myocardium was associated with mortality which may 
reflect a fibrosis pattern associated with adverse remodelling. Similarly, we have 
previously shown that T1-native values derived from the mid-septum outside of visible 
scar are predictive of appropriate ICD therapy in patients with NICM, supporting the use 
of T1-native values as an inherent tissue-specific index that is effective in differentiating 
healthy myocardium from diffusely diseased tissue.40,246,247 
 
5.4.3 Clinical importance 
Our work supports the hypothesis that patients with greater scar heterogeneity are at 
higher risk of malignant VAs that may ultimately require shock therapy to restore a 
stable heart rhythm. Furthermore, these findings substantiate previous computer 
modelling work that correlates the risk of VAs occurring with increasing heterogeneity 
of fibrosis.249 Predicting which patients are at higher risk of receiving ICD shocks may be 
of significant benefit in counselling of ICD patients (helping to quantify the risk of shock 
therapy), device programming (using more aggressive ATP therapy in those likely to 
respond and less in those unlikely to respond) and also in device selection. Greater use 
of stand-alone subcutaneous ICDs (that are currently unable to deliver ATP) in patients 
unlikely to benefit or respond to ATP therapy may reduce the transvenous and 
mediastinal lead burden and subsequently reduce morbidity and mortality from 
systemic infection from indwelling leads in the circulation/mediastinum as well as from 
transvenous lead extraction, offering additional long-term economic benefits to 
healthcare systems. Another potential application is the development of novel lead 
technologies to deliver ATP. If, as our results suggest, ATP success is dependent on local 
myocardial properties/degree of fibrosis in relation to the stimulus location relative to 
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the re-entrant circuit, then delivery of ATP at potentially more favourable sites could be 
achieved with guided lead placement or multipolar leads that may offer an advantage 
over current techniques to deliver ATP. Since CMR-TA has the potential to identify 
patients at high risk of ATP failure and ICD shock therapy, it may also be useful in guiding 
prophylactic VT ablation in high-risk patients. 
 
5.4.4 Limitations 
Our findings are subject to the inherent limitations of non-randomized controlled 
studies. The morphology and cycle length of VT was not captured in the prospective 
database which may have provided further scope to evaluate differences in the type of 
VT responding to ATP versus shock therapy. Additionally, use of appropriate ICD therapy 
as a surrogate endpoint does not necessarily parallel sudden arrhythmic death. Right 
ventricular scar was not evaluated which may contribute to the overall scar burden and 
arrhythmic substrate. We used a standardized device therapy protocol according to our 
institutional guidelines when the study commenced. The MADIT-RIT study later 
demonstrated optimized ICD programming and may potentially have reduced the event 
rate of this study.192 Nevertheless, by standardizing our ICD programming it is unlikely 
that device programming would have introduced any systemic bias in the associations 
studied, not least since in the group that received shock therapy the majority of patients 
had VF or failed ATP for a VA in the VF zone. We also acknowledge that there may be 
other potential mechanisms related to higher entropy in infarcted regions which could 
explain our findings that were not investigated with our computer modelling. Primarily, 
more complex scar (with additional bystander channels) could result in a more complex 
VT circuit that is harder to treat with bystander channels being responsible for VT 
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sustenance upon interaction with the paced ATP wavefront that could facilitate the 
degeneration into more complex VT/VF. Three-dimensional patient specific models of 
the subjects in this cohort to investigate VA circuits in relation to scar heterogeneity was 
not possible, due to the coarse out-of-plane resolution of the CMR data, meaning that 
full 3D realization of the infarct anatomy, including microscopic channels that might 
support VT, was not possible. Larger randomized multicentre trials are required to 
further evaluate our findings and correlation with histopathologic specimens would also 
be important to validate our findings which is beyond the scope of the current work.  
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5.5 Conclusion 
A higher degree of scar heterogeneity, quantified by mean entropy, predicts ICD shock 
therapy in a high-risk group of ICD recipients. Our novel findings suggest that high mean 
entropy may be associated with more aggressive VAs unresponsive to ATP requiring 
shock therapy. Furthermore, our in silico computer modelling proposes a physiologically 
plausible mechanism to explain ATP failure in the presence of greater scar heterogeneity 
that may aid clinical decision making in patients more likely to benefit from early shock 
therapy. 
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Chapter 6: Conclusion 
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6.1 Summary of thesis objectives 
The overall aim of this thesis was to explore novel ways to improve complex cardiac 
implantable electronic device therapy outcomes. Specifically, the main objectives were:  
 
1. To explore the feasibility and potential benefit of using real-time cardiac CT image 
overlay guidance and multisite LV pacing as two distinct approaches to improve CRT 
response rates through optimal LV lead delivery. 
 
2. To assess the benefit of quantifying scar heterogeneity, using cardiac MRI texture 
analysis (mean entropy), as a potential metric to predict appropriate ICD therapy 
and ATP failure and explore its potential role in ICD risk stratification.
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6.2 Original contributions 
The preceding body of work has successfully explored these primary objectives. In 
summary: 
 
1. Chapter 2 has shown that real-time cardiac CT image overlay guidance for optimal 
LV lead placement in delivering CRT is safe and feasible. There were significant 
improvement in echocardiographic volumetric response outcomes at 6-months 
follow-up compared to baseline and the overall CRT response rate was high given 
the large number of patients with ICM and use of volumetric response as a hard 
endpoint. Larger, multicentre, randomised controlled studies are needed to 
evaluate whether real-time CT image overlay guidance is superior to standard care 
in patients undergoing an LV lead upgrade to CRT. 
 
2. Chapter 3 was an interim analysis of the STRIVE HF study, a prospective, multicentre 
randomised controlled trial specifically designed to assess feasibility and outcome 
benefits of multisite LV (triventricular) pacing in patients with LBBB and an 
intermediate QRS duration 120-150ms. Whilst the results indicate that implantation 
of two LV leads and triventricular pacing is feasible without significant complication, 
there was no evidence that multisite LV pacing improves CRT response or has any 
clinical benefit to patients with LBBB and intermediate QRS prolongation. The 
completion of the STRIVE HF study is awaited before any final conclusions and 
recommendations to clinical practice are made. 
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3. Chapter 4 showed for the first time that scar heterogeneity, quantified by mean 
entropy using cardiac MRI texture analysis, was an independent predictor of 
appropriate ICD therapy in the mixed cardiomyopathy cohort and ICM-only group, 
suggesting a potential role in predicting ventricular arrhythmias and risk-stratifying 
patients for ICD implantation. 
 
4. Chapter 5 also revealed novel findings that suggest lower scar heterogeneity, 
quantified by mean entropy using cardiac MRI texture analysis, is associated with 
successful ATP whereas higher scar heterogeneity is associated with more 
aggressive ventricular arrhythmias unresponsive to ATP requiring shock therapy.
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6.3 Future work 
Cardiac CT has the potential to identify areas of latest mechanical activation and guide 
LV lead implants into optimal pacing sites using real-time image overlay technology. 
Furthermore, if late iodine enhancement protocols for cardiac CT improve and match 
the reliability of scar imaging obtained from CMR imaging, then cardiac CT may in the 
future become the imaging modality of choice for both de novo and upgrade image 
guided CRT procedures. Larger, multicentre, randomised controlled studies are needed 
to evaluate whether real-time CT image overlay guidance is superior to standard care in 
patients undergoing an LV lead upgrade to CRT.  
 
The completion of the STRIVE HF study is awaited, however, if the final results are similar 
to the ones presented in the interim analysis in Chapter 3, then it is unlikely that 
multisite LV pacing should be pursued in the future. 
 
CMR texture analysis has the potential to be incorporated into an ICD risk stratification 
score. Larger randomized multicentre trials are required to further evaluate the 
potential value of quantifying scar heterogeneity, using cardiac MRI texture analysis 
(mean entropy), as a potential metric for ICD risk stratification. Furthermore, correlation 
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using cardiac magnetic resonance texture analysis of scar heterogeneity. Heart 
Rhythm Elsevier, 2019; 16:1242–1250.  
 
3. Chapter 5 (Gould et al.) has recently been submitted for publication in a peer 
reviewed journal with the title High mean entropy is associated with anti-
tachycardia pacing failure in patients receiving ICD therapy: Insights using cardiac 
magnetic resonance texture analysis of scar heterogeneity and in silico computer 
modelling. 
 
4. Chapters 2 and 3 (Gould et al.) will be submitted for publication in a peer reviewed 
journal when further results are available.  
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